Prodrugs of compounds that inhibit trpv1 receptor

ABSTRACT

Compounds of formula (I) 
     
       
         
         
             
             
         
       
     
     wherein A, R 1 , R 2 , and R 3  are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

This application claims priority to the provisional application Ser. No.60/730,991 filed on Oct. 28, 2005.

FIELD OF INVENTION

The present invention relates to prodrugs of urea containing compounds,pharmaceutically acceptable salts and pharmaceutical compositionsthereof, which are useful for treating pain, bladder overactivity,urinary incontinence, and other disorders caused by or exacerbated byvanilloid receptor activity. The compounds of the present invention havebetter physicochemical properties permitting more active drug to beavailable.

BACKGROUND OF THE INVENTION

Nociceptors are primary sensory afferent (C and AS fibers) neurons thatare activated by a wide variety of noxious stimuli including chemical,mechanical, thermal, and proton (pH<6) modalities. The lipophillicvanilloid, capsaicin, activates primary sensory fibers via a specificcell surface capsaicin receptor, cloned as TRPV1. The intradermaladministration of capsaicin is characterized by an initial burning orhot sensation followed by a prolonged period of analgesia. The analgesiccomponent of TRPV1 receptor activation is thought to be mediated by acapsaicin-induced desensitization of the primary sensory afferentterminal. Thus, the long lasting anti-nociceptive effects of capsaicinhave prompted the clinical use of capsaicin analogs as analgesic agents.Further, capsazepine, a capsaicin receptor antagonist can reduceinflammation-induced hyperalgesia in animal models. TRPV1 receptors arealso localized on sensory afferents, which innervate the bladder.Capsaicin or resiniferatoxin has been shown to ameliorate incontinencesymptoms upon injection into the bladder.

The TRPV1 receptor has been called a “polymodal detector” of noxiousstimuli since it can be activated in several ways. The receptor channelis activated by capsaicin and other vanilloids and thus is classified asa ligand-gated ion channel. TRPV1 receptor activation by capsaicin canbe blocked by the competitive TRPV1 receptor antagonist, capsazepine.The channel can also be activated by protons and heat. Under mildlyacidic conditions (pH 6-7), the affinity of capsaicin for the receptoris increased, whereas at pH<6, direct activation of the channel occurs.In addition, when membrane temperature reaches 43° C., the channel isopened. Thus heat can directly gate the channel in the absence ofligand. The capsaicin analog, capsazepine, which is a competitiveantagonist of capsaicin, blocks activation of the channel in response tocapsaicin, acid, or heat.

The channel is a nonspecific cation conductor. Both extracellular sodiumand calcium enter through the channel pore, resulting in cell membranedepolarization. This depolarization increases neuronal excitability,leading to action potential firing and transmission of a noxious nerveimpulse to the spinal cord. In addition, depolarization of theperipheral terminal can lead to release of inflammatory peptides suchas, but not limited to, substance P and CGRP, leading to enhancedperipheral sensitization of tissue.

Recently, two groups have reported the generation of a “knock-out” mouselacking the TRPV1 receptor (TRPV1 (−/−)). Electrophysiological studiesof sensory neurons (dorsal root ganglia) from these animals revealed amarked absence of responses evoked by noxious stimuli includingcapsaicin, heat, and reduced pH. These animals did not display any overtsigns of behavioral impairment and showed no differences in responses toacute non-noxious thermal and mechanical stimulation relative towild-type mice. The TRPV1 (−/−) mice also did not show reducedsensitivity to nerve injury-induced mechanical or thermal nociception.However, the TRPV1 knock-out mice were insensitive to the noxiouseffects of intradermal capsaicin, exposure to intense heat (50-55° C.),and failed to develop thermal hyperalgesia following the intradermaladministration of carrageenan.

The compounds of the present invention are novel TRPV1 antagonists andhave utility in for treating pain, bladder overactivity, urinaryincontinence, and other disorders associated with pain that are causedby or exacerbated by vanilloid receptor activity.

SUMMARY OF THE PRESENT INVENTION

The present invention discloses prodrugs of urea containing compounds,pharmaceutically acceptable salts and pharmaceutical compositionsthereof. More particularly, the present invention is directed tocompounds of formula (1),

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or acombination thereof, wherein

A is

R₁ is alkyl, cycloalkyl, alkenyl; halogen or haloalkyl;

R₂ is hydrogen or heterocyclealkyl wherein the heterocycle moiety of theheterocyclealkyl is unsubstituted or substituted with 1, 2, 3 or 4substituents selected from the group consisting of alkyl, -alkyl-OR_(B),and -alkyl-N(R_(B))₂;

R₃ is

wherein

-   -   R⁴ is —C(O)—O—(CH₂)_(m)R₅, —C(O)(CH₂)_(n)—R₆, —(CH₂)_(r)—R₇,        —C(O)R₈, or —CH₂C(H)(OH)R₉ when R₂ is hydrogen; or    -   R₄ is hydrogen when R₂ is heterocyclealkyl; wherein the        heterocycle moiety of the heterocyclealkyl is unsubstituted or        substituted with 1, 2, 3 or 4 substituents selected from the        group consisting of alkyl, -alkyl-OR_(B), and -alkyl-N(R_(B))₂;

m is 1, 2, or 3;

n is 1, 2 or 3;

r is 1, 2 or 3;

t is 0, 1, 2, 3 or 4;

u is 0, 1, 2 or 3;

R₅ is alkyl, —O—P(O)(OR_(A))(OR_(A)), —P(O)(OR_(A))(OR_(A)), —OR_(A),—OC(O)(R_(A)), heterocycle, —C(O)OR_(A), —C(O)N(R_(B))₂, —C(O)(R_(A)),—NR_(A)R_(B), or -N(R_(B))C(O)OR_(A),

R₆ is alkyl, —OC(O)(R_(A)), —OR_(A), —C(O)OR_(A), —NR_(A)R_(B),—OP(O)(OR_(A))(OR_(A)), or —P(O)(OR_(A))(OR_(A));

R₇ is alkoxy, heterocycle, —OC(O)(R_(A)), —OC(O)(hydroxyalkyl),—OP(O)(OR_(A))(OR_(A)), or —P(O)(OR_(A))(OR_(A)),

R₈ is heterocycle or N(R_(8a))(R_(8b)) wherein R_(8a) and R_(8b) areindependently hydrogen or alkyl;

R₉ is alkoxyalkyl, —C(O)OR_(A), -alkyl-N(R_(B))C(O)OR_(A), orheterocyclealkyl;

R₁₀ is alkyl;

each occurence of R₁₁ are independently hydrogen, alkyl or aryl, or twoR₁₁ groups that are attached to a single carbon atom together form acycloalkyl ring;

R_(A) is hydrogen, alkyl, alkoxyalkyl, aryl or arylalkyl;

R_(B) is hydrogen or alkyl;

the heterocycle and the heterocycle moiety of the heterocyclealkyl,represented by R₅, R₇, R₈, and R₉, are each independently substitutedwith 0, 1, 2 or 3 substituents independently selected from the groupconsisting of alkyl, haloalkyl, alkoxy, haloalkoxy, —C(O)OH,-alkyl-C(O)OH, and —N(Z_(A))(Z_(B));

Z_(A) and Z_(B) are each independently hydrogen, alkyl, —C(O)alkyl,formyl, aryl, or arylalkyl; and

the aryl and the aryl moiety of the arylalkyl, represented by R_(A),Z_(A) and Z_(B) are each independently substituted with 0, 1, 2 or 3substituents selected from the group consisting of alkyl, haloalkyl,alkoxy and haloalkoxy.

The compounds of the present invention are useful for treating pain,bladder overactivity, urinary incontinence, and other disorders causedby or exacerbated by vanilloid receptor activity.

Also described are pharmaceutical compositions comprising atherapeutically effective amount of one or more compounds of formula(I), or a therapeutically acceptable salt, solvate, or combinationthereof, and a pharmaceutically acceptable carrier.

One particular embodiment of the present invention describes a method oftreating a disease or preventing disorders that may be ameliorated byinhibiting vanilloid receptor subtype 1 activity in a mammal comprisingadministering a therapeutically effective amount of one or morecompounds of formula (I) or a pharmaceutically acceptable salt thereof.

The compounds of formula (I) may be used in the manufacture of amedicament for the treatment or prevention of a disease or disorder thatmay be ameliorated by inhibiting vanilloid receptor subtype 1 activity.

Furthermore, the disclosed compounds of formula (I) are useful intreating a disease or a disorder, wherein the disease or disorder isassociated with pain, inflammation, urinary incontinence and bladderdysfunction.

The disclosed methods of treating or preventing disease or disorderassociated with pain wherein the pain is neuropathic pain, inflammatorypain, or both, which method comprises administering a therapeuticallyeffective amount of a compound of formula (I) or a pharmaceuticallyacceptable salt thereof.

There is also disclosed methods of treating or preventing a disease ordisorder associated with bladder overactivity or urinary incontinence,or both, which method comprises administering a therapeuticallyeffective amount of a compound of formula (I) according to claim 1 or apharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

Compounds of the invention have the formula (I) as described above. Ingeneral, the compounds of formula (I) can include, but are not limitedto, compounds in which A is

More particularly, compounds of formula (I) contain A which is

In another series of embodiments, compounds of formula (I) contain Awhich is

In a further series of embodiments, compounds of formula (I) contain Awhich is

In yet another series of embodiments, compounds of formula (I) contain Awhich is

Lastly in yet another series of embodiments, compounds of formula (1)contain A which is

For each substructure as defined by ring A, there exist the followingembodiments which further define the scope of the compounds of thepresent invention. These further embodiments are contemplated to applyto each series of compounds of the present invention defined under ringA.

In one embodiment there is described compounds of formula (I) wherein R₁is alkyl, cycloalkyl, halogen or haloalkyl, R₂ is hydrogen orheterocyclealkyl, R₃ is selected from the groups

and R₄ is selected form the group consisting of —C(O)—O—(CH₂)_(m)R₅,—C(O)(CH₂)_(n)—R₆, —(CH₂)_(r)—R₇, —C(O)R₈, or —CH₂C(H)(OH)R₉ when R₂ ishydrogen.

Compounds of the invention include those wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ is hydrogen, R₃is

and R₄ is —(CH₂)_(r)—R₇, in which R₇ selected from the group consistingof heterocycle, —OC(O)(R_(A)), —OC(O)(hydroxyalkyl), and—P(O)(OR_(A))(OR_(A)). Preferred compounds include those in which R₇ is—OC(O)(R_(A)), and R_(A) is hydrogen or those in which R₇ is—OC(O)(hydroxyalkyl).

Other compounds of the present invention include those wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ ishydrogen, R₃ is

and R₄ is —C(O)(CH₂)_(n)—R₆, wherein R₆ is selected from the groupconsisting of is —OC(O)(R_(A)), —OR_(A), —C(O)OR_(A), —NR_(A)R_(B),—OP(O)(OR_(A))(OR_(A)) or —P(O)(OR_(A))(OR_(A)). Examples of compoundsof the present invention are those in which R_(A) is hydrogen, alkyl,aryl or arylalkyl.

Other compounds of the present invention include those wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ ishydrogen, R₃ is

and R₄ is —CH₂C(H)(OH)R₉, wherein R₉ is selected from the groupconsisting of alkoxyalkyl, —C(O)OR_(A), -alkyl-N(R_(B))C(O)OR_(A), andheterocyclealkyl. Examples of compounds of the present invention arethose in which R₉ is alkoxyalkyl, —C(O)OR_(A), and heterocyclealkyl, andR_(A) is hydrogen, alkyl, aryl or arylalkyl.

Other compounds included in the present invention are those in which R₁is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ ishydrogen, R₃ is

and R₄ is —C(O)R₈ , wherein R₈ is heterocycle or N(R_(8a))(R_(8b)).Examples of compounds of the present invention are those in which R₈ isheterocycle.

Other compounds included in the present invention are those in which R₁is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ isheterocyclealkyl, R₃ is

and R₄ is hydrogen. Examples of the present invention comprise compoundsin which the heterocycle moiety of the heterocyclealkyl isunsubstituted. However, compounds in which the heterocycle moiety of theheterocyclealkyl is substituted with 1, 2, 3 or 4 substituents selectedfrom the group consisting of alkyl, -alkyl-OR_(B), and -alkyl-N(R_(B))₂,are also comprised in the present invention.

Other compounds included in the present invention are those in which R₁is alkyl, cycloalkyl, halogen or haloalkyl, R₂ is heterocyclealkyl, R₃is

and R₄ is hydrogen.

Compounds of the present invention include those wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ is hydrogen, R₃is

and R₄ is —C(O)—O—(CH₂)_(m)R₅, wherein R₅ is selected from the groupconsisting of —O—P(O)(OR_(A))(OR_(A)), —P(O)(OR_(A))(OR_(A)), —OR_(A),—OC(O)(R_(A)), heterocycle, —C(O)OR_(A), —C(O)N(R_(B))₂, —C(O)(R_(A)),and —N(R_(B))C(O)OR_(A). Examples of these compounds include those inwhich R₅ is —O—P(O)(OR_(A))(OR_(A)), and R_(A) is independently selectedfrom the group consisting of hydrogen, alkyl, aryl or arylalkyl. Otherexamples include those compounds in which R₅ is —P(O)(OR_(A))(OR_(A)),and R_(A) is independently selected from the group consisting ofhydrogen, alkyl, aryl or arylalkyl. Examples of compounds include thosein which R₅ is OR_(A) and R_(A) is independently selected from the groupconsisting of hydrogen, alkyl, aryl or arylalkyl. Other examples includethose in which R₅ is heterocycle. Examples include compounds in which R₅is OC(O)(R_(A)), and R_(A) is independently selected from the groupconsisting of hydrogen, alkyl, aryl or arylalkyl. Other examples includethose compounds in which R₅ is —C(O)OR_(A), and R_(A) is independentlyselected from the group consisting of hydrogen, alkyl, aryl orarylalkyl. Other compounds included in the examples of the presentinvention are those in which R₅ is —C(O)N(R_(B))₂, and R_(B) is selectedbetween hydrogen and alkyl. Other compounds included in the examples ofthe present invention are those in which R₅ is —N(R_(B))C(O)OR_(A)wherein R_(B) is selected between hydrogen and alkyl, and R_(A) isindependently selected from the group consisting of hydrogen, alkyl,aryl or arylalkyl.

Other compounds of the present invention are those in which R₁ is alkyl,cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ is hydrogen, R₃is

and R⁴ is —C(O)R₈, in which R₈ is heterocycle or N(R_(8a))(R_(8b))wherein R^(8a) and R_(8b) are independently hydrogen or alkyl. Examplesof the present invention include compounds in which Rg is heterocycle.

Other compounds of the present invention are those in which R₁ is alkyl,cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ is hydrogen, R₃is

and R₄ is —CH₂C(H)(OH)R₉, wherein R₉ is selected from the groupconsisting of alkoxyalkyl, —C(O)OR_(A), -alkyl-N(R_(B))C(O)OR_(A), andheterocyclealkyl. Examples of the present invention include compounds inwhich R₉ is alkoxyalkyl. Other examples include compounds in which R₉ is—C(O)OR_(A) and R_(A) is alkyl. Other examples include compounds inwhich R₉ is heterocyclealkyl.

Other compounds of the present invention include compounds in which R₁is alkyl, cycloalkyl, halogen or haloalkyl, preferably alkyl, R₂ ishydrogen, R₃ is

and R4 is —C(O)—O—(CH₂)_(m)R₅. Other compounds included in the inventionare those in which, R₁ is alkyl, cycloalkyl, halogen or haloalkyl,preferably alkyl, R₂ is hydrogen, R₃ is

and R₄ is —(O)(CH₂)_(n)—R₆. Other compounds included in the inventionare those in which, R₁ is alkyl, cycloalkyl, halogen or haloalkyl,preferably alkyl, R₂ is hydrogen, R₃ is

and R₄ is and —(CH₂)_(n)—R₇. Other compounds included in the presentinvention have R₁ is alkyl or alkenyl, preferably alkyl, R₂ isheterocyclealkyl, R₃ is

and R₄ is hydrogen.

Furthermore, compounds of formula (II) are considered within the scopeof the present invention,

wherein R₁, R₂, R₃ and t are defined in compounds of formula (I).

Other compounds of the present invention include compounds of formula(III)

wherein R₁, R₂, R₃ and t are defined in compounds of formula (I).

Other compounds of the present invention include compounds of formula(IV)

wherein R₁, R₂, R₃ and t are defined in compounds of formula (I).

Other compounds of the present invention include compounds of formula(V)

wherein R₁, R₂, R₃ and t are defined in compounds of formula (I).

The following compounds are contemplated to be within the scope of thepresent invention:

It is contemplated that any of the embodiments described above may becombined and the scope of the compounds of the present invention definedunder formula (I) is described by any such combinations. Compounds andcompositions of the invention are useful for modulating the effects ofvanilloid receptor activity, and more particularly the receptor typeTRPV1. In particular, the compounds and compositions of the inventioncan be used for treating and preventing disorders modulated by TRPV1.Typically, such disorders can be ameliorated by selectively modulatingthe TRPV1 receptor in a mammal, preferably by administering a compoundor composition of the invention, either alone or in combination withanother active agent, for example, as part of a therapeutic regimen. Thecompounds of the invention, including but not limited to those specifiedin the examples, possess an affinity for TRPV1′s. As TRPV1 ligands, thecompounds of the invention can be useful for the treatment andprevention of a number of diseases or conditions mediated by the TRPV1activity.

For example, TRPV1 have been shown to play a significant role in therelease of inflammatory peptides such as, but not limited to, substanceP and CGRP, leading to enhanced peripheral sensitization of tissue. Assuch, TRPV1 ligands are suitable for the treatment of disordersassociated with pain and inflammation. Further, capsazepine, a capsaicinreceptor antagonist can reduce inflammation-induced hyperalgesia inanimal models.

TRPV1 receptors are also localized on sensory afferents, which innervatethe bladder. Capsaicin or resiniferatoxin has been shown to ameliorateincontinence symptoms upon injection into the bladder. Therefore, TRPV1ligands are suitable for the treatment of disorders associated withurinary incontinence and bladder dysfunction.

Definition of Terms.

As used throughout this specification and the appended claims, thefollowing terms have the following meanings:

The term “alkenyl” as used herein, means a straight or branched chainhydrocarbon containing from 2 to 10 carbons and containing at least onecarbon-carbon double bond formed by the removal of two hydrogens.Representative examples of alkenyl include, but are not limited to,ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl,5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “alkoxy” as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of alkoxy include, but are not limited to,methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, andhexyloxy.

The term “alkoxyalkyl” as used herein, means an alkoxy group, as definedherein, appended to the parent molecular moiety through an alkyl group,as defined herein. Representative examples of alkoxyalkyl include, butare not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl,and methoxymethyl.

The term “alkyl” as used herein, means a straight or branched chainhydrocarbon containing from 1 to 10 carbon atoms. Representativeexamples of alkyl include, but are not limited to, methyl, ethyl,n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl,n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl,2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, andn-decyl.

The term “aryl” as used herein, means phenyl or a bicyclic aryl. Thebicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl,or a phenyl fused to a monocyclic cycloalkenyl. The phenyl and thebicyclic aryl groups of the present invention are unsubstituted orsubstituted. The bicyclic aryl is attached to the parent molecularmoiety through any carbon atom contained within the bicyclic aryl.Representative examples of the aryl groups include, but are not limitedto, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl,1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxin-6-yl, and5,6,7,8-tetrahydronaphthalenyl.

The term “arylalkyl” as used herein, means an aryl group, as definedherein, appended to the parent molecular moiety through an alkyl group,as defined herein. Representative examples of arylalkyl include, but arenot limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and2-naphth-2-ylethyl.

The term “halo” or “halogen” as used herein, means —Cl, —Br, —I or —F.

The term “haloalkoxy” as used herein, means an alkoxy group as definedherein, wherein one to six hydrogen atoms are replaced by halogens.Representative examples of haloalkoxy include, but are not limited to,chloromethoxy, 2-fluoroethoxy, trifluoromethoxy,2-chloro-3-fluoropentyloxy, and pentafluoroethoxy.

The term “haloalkyl” as used herein, means an alkyl group as definedherein, wherein one to six hydrogen atoms are replaced by halogens.Representative examples of haloalkyl include, but are not limited to,chloromethyl, 2-fluoroethyl trifluoromethyl, pentafluoroethyl, and2-chloro-3-fluoropentyl.

The term “heterocycle” or “heterocyclic” as used herein, means amonocyclic three-, four-, five-, six-, seven- or eight-membered ringcontaining at least one heteroatom independently selected from the groupconsisting of O, N, and S. The three- or four-membered ring containszero or one double bond, and one heteroatom selected from the groupconsisting of O, N and S. The five-membered ring contains zero or onedouble bond and one, two or three heteroatoms selected from the groupconsisting of O, N and S. The six-membered ring contains zero, one ortwo double bonds and one, two or three heteroatoms selected from thegroup consisting of O, N and S. The seven-membered ring contains zero,one, two, or three double bonds and one, two or three heteroatomsselected from the group consisting of O, N and S. The monocyclicheterocycle is unsubstituted or substituted and is connected to theparent molecular moiety through any carbon atom or any nitrogen atomcontained within the monocyclic heterocycle. Representative examples ofmonocyclic heterocycle include, but are not limited to, azetidinyl,azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolan-4-yl,1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl,isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl,morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl,piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl,pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl,thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl,thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone),thiopyranyl, and trithianyl.

The term “heterocyclealkyl” as used herein, means a heterocycle group,as defined herein, appended to the parent moiety through an alkyl group,as defined herein. Examples of heterocyclealkyl of the present inventioninclude, but not limited to, 2-morpholin-4-yl-ethyl and2-piperidin-1-yl-ethyl.

The term “hydroxy” as used herein, means an —OH group.

The term “hydroxyalkyl” as used herein, means at least one hydroxygroup, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein.

Representative examples of hydroxyalkyl include, but are not limited to,hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and2-ethyl-4-hydroxyheptyl.

The term “oxo” as used herein, means ═O.

Compounds of the present invention may exist as stereoisomers wherein,asymmetric or chiral centers are present. These stereoisomers are “R” or“S” depending on the configuration of substituents around the chiralcarbon atom. The terms “R” and “S” used herein are configurations asdefined in IUPAC 1974 Recommendations for Section E, FundamentalStereochemistry, Pure Appl. Chem., 1976, 45: 13-30. The presentinvention contemplates various stereoisomers and mixtures thereof andthese are specifically included within the scope of this invention.Stereoisomers include enantiomers and diastereomers, and mixtures ofenantiomers or diastereomers. Individual stereoisomers of compounds ofthe present invention may be prepared synthetically from commerciallyavailable starting materials that contain asymmetric or chiral centersor by preparation of racemic mixtures followed by resolution which iswell known to those of ordinary skill in the art. These methods ofresolution are exemplified by (1) attachment of a mixture of enantiomersto a chiral auxiliary, separation of the resulting mixture ofdiastereomers by recrystallization or chromatography and liberation ofthe optically pure product from the auxiliary, (2) direct separation ofthe mixture of optical enantiomers on chiral chromatographic columns, orfractional recrystalization of salt of the compounds of the presentinvention with chrial carboxylic acids followed by neutralization toobtain the pure steroisomer of the compound of the present invention.

The compounds and processes of the present invention will be betterunderstood by reference to the following Examples, which are intended asan illustration of and not a limitation upon the scope of the invention.Further, all citations herein are incorporated by reference.

Compounds of the invention were named by ACD/ChemSketch version 5.01(developed by Advanced Chemistry Development, Inc., Toronto, ON, Canada)or were given names consistent with ACD nomenclature. Alternatively,compounds were assigned names using ChemDraw Ultra 9.0 (or higherversion) (Cambridgesoft). The practice of assigning names to chemicalcompounds from structures, and of assigning chemical structures fromgiven chemical names is well known to those of ordinary skill in theart.

Preparation of Compounds of the Present Invention

The compounds of this invention can be prepared by a variety ofsynthetic procedures. Representative procedures are shown in, but arenot limited to, Schemes 1-11.

As outlined in Scheme 1, ketone containing compounds of formula (3) maybe converted into compounds of formula (8) which are used in thesynthesis of compounds of formula (I). Compounds of formula (3) whenheated in the presence of a compound of formula (4) or similar chiralamine containing compound in toluene under Dean-Stark conditions with orwithout a catalytic amount of acid, followed by treatement with reducingconditions such as but not limited to sodium borohydride in ethanol willprovide a compounds of formula (5). Compounds of formula (5) whentreated with an atmosphere of hydrogen in the presence of a palladiumcatalyst such as palladium on carbon in solvents such as but not limitedto methanol or ethanol with our without a catalytic amount of an acidsuch as acetic acid will provide compounds of formula (8) wherein R₁ isas defined in formula (I).

Alternatively, compounds of formula (3) when treated with anhydroxylamine or O-substituted hydroxylamines such as, but not limitedto methoxyamine, in the presence of a solvent such as, but not limitedto, pyridine or mixtures of ethanol and pyridine at a temperature fromabout room temperature to about 50° C. will provide oximes of formula(6). Oximes of formula (6) can be reduced in the presence of anatmosphere of hydrogen gas from about 40 to about 60 psi and a catalystsuch as, but not limited to palladium on carbon at a temperature fromabout 50° C. to about 70° C. to provide compounds of formula (7).Compounds of formula (7) made through this method exist as a mixture ofenantiomers that may be resolved by fractional crystallization whenconverted to salt with chiral carboxylic acid. Chiral carboxylic acidsuseful in forming salts with compounds of formula (7) include chiralamino acids such as, but not limited to, N-acetyl-(D)-leucine andN-tert-butyloxycarbonyl phenylalanine. The fractional crystallization ofcompounds of formula (7) with chiral carboxylic acids will provide afterneutralization the individual isomers of (R) or the (S) form of theamine of formula (8).

Ureas of general formula (14) wherein R₁ and R₂ are as defined informula (I) can be prepared as described in Scheme 2. Indazoles ofgeneral formula (10), prepared using the procedures as described inExample 56C, when treated with a compound of formula (11), in solventssuch as but not limited to acetonitrile will provide a compound offormula (12). Compounds of formula (12) when treated with compounds offormula (9) in the presence of a base such as but not limited todiisopropylethylamine will provide ureas of formula (13). Typicalsolvents include but are not limited to acetonitrile orN,N-dimethylformamide. Ureas of general formula (13) when treated withsodium hydroxide or potassium hydroxide will provide indazoles ofgeneral formula (14). Typical solvents include but are not limited tomethanol, ethanol and mixtures of solvents such as N,N-dimethylformamideand methanol. Compounds of formula (13) and of formula (14) described inScheme 2 are drawn to represent chiral compounds which are the productof using the chiral compound of formula (9). Alternatively, the use ofracemic compounds of formula (7) in this synthetic pathway will produceracemic mixtures of compounds of formula (13) and racemic mixtures ofcompounds of formula (14).

Alternatively, compounds of formula (10) can be treated with phosgene ortriphosgene and 4-dimethylaminopyridine in a solvent such as, but notlimited to, dichloromethane, followed by treatment with amines ofgeneral formula (9) in a solvent such as, but not limited to, toluene ortetrahydrofuran or a combination thereof to provide ureas of generalformula (13) wherein R₂ is hydrogen or heterocyclealkyl.

It is also known to one skilled in the art that compounds of formula(10) can be treated with trichloroacetyl chloride and a base such as,but not limited to, triethylamine in a solvent such as dichloromethaneto provide trichloroacetamides, which in turn can be treated with aminesof formula (9) and a non-nucleophilic base such as, but not limited to,1,8-diazabicyclo[5.4.0]undec-7-ene in a solvent such as, but not limitedto, acetonitrile, to provide ureas of general formula (13) wherein R₂ ishydrogen or heterocyclealkyl. Compounds of formula (9) wherein R₂ isheterocyclealkyl can be obtained from amines of formula (8) by treatmentwith halides of formula R₂X wherein X is Cl, Br or I, in the presence ofa base such as but not limited to sodium carbonate or potassiumcarbonate, optioanally in the presence of catalytic amount oftetrabutylammonium iodide. The reaction is generally performed insolvents such as but not limited to N,N-dimethylformamide, methanol,ethanol, and mixtures thereof.

Compounds of formula (13) wherein R₂ is heterocyclealkyl can also beprepared from compounds of formula (13) wherein R₂ is hydrogen employingthe reaction conditions for the transformation of compounds of formula(8) to compounds of formula (9).

Compounds of formula (16) and (17) wherein r, R_(i)and R₇ are as definedin formula (1) can be obtained from compounds of formula (15) bytreatment with halides of formula R₇(CH₂)_(r)X, wherein X is Cl, Br orI, in the presence of a base such as but not limited to potassiumcarbonate, sodium carbonate or sodium hydride, and optionally in thepresence of tetrabutyl ammonium iodide. The reaction is generallyconducted in a solvent such as, but not limited toN,N-dimethylformamide, and at a temperature from about room temperatureto about 100° C. The two regioisomers obtained can be separated usingpurification techniques such as but not limited to column chromatographyon silica gel.

The compounds of formula (15), (16) and (17) are drawn to representchiral compounds in this Scheme are for clarity purposes only. The samesynthetic strategy may be carried out with the racemic compound offormula (15), which will produce the racemic mixtures of compounds offormula (16) and of formula (17). Similarly, the following schemes alsoare depicting using a chiral starting material but alternatively whencarried out using a racemic mixture of a starting material or theopposite enantiomer will produce a racemic mixture of products or theopposite enantiomeric product, respectively.

Compounds of formula (18) wherein n, R₁ and R₆ are as defined in formula(1) can be synthesized as outlined in Scheme 4. Acyl chlorides offormula R₆(CH₂)_(n)COCl, or anhydrides such as, but not limited to,glutaric anhydride, succinic anhydride or acetic anhydride, purchased orprepared using methodologies known to one skilled in the art, and anamine such as, but not limited to triethylamine, pyridine or mixturethereof, when treated with imidazoles of formula (15), providescompounds of formula (18). The reaction can be conducted with or withouta solvent at about room temperature, for a period of about 1 hour toabout 5 days. Example of a solvent that can be employed includes, butnot limited to, tetrahydrofuran.

Alternatively, compounds of formula (18) can also be obtained fromcompounds of formula (15) by treatment with acids of formulaR₆(CH₂)_(n)COOH, purchased or prepared by known methodologies, in thepresence of a coupling agent such as, but not limited to,N,N′-dicyclohexylcarbodiimide. The reaction can be conducted at ambienttemperature and in a solvent such as, but not limited to,dichloromethane, tetrahydrofuran, N,N-dimethylformamide, or mixturethereof.

Compounds of formula (15) can be transformed to compounds of formula(19) and (20) wherein R₁ and R₈ are as defined in formula (1) as shownin Scheme 5.

Treatment of compounds of formula (15) and carbonyl chlorides of formulaR₈COCl wherein R₈ is either N(R_(8a))(R_(8b)) or a heterocycle whereinthe ring nitrogen atom is attached to the carbonyl moiety of thecarbonyl chloride, followed by separation of the two regioisomersemploying known purification technique such as but not limited to columnchromatograph on silica gel, furnished compounds of formula (19) or(20). The reaction can be performed in a solvent such as but not limitedto N,N-dimethylformamide, and in the presence of a base such as but notlimited to sodium hydride. Treatment of compounds of formula (15) withcarbonyl chlorides of formula R₈COCl wherein the carbonyl moiety isappended to the carbon atom of the heterocycle ring afford compounds offormula (19) under the forgoing reaction conditions.

Carbonyl chlorides of formula R₈COCl can be purchased or prepared fromacids of formula R₈COOH with thionyl chloride in the presence ofcatalytic amount of N,N-dimethylformamide, at a temperature of aboutroom temperature, in a solvent such as, but not limited to,dichloromethane.

Compounds of formula (24) wherein R₁, R₅ and m are as defined in formula(I) can be prepared as outlined in Scheme 6.

Compounds of formula (15) when treated with compounds of formula (21) or(23) and a base such as but not limited to potassium tert-butoxide, in asolvent such as, but not limited to, N,N-dimethylformamide, at atemperature from about 0° C. to about room temperature, providescompounds of formula (24).

Alternatively, compounds of formula (24) can be obtained by treatingcompounds of formula (15) with chloroformates of formula R₅(CH₂)m0C(O)C1(purchased or prepared by known methodologies) in the presence of a basesuch as but not limited to 4-methylmorpholine, in a solvent such as, butnot limited to, tetrahydrofuran.

Compounds of formula (21) or (23) can be prepared from alcohols offormula (20), by treatment with 4-nitrophenyl chloroformate or carbonateof formula (22) respectively, in the presence of a base such as, but notlimited to, triethylamine or pyridine, in a solvent such as, but notlimited to, dichloromethane or acetonitrile.

Compounds of formula (25) or (26) wherein R₁ and R₉ are as defined informula (I), can be prepared from compounds of formula (15), bytreatment with substituted oxiranes (prepared by known methodologies orpurchased) and a base such as, but not limited to, sodium tert-butoxide,sodium carbonate or potassium carbonate. The two regioisomers obtainedcan be separated by column chromatography or other purificationtechniques known to one skilled in the art. The reaction can beconducted at an elevated temperature from about 70° C. to about 120° C.,in a solvent such as, but not limited to, methanol, ethanol, oracetonitrile.

It is understood that Schemes 2-7 depicting chiral compounds is doneonly for illustrative purposes only, and that the use of a racemicmixture of one starting material or the opposite enantiomer will producea racemic mixture of products or the opposite enantiomeric product,respectively.

More specifically, compounds of the present invention which contain anamino-indane moiety may be prepared as outlined in Scheme 8. Forexample, chloropropionyl chloride when treated with aluminum chloride ina solvent such as but not limited to methylene chloride followed by theaddition of a compound of formula (28) will provide a compound offormula (29). Compounds of formula (29) when treated with concentratedsulfuric acid or poly phosphoric acid followed by heating will providecompounds of formula (30). Compounds of formula (30) when treatedaccording to the procedure outlined in Scheme 1 will provide amines offormula (31). Furthermore compounds of formula (31) when treatedaccording to the procedures outlined in Scheme 2 will provide compoundsof formula (32). Compounds of formula (32) when treated according to theprocedures outlined in Scheme 3-5 will provide compounds of formula (33)which are representative of compounds of the present invention.

As outlined in Scheme 9, compounds of formula (34) when treated with aketone substituted with R₁₁, wherein each occurance of R₁₁ areindependently hydrogen, alkyl or aryl, or two R₁₁ groups that areattached to a single carbon atom or two adjacent carbon atoms togetherform a cycloalkyl ring; and a base such as but not limited topyrrolidine in a solvent such as but not limited to toluene heated toreflux containing a Dean-Stark trap will provide compounds of formula(35). Compounds of formula (35) when treated according to the proceduresoutlined in Schemes 1-5 will provide compounds of formula (33), whichare representative of compounds of the present invention.

As shown in Scheme 10, compounds of formula (37), wherein R₁ and t aredefined in formula(I) when treated with propargyl bromide in thepresence of a base such as but not limited to potassium carbonate in asolvent such as but not limited to acetonitrile will provide compoundsof formula (39). Compounds of formula (39) when treated withN-chlorosuccinimide and silver acetate in a solvent such as but notlimited to acetone with heating will provide compounds of formula (40).Compounds of formula (40) when treated with ethylene glycol at refluxwill provide compounds of formula (41). Compounds of formula (41) whentreated according to the procedures outlined in Schemes 1-5 will providecompounds of formula (42)

As outlined in Scheme 11, compounds of formula (43) wherein R₁ and t aredefined in formula (I), when treated with a base such as cesiumcarbonate in acetonitrile or sodium hydride in DMF followed by thetreatment with methyl 3-bromopropionate will provide compounds offormula (44). Compounds of formula (44) when treated with sodium,lithium or potassium hydroxide in an aqueous alcoholic solvent willprovide compounds of formula (45). Compounds of formula (45) when heatedin the presence of polyphosphoric acid will provide compounds of formula(46). Compounds of formula (46) when treated according to conditionsoutlined in Schemes 1-5 will provide compounds of formula (47), whichare representative of compounds of the present invention.

It is understoond that the schemes described herein are for illustrativepurposes and that routine experimentation, including appropriatemanipulation of the sequence of the synthetic route, protection of anychemical functionality that are not compatible with the reactionconditions and the removal of such protecting groups are included in thescope of the invention.

It is understood that Schemes 8-11 depicting racemic mixtures ofcompounds is done only for illustrative purposes only, and that the useof a single enantiomeric starting material will produce a singleenantiomeric product.

The following Examples are intended as an illustration of and not alimitation upon the scope of the invention as defined in the appendedclaims.

EXAMPLE 2N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-morpholin-4-ylethyl)-1H-indazol-4-yl]urea

To a solution of compound from Example 56J (150 mg, 0.43 mmol) in 2 mldimethylformamide was added potassium carbonate (180 mg, 1.3 mmol) and4-(2-chloro-ethyl)-morpholine hydrochloride (121 mg, 0.65 mmol). Thereaction was stirred for eleven days at ambient temperature. At thispoint, a catalytic amount (10 mg) of tetrabutylammonium iodide wasadded, and the reaction continued for 16 hours longer. The reactionmixture was diluted with water and filtered. The filtercake was thenpurified by chromatography on silica gel, using 5% ethanol/ethyl acetateas solvent, to give 92 mg of the title compound. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 8.56 (s, 1H), 8.02 (s, 1H), 7.70 (d, J=7.12 Hz, 1H),7.17-7.32 (m, 5H), 6.68 (d, J=7.80 Hz, 1H), 5.15 (m, 1H), 4.46 (t,J=6.61 Hz, 2 14), 3.44-3.53 (m, 4H), 2.87-2.79 (m, 4H), 2.38-2.52 (m,5H), 1.76-1.90 (m, 1H), 1.28 (s, 9H). MS (ESI) m/e 462 (M+H)⁺ Calcd. ForC₂₇H₃₅N₅O₂.0.4H₂O: C, 69.17; H, 7.70; N, 14.94; Found C, 69.39; H, 7.78;N, 14.95.

EXAMPLE 32-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-oxoethylacetate

To a solution of compound from Example 56J (1.05 g, 3 mmol) in 10 mlpyridine and 1.5 ml triethylamine was added acetoxyacetyl chloride (0.54ml, 0.68 g, 5 mmol). The reaction was stirred at ambient temperature forfour days and the solvent was removed under reduced pressure. Theresidue was purified twice by chromatography on silica gel, using 25% to40% ethyl acetate/hexane, to give 0.26 g of the title compound. ¹H NMR(300 MHz, DMSO-d₆) δ ppm 8.46 (s, 1H) 8.90 (s, 1H), 7.91 (d, J=7.80 Hz,1H), 7.80 (d, J=8.14 Hz, 1H), 7.54 (t, J=8.14 Hz, 1H), 7.25-7.37 (m,3H), 6.71 (d, J=8.14 Hz, 1H), 5.49 (s, 2H), 5.17 (m, 1H), 2.89-3.10 (m,1H), 2.74-2.88 (m, 1H), 2.36-2.52 (m, 1H), 2.19 (s, 3H), 1.71-1.96 (m,1H), 1.27 (s, 9H). MS (ESI) m/e 489 (M+H)⁺. Calcd. For C₂₅H₂₈N₄O₄: C,66.95; H, 6.29; N, 12.49; Found C, 66.74; H, 6.43; N, 12.28.

EXAMPLE 4 methyl4-({[[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl](2-morpholin-4-ylethyl)amino]carbonyl}amino)-1H-indazole-1-carboxylateEXAMPLE 4AN-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N-(2-morpholin-4-ylethyl)amine

4-(2-Chloro-ethyl)-morpholine hydrochloride (0.56 g, 3 mmol), compoundfrom Example 56K (1.08 g, 3 mmol), and sodium carbonate (1.06 g, 10mmol) were suspended in 5 ml of ethanol and heated to reflux for fourhours. The reaction mixture was then cooled, stirred for two days atambient temperature, and diluted with water. The aqueous solution wasextracted with diethyl ether, and the combined organic layers were driedwith magnesium sulfate. The solvent was removed under vacuum to give0.85 g crude title compound as an oil that was used without furtherpurification.

EXAMPLE 4B methyl4-({[[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl](2-morpholin-4-ylethyl)amino]carbonyl}amino)-1H-indazole-1-carboxylateStep A

The product of Example 56C (1.9 g, 10 mmol) and disuccinimidylcarbonate(2.8 g, 11 mmol) in acetonitrile (100 mL) was stirred for 48 hours undernitrogen atmosphere. The solid was isolated by filtration, washed withacetonitrile (10 mL) and dried under vacuum at ambient temperature togive an off-white solid (2.56 g, 77%).

Step B:

Example 4A (0.85 g 2.8 mmol) and intermediate from Step A of Example 4B(0.66 g, 2 mmol) were dissolved in 5 ml dimethylformamide, anddiisopropylethylamine (0.39 g, 0.52 ml, 3 mmol). The reaction wasstirred at ambient temperature for 16 hours, then diluted with water andfiltered. The solid collected was purified via flash chromatographyusing a gradient of 35% to 50% ethyl acetate in hexanes. Afterevaporation of solvent, the purified product was further dried by theaddition of toluene followed by evaporation under vacuum, giving 0.70 gof title compound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 8.27 (s, 1H), 7.83(d, J=8.48 Hz, 1H), 7.55 (t, J=8.14 Hz, 1H), 7.37 (d, J=7.46 Hz, 1H),7.11-7.33 (m, 4H), 5.76 (t, J=7.97 Hz, 1H), 4.04 (s, 3H),3.47-3.51 (m,4H), 3.11-3.42 (m, 4H), 2.96-3.02 (m, 1H), 2.71-2.89 (m, 1H), 2.33-2.47(m, 5H), 2.30 (s, toluene, 1.2H), 1.89-2.14 (m, 1H), 1.29 (s, 9H). MS(ESI) m/e 520 (M+H)⁺. Calcd. For C₂₉H₃₇N₅O4.0.4toluene.0.3H₂O: C, 67.97;H, 7.32; N, 12.46; Found C, 68.07; H, 7.05; N, 12.41.

EXAMPLE 5N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-yl-N-(2-morpholin-4-ylethyl)urea

Example 4B (0.49 g, 0.94 mmol) was dissolved in a minimum amount ofmethanol. 1 ml of 5M sodium hydroxide in methanol was added, and thereaction stirred at ambient temperature for one hour. The reactionmixture was then diluted with water, and the product collected byfiltration. Tituration with diethyl ether followed by drying undervacuum gave 0.35 g of the title compound. ¹H NMR (300 MHz, DMSO-d₆) δppm 12.94 (s, 1H), 9.38 (s, 1H), 7.80 (s, 1H), 6.83-7.53 (m, 6H), 5.73(t, J=7.97 Hz, 1H), 3.48-3.51 (m, 4H), 3.38-3.48 (m, 1H), 3.18-3.24 (m,1H), 2.96-3.01 (m, 1H), 2.80-2.86 (m, 1H), 2.40-2.56(m, 7H), 1.96-2.03(m, 1H), 1.30 (s, 9H). MS (ESI) m/e 462 (M+H)⁺. Calcd. ForC₂₇H₃₅N₅O₂.0.3tetrahydrofuran.0.1H₂O: C, 69.74; H, 7.93; N, 14.42; FoundC, 69.70; H, 7.73; N, 14.30.

EXAMPLE 6N-{1-[(benzyloxy)acetyl]-1H-indazol-4-yl}-N′-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]urea

To a solution of compound from Example 56J (1.05 g, 3 mmol) in 10 mlpyridine and 1.5 ml triethylamine was added benzyloxy-acetyl chloride (1ml, 1.11 g, 6 mmol). The reaction was stirred at ambient temperature forthree days and the solvent was removed under reduced pressure. Theresidue was dissolved in ethyl acetate, washed with water, the organiclayer dried with magnesium sulfate, and the solvent removed underreduced pressure. The residue was purified by chromatography on silicagel, using 2% methanol in methylene chloride, then titurated with 1:1ether:hexanes, to give 1.19 g of the title compound. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 8.86 (s, 1H), 8.39 (s, 1H), 7.86-7.94 (m, 2H), 7.54 (t,J=8.14 Hz, 1H), 7.30-7.45 (m, 6H), 7.27 (s, 2H), 6.70 (d, J=7.80 Hz,1H), 5.16 (m, 1H), 5.02 (s, 2H), 4.71 (s, 2H), 2.91-3.01 (m, 1H),2.77-2.88 (m, 1H), 2.41-2.49 (m, 1H), 1.85 (dd, J=12.55, 7.80 Hz, 1H),1.28 (s, 9H). MS (ESI) m/e 497 (M+H)⁺. Calcd. For C₃₀H₃₂N₄O₃: C, 72.56;H, 6.49; N, 11.28; Found C, 72.42; H, 6.52; N, 11.02.

EXAMPLE 7N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(methoxyacetyl)-1H-indazol-4-yl]urea

The title compound was prepared using the procedure as described inExample 6, substituting methyloxy-acetyl chloride for benzyloxy-acetylchloride. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 8.86 (s, 1H), 8.40 (s, 1H),7.88 (dd, J=10.51, 8.14 Hz, 2H), 7.53 (t, J=8.14 Hz, 1H), 7.24-7.32 (m,3H), 6.70 (d, J=7.80 Hz, 1H), 5.16 (q, J=7.23 Hz, 1H), 4.90 (s, 2H),3.45 (s, 3H), 2.96 (m, 1H), 2.82 (m, 1H), 2.41-2.48 (m, 1H), 1.79-1.91(m, 1H), 1.28 (s, 9H). MS (ESI) m/e 421 (M+H)⁺. Calcd. ForC₂₄H₂₈N₄O₃.0.2H₂O: C, 67.97; H, 6.75; N, 13.21; Found C, 68.03; H, 6.68;N, 13.13.

EXAMPLE 84-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-4-oxobutanoicacid

To a solution of Example 56J (2.09 g, 6 mmol) in 50 ml tetrahydrofuranand 6 ml triethylamine was added succinic anyhdride (1.20 g 12 mmol).The reaction was stirred 7 days at ambient temperature, then dilutedwith water and ethyl acetate, made acidic with 1N aqueous HCl, andextracted with ethyl acetate. The combined organic layers were driedwith magnesium sulfate and the solvent removed under reduced pressure togive 2.95 g of the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 12.21(s, 1H), 8.87 (s, 1H), 8.42 (s, 1H), 7.88 (m, 2H), 7.50 (t, J=8.14 Hz,1H), 7.04-7.37 (m, 3H), 6.72 (d, J=7.80 Hz, 1H), 5.17 (m, 1H), 4.03 (q,Ethyl acetate), 3.37-3.42 (m, 2H), 2.89-3.06 (m, 1H), 2.75-2.89 (m, 1H),2.67-2.71 (m, 2H), 2.33-2.46 (m, 1H), 1.99 (t, Ethyl acetate), 1.67-1.95(m, 1H), 1.28 (s, 9H), 1.17 (t, Ethyl acetate). MS (ESI) m/e 449 (M+H)⁺.Calcd. For C₂₅H₂₈N₄O₄.0.4ethyl acetate.1.2H₂O: C, 63.22; H, 6.70; N,11.09; Found C, 63.06; H, 6.26; N, 10.94.

EXAMPLE 9N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea,trifluoroacetic acid salt

To a solution of Example 56J (3.48 g, 10 mmol) in 33 ml pyridine and 10ml triethylamine was added dimethylamino-acetyl chloride hydrochloride(4.74 g, 30 mmol). The reaction was stirred at ambient temperature fortwo days and the solvent was removed under reduced pressure. The residuewas dissolved in ethyl acetate, washed with water and saturated aqueoussodium bicarbonate, the organic layer dried with magnesium sulfate, andthe solvent removed under reduced pressure. The crude product obtainedwas purified using reverse-phase HPLC (acetonitrile-water with 0.1%trifluoroacetic acid as eleuent) to give the title compound. ¹H NMR (300MHz, DMSO-d₆) δ ppm 8.98 (s, 1H), 8.54 (s, 1H), 7.85-7.92 (m, 2H), 7.60(t, J=8.14 Hz, 1H), 7.26-7.33 (m, 3H), 6.75 (d, J=7.80 Hz, 1H), 5.17 (m,1H), 4.99 (s, 2H), 3.23-3.37 (s, 1H, under H₂O), 2.96 (s, 6H), 2.91-3.01(m, 1H), 2.77-2.88 (m, 1H), 1.82-1.91 (m, 1H), 1.28 (s, 9H). MS (ESI)m/e 434 (M+14)⁺. Calcd. For C₂₅H₃₁N₅O₂.1.2trifluoroacetic acid: C,57.70; H 5.69; N, 12.28; Found C, 57.63; H, 5.51; N, 12.27.

EXAMPLE 10N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-(1-glycoloyl-1H-indazol-4-yl)urea

Example 6 (1.06 g, 2.1 mmol) was dissolved in 10 ml tetrahydrofuran andwas then subjected to hydrogenolysis over palladium hydroxide (1.10 g of20% Pd(OH)₂ on carbon, wet). The reaction was stirred at ambienttemperature for 16 hours under a 50 psi hydrogen atmosphere. Filtrationand removal of solvent under vacuum gave 0.54 g of title compound. ¹HNMR (300 MHz, DMSO-d₆) δ ppm 8.85 (s, 1H), 8.39 (s, 1H), 7.88 (t, J=7.80Hz, 2H), 7.52 (t, J=8.14 Hz, 1H), 7.25-7.37 (m, 3H), 6.70 (d, J=7.80 Hz,1H), 5.43 (t, J=6.44 Hz, 1H), 5.16 (q, J=7.35 Hz, 1H), 4.87 (d, J=6.44Hz, 2H), 2.66-3.07 (m, 2H), 2.35-2.48 (m, 1H), 1.78-1.94 (m, 1H),1.22-1.32 (m, 9H). MS (ESI) m/e 407 (M+H)⁺

EXAMPLE 11N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-yl-N-(2-piperidin-1-ylethyl)ureaEXAMPLE 11A ((R)-5-tert-Butyl-indan-1-yl)-(2-piperidin-1-yl-ethyl)-amine

The title compound was prepared using the procedure as described inExample 4A, substituting 1-(2-chloro-ethyl)-piperidine hydrochloride for4-(2-chloro-ethyl)-morpholine hydrochloride. The crude compound was usedwithout further purification.

EXAMPLE 11B methyl4-({[[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl](2-piperidin-1-ylethyl)amino]carbonyl}amino)-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 4B, substituting Example 11A for Example 4A. The crude productwas purified using reverse-phase HPLC (acetonitrile-water with 0.1%trifluoroacetic acid as eleuent) to give 0.32 g of the desired compound.¹H NMR (300 MHz, DMSO-d₆) δ ppm 9.16 (s, 1H), 8.97 (s, 1H), 8.34 (s,1H), 7.86 (d, J=8.48 Hz, 1H), 7.46-7.65 (m, 1H), 7.30-7.42 (m, 2H), 7.23(d, J=7.80 Hz, 1H), 5.73 (t, J=7.80 Hz, 1H), 4.04 (s, 3H), 2.65-3.89 (m,11H), 2.49-2.65 (m, 1H), 1.30-1.89 (m, 6H), 1.30 (s, 9H). MS (ESI) m/e518 (M+H)⁺.

EXAMPLE 11CN-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-yl-N-(2-piperidin-1-ylethyl)urea

The title compound was prepared using the procedure as described inExample 5, substituting Example 11B for Example 4B. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 12.89 (br s, 1H), 10.06 (br s, 1H), 7.86 (s, 1H),7.03-7.41 (m, 6H), 5.77 (t, J=7.97 Hz, 1H), 3.25-3.44 (m, 2H), 3.06-3.22(m, 1H), 2.89-3.05 (m, 1H), 2.69-2.89 (m, 1H), 2.32-2.48 (m, 6H),1.83-2.06 (m, 1H), 1.30-1.57 (m, 6H), 1.29 (s, 9H). MS (ESI) m/e 460(M+H)⁺. Calcd. For C₂₈H₃₇N₅O.0.1H₂O.0.33NaCl: C, 69.96; H, 7.80; N,14.57; Found C, 69.90; H, 7.80; N, 14.37.

EXAMPLE 125-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-5-oxopentanoicacid

To a solution of Example 56J (0.52 g, 1.5 mmol) in 7 ml tetrahydrofuranand 1.5 ml triethylamine was added glutaric anyhdride (0.34 g 3 mmol).The reaction was stirred 5 days at ambient temperature, then was dilutedwith water and ethyl acetate, made acidic with IN aqueous HCl, andextracted with ethyl acetate. The combined organic layers were driedwith magnesium sulfate and the solvent removed under reduced pressure.The residue was found to contain a large amount of glutaric acid, whichwas removed by tituration with water to give 0.61 g of the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 12.10 (br s, 1H), 8.85 (s,1H), 8.39 (s, 1H), 7.90 (d, J=4.75 Hz, 1H), 7.87 (d, J=5.42 Hz, 1H),7.50 (t, J=8.14 Hz, 1H), 7.23-7.35 (m, 2H), 6.71 (d, J=8.14 Hz, 1H),5.09-5.27 (m, 1H), 3.15-3.27 (t, J=7.46 Hz, 2H), 2.89-3.06 (m, 1H),2.73-2.89 (m, 1H), 2.41-2.48 (m, 1H), 2.37 (t, J=7.29 Hz, 2H), 1.88-2.00(m, 2H), 1.77-1.89 (m, 1H), 1.28 (s, 9H). MS (ESI) m/e 463 (M+H)⁺.Calcd. For C₂₆H₃₀N₄O₄.0.4H₂O: C, 66.48; H, 6.61; N, 11.93; Found C,66.43; H, 6.38; N, 11.82.

EXAMPLE 13 2-(phosphonooxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

To Example 14D (0.37 g, 0.6 mmol) in a 250 ml round bottom flask wasadded acetonitrile (40 ml) and 0.1% trifluoroacetic acid in water (40ml) and the reaction was stirred at room temperature for 4 days. Every24 hours 0.5 ml of trifluoroacetic acid was added. After four days, thereaction was concentrated to give a white powder in 84% yield. ¹H NMR(DMSO-d₆, 300 MHz); δ 1.28 (s, 9H), 1.74-1.91 (m, 2H), 2.41-2.54 (m,1H), 2.77-3.38 (m, 2H), 4.18-4.23 (m, 2H), 4.60-4.63 (m, 2H), 5.13-5.20(m, 1H), 6.68 (d, J=7.8 Hz, 1H), 7.24-7.28 (m, 2H), 7.50 (t, J=8.41,16.18 Hz, 1H), 7.71 (d, J=8.48 Hz, 1H), 7.90 (d, J=8.27 Hz, 1H), 8.41(s, 1H), 8.84 (s, 1H). MS (DCl/NH₃) m/z 517; Calc for C₂₄H₂₉N₄O₇P: C,55.04; H, 5.74; N, 10.70. Found: C, 55.18; H, 5.50; N, 10.52.

EXAMPLE 14 2-[(di-tert-butoxyphosphoryl)oxy]ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 14A Carbonic acid 2-benzyloxy-ethyl ester 4-nitro-phenyl ester

To a 250 ml round bottom flask was added 2-benzyloxyethanol (7.54 g,49.60 mmol) (Aldrich), 4-nitrophenyl chloroformate (10 g, 49.60 mmol)(Aldrich), dichloromethane (100 ml) followed by the addition of pyridine(5.89 g, 79.10 mmol) and the reaction was stirred at room temperaturefor 12 hours. The reaction was diluted with 200 ml of dichloromethanewas washed with 1N HCl (100 ml), sat NaHCO₃ (100 ml), dried (Na₂SO₄) andconcentrated in vacuo. The reaction was purified on SiO₂ and eluted withhexane/ethyl acetate 4/1 to provide a yellow solid (11.20 g) in 71%yield. ¹H NMR (CDCl₃, 300 MHz); δ ppm 3.70-3.80 (m, 2H), 4.30-4.57 (m,2H), 4.61 (s, 2H), 7.26-7.40 (m, 7H), 8.26 (d, J=8.82 Hz, 2H); DCl/NH₃m/z 318.00.

EXAMPLE 14B 2-(benzyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

To a 250 ml round bottom flask was added Example 56J (5.0 g, 14.40mmol), anhydrous N,N-dimethylformamide (40 ml) and 1M in tetrahydrofuranpotassium tert-butoxide (17.30 ml) and the reaction was stirred at roomtemperature for 1 hour. To the reaction mixture was added Example 14A(5.50 g, 17.70 mmol) at 0° C. and the reaction was stirred for 12 hourswhile allowing to warm to room temperature. The reaction was poured intoa separatory funnel and extracted with ethyl acetate (200 ml) and washedwith H₂O (100 ml), brine (100 ml), dried (Na₂SO₄) and concentrated invacuo. The mixture was purified on SiO₂ eluting with hexane/ethylacetate 1/1 to provide a white solid (6.78 g) in 74% yield. ¹H NMR(DMSO-d₆, 300 MHz); δ ppm 1.27 (s, 9H), 1.74-1.84 (m, 1H), 2.50-2.60 (m,1H), 2.73-2.93 (m, 3H), 3.61 (t, J=4.41, 9.16 Hz, 2H), 3.75-3.82 (m,4H), 5.35-5.37 (m, 1H), 7.13-7.38 (m, 7H), 7.70-7.73 (m, 2H), 7.90-7.94(m, 1H), 8.32 (s, 1H); MS (DCl/NH₃) m/z 527.00.

EXAMPLE 14C 2-hydroxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

In a 250 ml Parr shaker flask was added Example 14B (6.0 g, 11.40 mmol),20% Pd/C, and ethanol (100 ml). The vessel was pressurized to 60 psiwith H₂ gas and shaken at room temperature for 6 hours. The reaction wasfilter and concentrated in vacuo. The material was purified on SiO₂ withdichloromethane/CH₃OH (98/2) to give a white solid (4.18 g) in 84%. ¹HNMR (DMSO-d₆, 300 MHz); δ ppm 1.32 (s, 9H), 1.86-1.93 (m, 2H), 2.57-2.63(m, 1H), 2.84-2.92 (m, 1H), 2.96-3.01 (m, 1H), 3.92-3.95 (m, 2H),4.55-4.58 (m, 2H), 5.27-5.32 (t, J=7.12, 14.58, 1H), 7.28-7.31 (m, 2H),7.52 (t, J=7.80, 16.28, 1H), 7.73 (d, J=7.72 Hz, 1H), 7.87 (d, J=8.48Hz, 1H), 8.38 (s, 1H); MS (DCI/NH₃) m/z 437.00.

EXAMPLE 14D 2-[(di-tert-butoxyphosphoryl)oxy]ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

To Example 14C (1.60 g, 3.70 mmol) was added methylene chloride (25 ml),tetrahydrofuran (25 ml), tetrazole (0.77 g, 11.0 mmol),4-(dimethylamino)pyridine (0.18 g, 1.50 mmol) and di-tert-butyldiisopropyl-phosphoramidite (2.04 g, 7.30 mmol) (Aldrich) and thereaction was stirred at room temperature for 2 hours. The reaction wasthen cooled to 0° C. and 30% hydrogen peroxide was added and the mixturewas stirred for 2 hours at room temperature. The reaction was pouredinto a separatory funnel and washed with water, sat NaHCO₃, dried overNa₂SO₄ and concentrated in vacuo. The mixture was purified by HPLC withacetonitrile and 0.1% trifluoroacetic acid buffer to give a white solidin 48% yield. ¹H NMR (CD₃OD, 300 MHz); δ ppm 1.32 (s, 9H), 1.45 (s,18H),1.83-1.95 (m,2H), 2.52.66 (m, 1H), 2.82-2.90 (m, 1H), 3.92-3.06 (m, 1H),4.35-4.40 (m, 2H), 4.73-4.84 (m, 2H), 5.29 (t, J=7.26, 14.68 Hz, 1H),7.28-7.31 (m, 2H), 7.52 (t, J=8.13, 16.27 Hz, 1H), 7.54 (d, J=8.14 Hz,1H), 7.76 (d, J=7.80 Hz, 1H), 8.37 (s, 1H); MS (DCUNH₃) m/z 629.00; Calcfor C₃₂H₂₄₅N₄O₇P: C, 60.44; H, 7.26; N, 8.81. Found: C, 60.45; H, 7.26;N, 8.68.

EXAMPLE 15 3-(phosphonooxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 15A Carbonic acid 3-benzyloxy-propyl ester 4-nitro-phenyl ester

To a 250 ml round bottom flask was added 3-benzyloxypropanol (8.24 g,49.60 mmol) (Aldrich), 4-nitrophenyl chloroformate (10 g, 49.60 mmol)(Aldrich), dichloromethane (100 ml) followed by the addition of pyridine(5.89 g, 79.10 mmol) and the reaction was stirred at room temperaturefor 12 hours. The reaction was diluted with 200 ml of dichloromethanewas washed with 1N HCl (100 ml), sat NaHCO₃ (100 ml), dried (Na₂SO₄) andconcentrated in vacuo. The reaction was purified on SiO₂ and eluted withhexane/ethyl acetate 4/1 to provide a yellow oil (8.26) in 50% yield. ¹HNMR (CDCl₃, 300 MHz); δ ppm 2.03-2.11 (m, 2H), 3.62 (t, J=6.0, 12.0 Hz,2H), 4.43 (t, J=6.0, 12.0 Hz, 2H), 4.53 (s, 2H), 7.26-7.37 (m, 7H),8.26(d, J=9.0 Hz, 2H); MS (DCl/NH₃) m/z 332.0.

EXAMPLE 15B 3-(benzyloxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

To a 250 ml round bottom flask was added Example 56J (7.35 g, 21.10mmol), anhydrous N,N-dimethylformamide (60 ml) and potassiumtert-butoxide (1M in tetrahydrofuran, 25.32 ml) and the reaction mixturewas stirred at room temperature for 1 hour. To the reaction mixture wasadded Example 15A (7.0 g, 21.10 mmol) at 0° C., stirred for 12 hourswhile allowing to warm to room temperature. The reaction mixture waspoured into a separatory funnel and extracted with ethyl acetate (500ml) and washed with H₂O (200 ml), brine (200 ml), dried (Na₂SO₄) andconcentrated in vacuo. The mixture was purified on silica gel and elutedwith hexane/ethyl acetate 1/1 to provide a white solid (4.96 g) in 43%yield. ¹H NMR (CDCl₃, 300 MHz); δ 1.27 (s, 9H), 1.72-1.87 (m, 1H),2.07-2.21 (m, 2H), 2.51-2.61 (m, 1H), 2.73-2.94 (m, 3H), 3.64 (t,J=5.77, 16.95 Hz, 2H), 4.49-4.68 (m, 4H), 5.34-5.39 (m, 1H), 7.13-7.38(m, 7H), 7.70-7.73 (m, 2H), 7.90-7.94 (m, 1H), 8.32 (s, 1H). DCI/NH₃ m/z540.00.

EXAMPLE 15C 3-hydroxypropyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

In a 250 ml Parr shaker flask was added product of Example 15B (2.2 g,4.10 mmol), 20% Pd/C and ethanol (100 ml). The vessel was pressurized to60 psi with H₂ gas and shaken at room temperature for 6 hours. Thereaction was filtered and concentrated in vacuo. The material waspurified on SiO₂ with dichloromethane/CH₃OH (98/2) to give a white solid(1.57 g) in 85%. ¹H NMR (CDCl₃, 300 MHz); δ ppm 1.28 (s, 9H), 1.81-2.08(m, 2H), 2.41-2.52 (m, 3H), 2.77-2.87 (m, 1H), 2.91-3.01 (m, 1H),3.55-3.68 (m, 2H), 4.49 (t, J=4.43, 11.82 Hz, 2H),5.13-5.20 (m, 1H),7.22-7.27 (m, 2H), 7.50 (t, J=8.14, 16.28 Hz, 1H),6.67 (d, J=9.13 Hz,1H), 7.89 (d, J=8.14 Hz, 1H), 8.39 (s, 1H); MS (DCl/NH₃) m/z 451.00.

EXAMPLE 15D 3-[(di-tert-butoxyphosphoryl)oxy]propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

To the product from Example 15C (1.49 g, 330 mmol) was added methylenechloride (50 ml), tetrazole (0.70 g, 9.90 mmol),4-(dimethylamino)pyridine (0.16 g, 1.30 mmol) and di-tert-butyldiisopropyl-phosphoramidite (3.15 g, 9.90 mmol) (Aldrich) and thereaction was stirred at room temperature for 2 hours. The reaction wasthen cooled to 0° C. and 30% hydrogen peroxide was added and the mixturewas stirred for 2 hours at room temperature. The reaction was pouredinto a seperatory funnel and washed with water, sat NaHCO₃, dried overNa₂SO₄ and concentrated in vacuo. The mixture was purified on SiO₂ withhexane/ethyl acetate (1/1) to give a white solid (2.12 g) in 97% yield.¹H NMR (CDCl₃, 300 MHz); δ ppm 1.22 (s, 9H), 1.30(s, 18H), 2.17-2.27 (m,1H), 2.58-2.65 (m,1H), 2.81-2.94 (m, 1H), 3.20-3.51 (m, 2H), 3.72-3.78(m, 2H), 4.12-4.18 (m, 2H), 4.59 (t, J=6,78, 13.22, 2H), 5.42 (t,J=7.46, 12.24 Hz, 1H), 7.19-7.32 (m, 2H), 7.45 (t, J=8.14, 16.24 Hz,1H), 7.76 (d, J=8.48 Hz, 1H), 7.95 (d, J=7.80 Hz, 1H), 8.47 (s, 1H); MS(DCl/NH₃) m/z 642.00.

EXAMPLE 15E 3-(phosphonooxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

To the product from Example 15D (2.12 g, 3.30 mmol) in a 250 ml roundbottom flask was added acetonitrile (40 ml) and 0.1% trifluoroaceticacid in water (40 ml) and the reaction was stirred at room temperaturefor 4 days. Every 24 hours 0.5 ml of trifluoroacetic acid was addeduntil day four. The reaction was concentrated to give a white powder in81% yield. ¹H NMR (CDCl₃, 300 MHz); δ ppm 1.32 (s, 9H), 1.88-1.92 (m,1H), 2.22-2.26 (m, 2H), 2.57-2.63 (m, 1H), 2.84-2.90 (m, 1H), 2.96-3.32(m, 1H), 4.21 (m, 2H), 4.65 (t, J=6.11, 12.55 Hz, 2H), 5.29 (t, J=7.46,14.58 Hz, 1H), 7.28-7.31 (m, 3H), 7.52 (t, J=8.14, 16.28 Hz, 1H), 7.73(d, J=7.45 Hz, 1H), 7.83 (d, J=8.48 Hz, 1H), 8.36 (s, 1H); MS (DCl/NH₃)m/z 531.00; Calc for C₂₅H₃₁N₄O₇P: C, 54.45; H, 5.59; N, 9.92. Found: C,54.84; H, 5.88; N, 9.92.

EXAMPLE 16N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N41-(hydroxymethyl)-[1H-indazol-4-yl]urea

To a solution of compound from Example 56J (67 mg, 0.192 mmol) in 4 mLethanol was added 0.5 mL of 37% aqueous formaldehyde solution. Themixture was stirred at room temperature for 3 days, and then wasevaporated in vacuo. The crude product was purified by silica gelchromatography (96:4 dichloromethane:methanol, eluant) to afford a whitesolid, 24 mg (33%). ¹H NMR (d₆-DMSO) δ ppm 8.60 (s, 1H), 8.04 (s, 1H),7.72 (dd; 1H; J=7.2, 0.8 Hz), 7.27 (m, 4H), 6.67 (d, 1H, J=8.0 Hz), 6.64(t, 1H, J=7.5 Hz), 5.66 (d, 2H, J=7.5 Hz), 5.15 (q, 1H, J=7.5 Hz), 2.87(m, 2H), 2.43 (m, 1H), 1.82 (m, 1H), 1.28 (s, 9H); MS (ESI⁺) m/z 379(M+H).

EXAMPLE 17 {4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-ylJam i no}carbonyl)amino]-1H-indazol-1-yl}methyl acetate

The product from Example 16 (50 mg, 0.132 mmol) and acetic anhydride (1mL) were heated for 4 hours at 60°. The mixture was evaporated in vacuoand chromatographed on silica gel (65:35 hexane:ethyl acetate, eluant)to afford the desired product as a white solid, 12 mg (22%). ¹H NMR(d₆-DMSO) δ 8.67 (s, 1H), 8.16 (s, 1H), 7.75 (d, 1H, J=7.5 Hz), 7.27 (m,5H), 6.67 (d, 1H, J=7.8 Hz), 6.34 (s, 2H), 5.15 (q, 1H, J=6.7 Hz), 2.85(m, 2H), 2.42 (m, 1H), 2.02 (s, 3H), 1.85 (m, 1H), 1.28 (s, 9H); MS(ESI⁺) m/z 421 (M+H), 443 (M+Na).

EXAMPLE 18{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}methyl3-hydroxypropanoate EXAMPLE 18A3-{[tert-butyl(diphenyl)silyl]oxy}propan-1-ol

To a solution of 1,3-propanediol (1.25 g, 16.4 mmol) inN,N-dimethylformamide (50 mL) was added imidazole (2.23 g, 32.8 mmol)and tert-butyldiphenylsilyl chloride (4.97 g, 18.1 mmol). The reactionwas stirred for 3 days at room temperature, then was diluted with ethylacetate and was washed with water and brine. Concentration in vacuoafforded the crude product as a thick colorless oil which was useddirectly in the next step.

EXAMPLE 18B 3-{[tert-butyl(diphenyl)silyl]oxy}propanoic acid

Example 18A (˜5.0 g, 16.4 mmol) was dissolved in acetone (700 mL) andthen chilled in ice. Jones reagent (10 mL, prepared by dissolution of26.72 g CrO₃ in 23 mL conc. H₂SO₄ and dilution to 100 mL with H₂O) wasadded slowly. The reaction mixture was stirred in the ice bath for 10minutes, then the acetone was removed in vacuo. Ethyl acetate was added,and this solution was washed several times with H₂O and once with brine.The solution was dried over Na₂SO₄ and was then evaporated in vacuo toafford a crude yellow oil, 5.9 g (quantitative). MS (ESI^(÷)) m/z 351(M+Na); MS (ESI⁻) m/z 327 (M−H).

EXAMPLE 18C chloromethyl 3-{[tert-butyl(diphenyl)silyl]oxy}propanoate

The title compound was prepared from the compound of Example 18B usingthe procedure as described in Synth. Commun. 2003, 33, 1683. ¹H NMR(d₆-DMSO) δ 7.58-7.64 (m, 4H), 7.37-7.48 (m, 6H), 5.88 (s, 2H), 3.80 (t,2H, J=6.1 Hz), 2.68 (t, 2H, J=5.8 Hz), 0.96 (s, 9H).

EXAMPLE 18D{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}methyl3-hydroxypropanoate

To a solution of compound from Example 56J (500 mg, 1.44 mmol) inN,N-dimethylformamide (8 mL) was added 60% NaH (65 mg, 1.63 mmol). Thereaction was stirred at room temperature for 10 minutes and was thentreated with Example 18C (1.35 g, ˜40% pure) in 3 mLN,N-dimethylformamide. The mixture was stirred overnight at 60° C. andwas then evaporated in vacuo. To this crude mixture in tetrahydrofuran(50 mL) in a polyethylene bottle was added hydrogenfluoride-triethylamine complex (3 mL). The reaction was stirred at roomtemperature for 5 hours and was then evaporated in vacuo. Chromatographyon silica gel (97:3 dichloromethane:methanol to 94:6dichloromethane:methanol) afforded the desired product as a white solid.¹H NMR (d₆-DMSO) δ 8.68 (s, 1H), 8.16 (s, 1H), 7.75 (dd; 1H; J=7.5, 1.0Hz), 7.27-7.37 (m, 5H), 6.68 (d, 1H, J=7.8 Hz), 6.35 (s, 2H), 5.15 (q,1H, J=6.9 Hz), 4.69 (t, 1H, J=5.0 Hz), 3.60 (m, 2H), 2.73-3.01 (m, 2H),2.44 (t, 2H, J=6.1 Hz), 1.78-1.92 (m, 2H), 1.28 (s, 9H); MS (ESI⁺) m/z451 (M+H).

EXAMPLE 19 (phosphonooxy)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino}-1H-indazole-1-carboxylateEXAMPLE 19A Thiocarbonic acid O-sec-butyl ester O-chloromethyl ester

Sodium methoxide (11.5 g 0.2 moles) of 95% was added to 200 ml ofmethanol and the solution was cooled to 0° C. Sec-butanethiol (21.4 ml,0.2 mol) was then added dropwise and the solution stirred for 2 hours.The solvent was removed and the residue was evaporated from ether twice.300 ml of diethyl ether was added to the residue and the mixture wascooled to −78° C. Chloromethyl chloroformate (19 ml, 0.2 mol) in 75 mlof ether was added dropwise and the reaction mixture was allowed to warmto room temperature and then stirred for 18 hours. The reaction wasfiltered through celite and washed with ether. The filtrate wasevaporated, resuspended in in ether and filtered through a silica plug,and the solvent was evaporated to give 29 g of a clear liquid. ¹H NMR(300 MHz, CDCl₃) δ ppm 0.94 (t, J=7.29 Hz, 3H) 1.36-1.48 (m, 2H)1.60-1.70 (m, 2H) 2.89-2.95 (m, 2H) 5.76 (s, 2H).

EXAMPLE 19B Thiocarbonic acid O-sec-butyl ester O-iodomethyl ester

Example 19A (6.0 g 33 mmol) in 45 mL of acetone was combined with (9.8 g66 mmol) of sodium iodide and (0.3 g 3.3 mmol) of sodium bicarbonate andheated at 40° C. for 4 hours. 100 ml of diethyl ether was added and themixture was washed with 10% sodium bicarbonate then 1% sodiumthiosulfate until the organic phase was clear. The organic phase wasdried with sodium sulfate and the solvent was evaporated. The residuewas resuspended in pentane and the organic layer was washed with 10%sodium bicarbonate then 1% sodium thiosulfate. The organic phase wasthen dried with magnesium sulfate and the solvent was evaporated to give7.3 g of a clear oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.93 (t, J=7.29 Hz,3H) 1.35-1.48 (m, 2H) 1.58-1.70 (m, 2H) 2.88-2.94 (m, 2H) 5.99 (s, 2H).

EXAMPLE 19CO-({[bis(benzyloxy)phosphoryl]oxy}methyl)O-(sec-butyl)thiocarbonate

The product of Example 19B (7.3 g, 27 mmoles) and tetrabutylammoniumdibenzylphosphate (13.8 g, 26.6 mmol)were mixed in 20 ml oftetrahydrofuran and stirred at room temperature for 24 hours. Themixture was diluted with 100 mL of tetrahydrofuran, filtered throughcelite and the solvent was evaporated. The residue was resuspended in200 mL of 20% ethyl acetate in hexane and the precipitate was filteredand washed with an additional 100 mL of 20% ethyl acetate. The organicfiltrates were combined and the solvent was evaporated. Final productwas obtained by flash chromatography on silica using 20% ethyl acetatein hexane. Fractions containing product were combined and the solventwas removed to give 8.7 g (78%) of a colorless oil. ¹H NMR (300 MHz,CDCl₃) δ ppm 0.91 (t, J=7.29 Hz, 3H) 1.31-1.45 (m, 2H) 1.55-1.65 (m, 2H)2.80-2.90 (m, 2H) 5.07 (d, J=7.80 Hz, 4H) 5.65 (d, J=13.90 Hz, 2H) 7.34(s, 10H).

EXAMPLE 19D O-dibenzylphosphonooxymethyl chloroformate

7.3 g (17 mmol) of the compound from Example 19C was cooled to 4° C. 1.7mL (21 mmol) of sulfuryl chloride was added dropwise. Reaction wasstirred at 4° C. for an additional 20 minutes, the cooling bath wasremoved and the mixture was allowed to stir at room temperature for anadditional 3 hours. Diethyl ether was added and then was evaporatedunder vacuum. The remaining oil was dried under high vacuum for 18 hoursyielding 6.1 g (quantitative) of a colorless oil. ¹H NMR (300 MHz,CDCl₃) δ ppm 5.08 (d, J=8.14 Hz, 4H) 5.62 (d, J=14.24 Hz, 2H) 7.35 (s,10H).

EXAMPLE 19E {[bis(benzyloxy)phosphoryl]oxy}methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

1.6 g (4.6 mmol) of compound from Example 56J in 15 mL oftetrahydrofuran was cooled to −40° C. in an acetonitrile dry ice bath. 1mL (9.1 mmol) of 4-methylmorpholine was added, then 4.1 g (11 mmol) ofcompound from Example 19D was added dropwise. The reaction was stirredat −40° C. for 20 minutes then the ice bath removed and the reactionallowed to warm to room temperature. The mixture was diluted with 200 mLof diethyl ether, extracted 4 times with 25 mL of water, dried overmagnesium sulfate, 2 mL of dimethylformamide was added and the etherremoved by rotory evaporation leaving a clear oil which was purified byreverse phase HPLC with 0.1% trifluoroacetic acid in water andacetonitrile as mobile phases to provide 1.3 g of a white powder. ¹H NMR(400 MHz, DMSO-d₆) δ ppm 1.31 (s, 9H) 1.88-1.98 (m, 1H) 2.48-2.57 (m,1H) 2.87 (m, 1H) 2.97-3.05 (m, 1H) 5.16 (d, J=7.98 Hz, 4H) 5.26 (q,J=7.06 Hz, 1H) 6.05 (d, J=14.73 Hz, 2H) 6.79 (d, J=7.67 Hz, 1H)7.29-7.39 (m, 13H) 7.55 (t, J=8.13 Hz, 1H) 7.74 (d, J=8.29 Hz, 1H) 8.01(d, J=7.98 Hz, 1H) 8.53 (s, 1H) 8.97 (s, 1H). MS(ESI) m/z 683.3 (M+H)⁺.

EXAMPLE 19F (phosphonooxy)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

1.3 g (1.9 mmol) of Example 19E in 150 mL of tetrahydrofuran was addedto 0.7 g of 20% Pd(OH)₂ on carbon, wet, under argon. The vessel wascharged to 60 psi with hydrogen and reacted for 3.2 hours with shaking.The catalyst was removed by filtration and the solvent removed. Thecompound was purified by reverse phase HPLC with 0.1% trifluoroaceticacid in water and acetonitrile as mobile phases to obtain 0.3 g of titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.28 (s, 9H) 1.79-1.91 (m, 1H)2.41-2.48 (m, 1H) 2.77-2.88 (m, 1H) 2.91-3.01 (m, 1H) 5.16 (q, J=7.35Hz, 1H) 5.84 (d, J=14.24 Hz, 2H) 6.69 (d, .1=7.80 Hz, 1H) 7.25-7.33 (m,3H) 7.52 (t, J=8.14 Hz, 1H) 7.72 (d, J=8.48 Hz, 1H) 7.90 (d, J=7.80 Hz,1H) 8.44 (s, 1H) 8.86 (s, 1H)MS (DCl/NH₃) m/z 503.2 (M +H)⁺.

EXAMPLE 203-{4-[({[(1R)-5-cert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropyldihydrogen phosphate EXAMPLE 20A3-{[bis(benzyloxy)phosphoryl]oxy}propanoic acid

The water was removed in vacuo from 3-hydroxy-propionic acid and theresidue dried twice from toluene. 0.8 g (8.9 mmol), and dissolved in 10mL of dry tetrahydrofuran. 1 ml (9 mmol) of 4-methyl-morpholine wasadded, then 10 mL of a 1 M solution of tert-butyldimethylsilyl chloridein tetrahydrofuran was added and the mixture stirred at room temperaturefor 10 minutes. 5 g (14.5 mmol) of dibenzyl diisopropylphosphoramiditeand 1.2 g (17.1 mmol) of tetrazole was premixed in 20 mL oftetrahydrofuran then added to the reaction mixture and allowed to reactat room temperature for 30 minutes. The mixture was cooled to 0° C. inan ice bath, then 3.5 mls of 35% aqueous hydrogen peroxide was added andthe mixture stirred for 30 minutes. 10 mL of 10% sodium bisulfite wasadded slowly then 200 mL of diethyl ether. The organic phase was washedthree times with 10% potassium dihydrogen phosphate, dried overmagnesium sulfate and the was solvent evaporated. Product was obtainedby flash chromatography of the crude material on silica using hexanesand ethyl acetate (70:30). ¹H NMR (300 MHz, CDCl₃) δ ppm 2.65 (t, J=6.10Hz, 2H) 4.26 (q, J=6.44 Hz, 2H) 5.04 (d, J=8.14 Hz, 4H) 7.33 (s, 10H).MS (ESI) m/z 351.1 (M +H)⁺.

EXAMPLE 20B dibenzyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropylphosphate

1.1 g (3.1 mmol) of Example 20A in 8 mL of dichloromethane and 3.1 mL ofa 1M solution of N,N′-dicyclohexylcarbodiimide in dichloromethane weremixed and 1.0 g (2.9 mmol) of Example 56J in 8 mL of dimethylformamidewas added. The mixture was allowed to react at room temperature for 18hours. 200 mL of diethyl ether was added to the mixture and the organicphase was washed three times with water, dried over magnesium sulfateand the solvent removed. The product was isolated by flashchromatography on silica using hexanes and ethyl acetate (80:20). ¹H NMR(300 MHz, DMSO-d₆) δ ppm 1.28 (s, 9H) 1.79-1.92 (m, 1H) 2.41-2.49 (m,1H) 2.77-2.89 (m, 1H) 2.91-3.02 (m, 1H) 3.56 (t, J=5.93 Hz, 2H)4.39-4.49 (m, 2H) 5.01 (d, J=8.14 Hz, 4H) 5.17 (q, J=7.23 Hz, 1H) 6.70(d, J=7.80 Hz, 1H) 7.25-7.38 (m, 13H) 7.52 (t, J=8.14 Hz, 1H) 7.89 (t,J=8.14 Hz, 2H) 8.41 (s, 1H) 8.85 (s, 1H). MS(ESI) m/z 681.5 (M+H)⁺.

EXAMPLE 20C3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropyldihydrogen phosphate

0.45 g (0.7 mmol) of Example 20B in 100 mL of tetrahydrofuran was addedto 0.7 g of 20% Pd(OH)₂ on carbon, wet, under argon. The vessel wascharged to 60 psi with hydrogen and reacted for 3.2 hours with shaking.The catalyst was removed by filtration and the solvent was evaporated.The compound was purified by reverse phase HPLC with 0.1%trifluoroacetic acid in water and acetonitrile as mobile phases toobtain 0.15 g of title compound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.28(s, 9H) 1.79-1.92 (m, 1H) 2.41-2.49 (m, 1H) 2.76-2.88 (n, 1H) 2.89-3.01(m, 1H) 3.53 (t, J=6.27 Hz, 2H) 4.23-4.32 (m, 2H) 5.17 (q, J=7.12 Hz,1H) 6.71 (d, J=7.80 Hz, 1H) 7.25-7.33 (m, 3H) 7.52 (t, J=8.14 Hz, 1H)7.89 (t, J=7.46 Hz, 2H) 8.42 (d, J=0.68 Hz, 1H) 8.86 (s, 1H). MS(ESI)m/z 501.3 (M+H)⁺.

EXAMPLE 21[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid EXAMPLE 21A Hydroxymethyl-phosphonic acid dibenzyl ester

Charged an Emrys 5 mL process vial with 2.0 g (7.63 mmol) dibenzylphosphite, 229 mg (7.63 mmol) paraformaldehyde powder, and 0.11 mL (0.76mmol) triethylamine. The white mixture was heated in a microwave(Personal Chemistry) at 130° for 5 minutes. The crude oil was purifiedon silica gel, eluting with 50-100% ethyl acetate in hexane to provide947 mg (42% yield) of the title compound, a colorless oil. MS (ESI) m/z:181.1, 293.0 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 3.83 (m, 2H), 5.02 (d, 4H), 5.50(m, 1H), 7.37 (m, 10H).

EXAMPLE 21B (4-Nitro-phenoxycarbonyloxymethyl)-phosphonic acid dibenzylester

Charged a round bottom flask with 20 mL dichloroethane, 947 mg (3.24mmol) of Example 21A, 718 mg (3.56 mmol) 4-nitrophenyl chloroformate,and 0.31 mL (3.89 mmol) pyridine. The reaction mixture was stirred at 0°C. for 40 minutes, treated with 50 mL ethyl acetate, filtered through asilica gel plug, rinsed with ethyl acetate, and concentrated. The crudeoil was purified on silica gel with 30-70% ethyl acetate in hexane toprovide 1.429 g (97% yield) of the title compound. MS (ESI) m/z: 181.0,351.1, 458.1 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 4.71 (d, 2H), 5.11 (d, 4H), 7.39(m, 10H), 7.48 (d, 2H), 8.29 (d, 2H).

EXAMPLE 21C [bis(benzyloxy)phosphoryl]methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

Dissolved 990 mg (2.84 mmol) of Example 56J in 10 mLN,N-dimethylformamide solution, added 3.12 mL (3.12 mmol) 1.0M potassiumtert-butoxide in tetrahydrofuran, stirred for 5 minutes at ambienttemperature, then added 1.429 g (3.12 mmol) of Example 21B in 10 mLN,N-dimethylformamide. After 15 minutes, the solution was partitionedbetween 200 mL ethyl acetate and 200 mL H₂O, dried the organic layerwith brine and Na₂SO₄, and concentrated. The crude oil was purified onsilica gel, eluting with 50-100% ethyl acetate in hexane to obtain 1.622g (86%) of title compound as yellow foam. MS (ESI) m/z: 349.1, 667.30[M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.79-1.91 (m, 1H), 2.41-2.47(m, 1H), 2.79-2.87 (m, 1H), 2.91-3.01 (m, 1H), 4.94 (d, 2H), 5.11-5.23(m, 5H), 6.70 (d, 1H), 7.27 (s, 2H), 7.29-7.41 (m, 11H), 7.45 (t, 1H),7.62 (d, 1H), 7.89 (d, 1H), 8.44 (s, 1H), 8.86 (s, 1H).

EXAMPLE 21D[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid

1.5 g (2.25 mmol) of the compound from Example 21C was added to amixture of 0.3 g 20% Pd(OH)₂/C and 150 mL methanol in a stainless steelautoclave. The reactor was sealed and flushed with nitrogen, and then itwas pressurized with hydrogen (60 psi). The mixture was stirred atambient temperature for 90 minutes. Product precipitated, added 150 mLtetrahydrofuran to redissolve, catalyst was filtered off, washed withmethanol and tetrahydrofuran, and the filtrate was concentrated toprovide 1.08 g (99%) of the title compound. MS (ESI) m/z: 485.21 [M−H]⁻¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.81-1.88 (m, 1H), 2.42-2.48 (m, 1H),2.79-2.87 (m, 1H), 2.91-3.01 (m, 1H), 4.56 (d, 2H), 5.16 (q, 1H), 6.69(d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.50 (t, 1H), 7.72 (d, 1H), 7.89(d, 1H), 8.43 (s, 1H), 8.85 (s, 1H).

EXAMPLE 22[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino}-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid triethylamine salt

Suspended 50.2 mg (103 μmol) of compound from Example 21D in 10 mLmethanol, added 10.4 mg (103 μmol) triethylamine, stirred the colorlesssolution for 10 minutes at ambient temperature, concentrated and vacuumdried. Obtained 61 mg (100% yield) of the title compound as an off-whitepowder. ¹H NMR (methanol-d₄) δ: 1.29 (t, 9H), 1.32 (s, 9H), 1.90 (m,1H), 2.59 (m, 1H), 2.89 (m, 1H), 3.00 (m, 1H), 3.16 (q, 6H), 4.54 (d,2H), 5.29 (t, 1H), 7.28 (s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.74 (d,1H), 7.97 (d, 1H), 8.36 (s, 1H). Anal Calcd for C₂₃H₂₇N₄O₆P.1.0triethylamine.0.7 methanol: C, 58.47; H, 7.40; N, 11.48. Found: C,58.46; H, 7.38; N, 11.44.

EXAMPLE 23 2-methoxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting methoxyethoxychloroformate for Example 21B. MS(ESI) m/z: 450.78 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H),2.48 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 3.33 (S, 3H), 332 (m, 2H),4.57 (m, 2H), 5.15 (q, 1H), 6.67 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H),7.50 (t, 1H), 7.67 (d, 1H), 7.88 (d, 1H), 8.40 (s, 1H), 8.84 (s, 1H).Anal Calcd for C₂₅H₃₀N₄O₄: C, 66.65; H, 6.71; N, 12.44. Found: C, 66.22;H, 6.75; N, 12.25.

EXAMPLE 24 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 24A Carbonic acid 2,2-dimethyl[1,3]dioxolane-4-ylmethyl ester2,5-dioxo-pyrrolidin-1-yl ester

To a solution of (2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol (0.4 g, 3.0mmol) in acetonitrile (10 mL) was added carbonic acidbis-(2,5-dioxo-pyrrolidin-1-yl) ester (1.15 g, 4.5 mmol) andtriethylamine (0.84 mL, 6.0 mmol). After stirring at ambient temperaturefor 10 min, the mixture was concentrated at reduced pressure, sat.NaHCO₃ (50 mL) was added, and the solution was extracted with ethylacetate and organic phase was separated and concentrated to obtain 1.0 gof crude product that was used without further purification in the nextstep. MS (APCI) m/z: 273 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 4.50 (m, 1H),4.40-4.29 (m, 2H), 4.04 (m, 1H), 3.73 (dd, J=6.0 and 9.0 Hz, 1H), 2.80(s, 4H), 1.35 (s, 3H), 1.30 (s, 3H).

EXAMPLE 24B (2,2-dimethyl-1,3-dioxolan-4-yl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 24A for Example 21B. MS (ESI) m/z:507.14 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.30 (s, 3H), 1.35 (s,3H), 1.86 (m, 1H), 2.48 (m, 1H), 2.85 (m, 1), 2.96 (m, 1H), 3.84 (dd,1H), 4.10 (dd, 1H), 4.45 (m, 3H), 5.15 (q, 1H), 6.67 (d, 1H), 7.27 (s,2H), 7.31 (s, 1H), 7.50 (t, 1H), 7.69 (d, 1H), 7.88 (d, 1H), 8.40 (s,1H), 8.83 (s, 1H). Anal Calcd for C₂₈H₃₄N₄O₅.1.4H₂O: C, 63.24; H, 6.97;N, 10.53. Found: C, 63.16; H, 6.60; N, 10.90.

EXAMPLE 25 (2-oxo-1,3-dioxolan-4-yl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 25A Carbonic acid 2,5-dioxo-pyrrolidin-1-yl ester2-oxo-[1,3]dioxolan-4-ylmethyl ester

The title compound was prepared using the procedure as described inExample 24A, substituting 4-hydroxymethyl41,3]dioxolan-2-one for(2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol. MS (APCI) m/z: 259 [M+H]⁺ ¹HNMR (DMSO-d₆) δ: 5.13 (m, 1H), 4.61 (m, 3H), 4.31 (dd, J=6.0 and 9.0 Hz,1H), 2.80 (s, 4H).

EXAMPLE 25B (2-oxo-1,3-dioxolan-4-yl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}lcarbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 25A for Example 21B. MS (ESI) m/z:492.93 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H), 2.48 (m,1H), 2.85 (m, 1H), 2.96 (m, 1H), 4.44 (dd, 1H), 4.66 (m, 3H), 5.15 (q,1H), 5.24 (m, 1H), 6.68 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.51 (t,1H), 7.64 (d, 1H), 7.89 (d, 1H), 8.42 (s, 1H), 8.85 (s, 1H). Anal Calcdfor C₂₆H₂₈N₄O₆.0.8H₂O: C, 61.60; H, 5.89; N, 11.05. Found: C, 61.62; H,5.66; N, 11.07.

EXAMPLE 26 2-hydroxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 26A 2-(benzyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting benzyloxyethoxychloroformate for Example 21BMS (ESI) m/z: 525 [M-H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H),2.44 (m, 1H), 2.82 (m, 1H), 2.95 (m, 1H), 3.82 (m, 2H), 4.61 (m, 2H),4.96 (s, 1H), 5.15 (m, 1H), 6.67 (d, J=4.5 Hz,1H), 7.38-7.25 (m, 9H),7.48 (t, J=4.5 Hz, 1H), 7.70 (d, J=6.0 Hz, 1H), 7.90 (d, J=6.0 Hz, 1H),8.40 (s, 1H), 8.84 (s, 1H).

EXAMPLE 26B 2-hydroxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

Example 26A (0.41 g, 0.77 mmol) and 20% Pd(OH)₂/C (0.42 g, 0.6 mmol) inethyl acetate (10 mL) was hydrogenated at ambient temperature at 50 psifor 2 hours. The resulting mixture was filtered through a nylon filterand concentrated to obtain the title compound (0.29 g, 86%). MS (ESI)m/z: 437.0 [M+H]⁺ ¹HNMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H), 2.48(m, 1H), 2.85 (m, 1H), 2.95 (m, 1H), 3.82 (q, 2H), 4.46 (dd, 2H), 5.00(t, 1H), 5.15 (q, 1H), 6.67 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.49(t, 1H), 7.69 (d, 1H), 7.87 (d, 1H), 8.40 (s, 1H), 8.84 (s, 1H). AnalCalcd for C₂₄H₂₈N₄O₄: C, 66.04; H, 6.47; N, 12.84. Found: C, 65.63; H,6.54; N, 11.94.

EXAMPLE 27 2-(benzyloxy)-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 27A (2,5-Dioxo-pyrrolidin-1-yloxycarbonyloxy)-acetic acid benzylester

The title compound was prepared using the procedure as described inExample 24A, substituting hydroxy-acetic acid benzyl ester for(2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol.

EXAMPLE 27B 2-(benzyloxy)-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting the compound from Example 27A for the compoundfrom Example 21B MS (ESI) m/z: 541.29 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28(s, 9H), 1.86 (m, 1H), 2.47 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 5.17(m, 3H), 5.25 (s, 2H), 6.69 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.38(m, 5H), 7.51 (t, 1H), 7.68 (d, 1H), 7.88 (d, 1H), 8.45 (s, 1H), 8.87(s, 1H). Anal Calcd for C₃₁H₃₂N₄O₅: C, 68.87; H, 5.97; N, 10.36. Found:C, 66.93; H, 5.05; N, 9.98.

EXAMPLE 28 2-{[(benzyloxy)carbonyl]amino}ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 28A Carbonic acid 2-benzyloxycarbonylamino-ethyl ester2,5-dioxo-pyrrolidin-1-yl ester

The title compound was prepared using the procedure as described inExample 24A, substituting (2-hydroxy-ethyl)-carbamic acid benzyl esterfor (2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol. MS (APCI) m/z: 337[M+H]⁺

EXAMPLE 28B 2-{[(benzyloxy)carbonyl]amino}ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting compound from Example 28A for the compoundfrom Example 21B. MS (ESI) m/z: 570.33 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28(s, 9H), 1.85 (m, 1H), 2.48 (m, 1H), 2.85 (m, 1H), 2.95 (m, 1H), 3.45(q, 2H), 4.47 (t, 2H), 5.01 (s, 2H), 5.15 (q, 1H), 6.67 (d, 1H), 7.27(s, 2H), 7.32 (m, 6H), 7.47 (t, 1H), 7.55 (m, 1H), 7.65 (d, 1H), 7.87(d, 1H), 8.39 (s, 1H), 8.83 (s, 1H). Anal Calcd for C₃₂H₃₅N₅O₅.0.9H₂O:C, 65.60; H, 6.33; N, 11.95. Found: C, 65.60; H, 5.97; N, 11.81.

EXAMPLE 29 [({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]aceticacid

The title compound was prepared using the procedure as described inExample 26B, substituting Example 27B for Example 26A. MS (ESI) m/z:451.20 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H), 2.45 (m,1H), 2.85 (m, 1H), 2.94 (m, 1H), 4.98 (s, 2H), 5.18 (q, 1H), 6.68 (d,1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.69 (d, 1H), 7.88 (d,1H), 8.43 (s, 1H), 8.86 (s, 1H), 13.38 (br s, 1H). Anal Calcd forC₂₄H₂₆N₄O₅.0.8H₂O: C, 62.00; H, 5.98; N, 12.05. Found: C, 62.13; H,5.78; N, 11.79.

EXAMPLE 30 2-aminoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate hydrochloride

A mixture of the product from Example 28B (0.53 g, 0.93 mmol) and 10%Pd/C (0.053 g, 0.047 mmol) in methanol (50 mL) and conc. HCl (86 μL,1.02 mmol) was hydrogenated under 60 psi of hydrogen gas at ambienttemperature for I h. The resulting mixture was filtered and concentratedto obtain title compound (0.47 g, quantitative yield). ¹H NMR (DMSO-d₆)δ: 1.28 (s, 9H), 1.84 (m, 1H), 2.46 (m, 1H), 2.85 (m, 1H), 2.94 (m, 1H),4.65 (dd, 2H), 5.18 (q, 1H), 6.96 (d, 1H), 7.26 (s, 2H), 7.31 (s, 1H),7.51 (t, 1H), 7.69 (d, 1H), 7.91 (d, 1H), 8.02 (br s, 2H), 8.59 (s, 1H),9.19 (s, 1H). ¹H NMR (methanol-d₄) 8: 1.32 (s, 9H), 1.91 (m, 1H), 2.59(m, 1H), 2.90 (m, 1H), 3.00 (m, 1H), 3.45 (dd, 2H), 4.71 (dd, 2H), 5.30(t, 1H), 7.28 (s, 2H), 7.32 (s, 1H), 7.57 (t, 1H), 7.67 (d, 1H), 7.90(d, 1H), 8.48 (s, 1H). MS (ESI) m/z: 436.2 [M+H]⁺ Anal Calcd forC₂₄H₂₉N₅O₃.HCl.1.8 H2O: C, 57.15; H, 6.71; N, 13.88. Found: C, 57.21; H,6.55; N, 13.60.

EXAMPLE 31 2-ethoxy-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 31A (4-Nitro-phenoxycarbonyloxy)-acetic acid ethyl ester

The title compound was prepared using the procedure as described inExample 21B, substituting hydroxy-acetic acid ethyl ester for Example21A. ¹H NMR (DMSO-d₆) δ: 8.36 (m, 2H), 7.57 (m, 2H), 4.90 (s, 2H), 4.20(q, J=7.5 Hz, 2H), 1.22 (t, J=7.5 Hz, 3H).

EXAMPLE 31B 2-ethoxy-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting compound from Example 31A for the compoundfrom Example 21B. MS (ESI) m/z: 479.27 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.24(t, 3H), 1.28 (s, 9H), 1.86 (m, 1H), 2.48 (m, 1H), 2.85 (m, 1H), 2.94(m, 1H), 4.20 (q, 2H), 5.09 (s, 2H), 5.18 (q, 1H), 6.69 (d, 1H), 7.28(s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.69 (d, 1H), 7.88 (d, 1H), 8.45(s, 1H), 8.88 (s, 1H). Anal Calcd for C₂₆H₃₀N₄O₅.0.4H₂O: C, 64.29; H,6.39; N, 11.53. Found: C, 64.22; H, 6.23; N, 11.46.

EXAMPLE 32 (diethoxyphosphoryl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 32A (4-Nitro-phenoxycarbonyloxymethyl)-phosphonic acid diethylester

The title compound was prepared using the procedure as described inExample 21B, substituting hydroxymethyl-phosphonic acid diethyl esterfor Example 21A. ¹H NMR (DMSO-d₆) δ: 8.38 (d, J=11.0 Hz, 2H), 7.60 (d,J-11.0 Hz, 2H), 4.63 (d, 7.5 Hz, 2H), 4.10 (m, 4H), 1.24 (t, J=6.0 Hz,6H).

EXAMPLE 32B (diethoxyphosphoryl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 32A for Example 21B. MS (ESI) m/z:543.3 [M+H]⁺. ¹H NMR (DMSO-d₆) δ: 1.26 (s, 6H), 1.28 (s, 9H), 1.86 (m,1H), 2.47 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 4.15 (m, 4H), 4.84 (d,2H), 5.15 (q, 1H), 6.70 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.52 (t,1H), 7.67 (d, 1H), 7.88 (d, 1H), 8.44 (s, 1H), 8.87 (s, 1H). Anal Calcdfor C₂₇H₃₅N₄O₆P.0.4 H₂O: C, 58.99; H, 6.56; N, 10.19. Found: C, 59.08;H, 6.40; N, 10.01.

EXAMPLE 33 2-(diethylamino)-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 33A Carbonic acid diethylcarbamoylmethyl ester 4-nitro-phenylester

The title compound was prepared using the procedure as described inExample 21B, substituting N,N-diethyl-2-hydroxy-acetamide for Example21A. ¹H NMR (DMSO-d₆) δ: 8.38 (d, J=11.0 Hz, 2H), 7.57 (d, J=11.0 Hz,2H), 5.0 (s, 2H), 3.20 (m, 4H), 1.12 (m 6H).

EXAMPLE 33B 2-(diethylamino)-2-oxoethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 33A for Example 21B. MS (ESI) m/z:506.32 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.05 (t, 3H), 1.18 (t, 3H), 1.28 (s,9H), 1.86 (m, 1H), 2.48 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 5.18 (m,3H), 6.68 (d, 1H), 7.28 (s, 2H), 7.31 (s, 1H), 7.50 (t, 1H), 7.70 (d,1H), 7.87 (d, 1H), 8.42 (s, 1H), 8.86 (s, 1H). Anal Calcd forC₂₈H₃₅N₅O₄.0.7 H₂O: C, 64.90; H, 7.08; N, 13.51. Found: C, 65.04; H,7.13; N, 13.41.

EXAMPLE 34 2-oxopropyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 34A Carbonic acid 4-nitro-phenyl ester 2-oxo-propyl ester

The title compound was prepared using the procedure as described inExample 21B, substituting 1-hydroxy-propan-2-one for Example 21A. ¹H NMR(DMSO-d₆) δ: 8.35 (d, J=11.0 Hz, 2H), 7.58 (d, J-11.0 Hz, 2H), 5.00 (m2H), 2.16 (s, 3H).

EXAMPLE 34B 2-oxopropyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 34A for Example 21B. MS (ESI) m/z:449.17 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H), 2.23 (s,3H), 2.47 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 4.84 (d, 1H), 5.17 (q,1H), 5.40 (d, 1H), 6.69 (d, 1H), 7.23 (d, 1H), 7.27 (s, 2H), 7.31 (s,1H), 7.39 (t, 1H), 7.82 (d, 1H), 8.23 (s, 1H), 8.71 (s, 1H). Anal Calcdfor C₂₅H₂₈N₄O₄.0.3 H₂O: C, 66.15; H, 6.35; N, 12.34. Found: C, 66.14; H,6.25; N, 12.46.

EXAMPLE 35 2-(acetyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 35A Acetic acid 2-(4-nitro-phenoxycarbonyloxy)-ethyl ester

The title compound was prepared using the procedure as described inExample 21B, substituting acetic acid 2-hydroxy-ethyl ester for Example21A. ¹H NMR (DMSO-d₆) δ: 8.38 (d, J=11.0 Hz, 2H), 7.59 (d, J-11.0 Hz,2H), 4.46 (m 2H), 4.12 (m, 2H), 2.05 (s, 3H).

EXAMPLE 35B 2-(acetyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 35A for Example 21B. MS (ESI) m/z:479.27 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.86 (m, 1H), 2.05 (s,3H), 2.48 (m, 1H), 2.85 (m, 1H), 2.96 (m, 1H), 4.41 (m, 2H), 4.65 (m,2H), 5.15 (q, 1H), 6.69 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.51 (t,1H), 7.66 (d, 1H), 7.88 (d, 1H), 8.41 (s, 1H), 8.86 (s, 1H). Anal Calcdfor C₂₆H₃₀N₄O₅. 0.4 H₂O: C, 64.29; H, 6.39; N, 11.53. Found: C, 64.29;H, 6.48; N, 11.24.

EXAMPLE 36 2-(dimethoxyphosphoryl)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 36A [2-(4-Nitro-phenoxycarbonyloxy)-ethyl]-phosphonic aciddimethyl ester

The title compound was prepared using the procedure as described inExample 21B, substituting (2-hydroxy-ethyl)-phosphonic acid dimethylester for Example 21A. MS (ESI) m/z: 320 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 8.35(d, J=11.0 Hz, 2H), 7.56 (d, J=11.0 Hz, 2H), 4.40 (m, 2H), 3.70 (s, 3H),3.66 (s, 3H), 2.37 (m, 2H).

EXAMPLE 36B 2-(dimethoxyphosphoryl)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 36A for Example 21B. MS (ESI) m/z:529.25 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.85 (m, 1H), 2.42 (m,3H), 2.85 (m, 1H), 2.94 (m, 1H), 3.64 (s, 3H), 3.68 (s, 3H), 4.60 (m,2H), 5.15 (q, 1H), 6.68 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.50 (t,1H), 7.71 (d, 1H), 7.87 (d, 1H), 8.40 (s, 1H), 8.84 (s, 1H). Anal Calcdfor C₂₆H₃₃N₄O₆P.0.5H₂O: C, 58.09; H, 6.38; N, 10.42. Found: C, 58.16; H,6.37; N, 10.30.

EXAMPLE 37 [bis(benzyloxy)phosphoryl]methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylateEXAMPLE 37A (4-Nitro-phenoxycarbonyloxymethyl)-phosphonic acid dibenzylester

The title compound was prepared using the procedure as described inExample 21B, substituting hydroxymethyl-phosphonic acid dibenzyl esterfor Example 21A. MS (ESI) m/z: 458 [M+H]⁺ ¹HNMR (DMSO-d₆) δ: 8.30 (d,J=11.0 Hz, 2H), 7.51 (d, J=11.0 Hz, 2H), 7.37 (m, 10H), 5.13 (d, J=7.5Hz, 4H), 4.72 (d J=8.0 Hz, 2H).

EXAMPLE 37B [bis(benzyloxy)phosphoryl]methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

The title compound was prepared using the procedure as described inExample 21C, substituting Example 37A for the compound from Example 21B.MS (ESI) m/z: 349.1, 667.30 [M+H4]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H),1.79-1.91 (m, 1H), 2.41-2.47 (m, 1H), 2.79-2.87 (m, 1H), 2.91-3.01 (m,1H), 4.94 (d, 2H), 5.11-5.23 (m, 5H), 6.70 (d, 1H), 7.27 (s, 2H),7.29-7.41 (m, 11H), 7.45 (t, 1H), 7.62 (d, 1H), 7.89 (d, 1H), 8.44 (s,1H), 8.86 (s, 1H). Anal Calcd for C₃₇H₃₉N₄O₆P: C, 66.66; H, 5.90; N,8.40. Found: C, 66.56; H, 5.76; N, 8.55.

EXAMPLE 38[({4-{({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid

The title compound was prepared using the procedure as described inExample 26B, substituting Example 37B for Example 26A. MS (ESI) m/z:485.21 [M−H]⁻ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.81-1.88 (m, 1H),2.42-2.48 (m, 1H), 2.79-2.87 (m, 1H), 2.91-3.01 (m, 1H), 4.56 (d, 2H),5.16 (q, 1H), 6.69 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.50 (t, 1H),7.72 (d, 1H), 7.89 (d, 1H), 8.43 (s, 1H), 8.85 (s, 1H). ¹H NMR(methanol-d₄) 6: 1.32 (s, 9H), 1.89 (m, 1H), 2.59 (m, 1H), 2.87 (m, 1H),3.01 (m, 1H), 4.72 (d, 2H), 5.29 (t, 1H), 7.28 (s, 2H), 7.32 (s, 1H),7.54 (t, 1H), 7.75 (d, 1H), 7.90 (d, 1H), 8.41 (s, 1H). Anal Calcd forC₂₃H₂₇N₄O₆P.0.6H₂O: C, 55.55; H, 5.72; N, 11.27. Found: C, 55.63; H,5.77; N, 10.99.

EXAMPLE 39[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonate,triethylamine salt

To a suspension of Example 38 (0.05 g, 0.1 mmol) in methanol (10 mL) wasadded triethylamine (0.01 g, 0.1 mmol) and the mixture stirred 10minutes at ambient temperature, concentrated under reduced pressure anddrying in vacuum to provide 0.06 g (100%) of title compound. ¹H NMR(methanol-d₄) δ: 1.29 (t, 9H), 1.32 (s, 9H), 1.90 (m, 1H), 2.59 (m, 1H),2.89 (m, 1H), 3.00 (m, 1H), 3.16 (q, 6H), 4.54 (d, 2H), 5.29 (t, 1H),7.28 (s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.74 (d, 1H), 7.97 (d, 1H),8.36 (s, 1H). Anal Calcd for C₂₃H₂₇N₄O₆P.1.0 triethylamine.0.7 methanol:C, 58.47; H, 7.40; N, 11.48. Found: C, 58.46; H, 7.38; N, 11.44.

EXAMPLE 40[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, diethylaminoethanol salt

The title compound was prepared using the procedure as described inExample 39, substituting diethylaminoethanol for triethylamine. ¹H NMR(methanol-d₄) δ: 1.30 (t, 6H), 1.32 (s, 9H), 1.90 (m, 1H), 2.59 (m, 1H),2.89 (m, 1H), 3.00 (m, 1H), 3.20 (m, 6H), 3.83 (dd, 2H), 4.54 (d, 2H),5.29 (t, 1H), 7.28 (s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.74 (d, 1H),7.98 (d, 1H), 8.36 (s, 1H). Anal Calcd for C₂₃H₂₇N₄O₆P.0.8 C₆H₅NO.0.65methanol: C, 56.85; H, 6.98; N, 11.19. Found: C, 56.85; H, 7.01; N,11.23.

EXAMPLE 41 [({4-[({[(1R) -5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, triethanolamine salt

The title compound was prepared using the procedure as described inExample 39, substituting triethanolamine for triethylamine. ¹H NMR(methanol-d₄) δ: 1.31 (s, 9H), 1.90 (m, 1H), 2.59 (m, 1H), 2.89 (m, 1H),3.00 (m, 1H), 3.37 (m, 6H), 3.87 (dd, 6H), 4.54 (d, 2H), 5.29 (t, 1H),7.28 (s, 2H), 7.31 (s, 1H), 7.52 (t, 1H), 7.74 (d, 1H), 7.98 (d, 1H),8.36 (s, 1H). Anal Calcd for C₂₃H₂₇N₄O₆P.1.1 C₆H₁₅NO₃.0.7 methanol: C,54.08; H, 6.93; N, 10.61. Found: C, 54.08; H, 6.82; N, 10.67.

EXAMPLE 42[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, piperazine salt

The title compound was prepared using the procedure as described inExample 39, substituting piperazine for triethylamine. ¹H NMR(methanol-d₄) δ: 1.32 (s, 9H), 1.90 (m, 1H), 2.59 (m, 1H), 2.89 (m, 1H),3.01 (m, 1H), 3.04 (s, 8H), 4.54 (d, 2H), 5.29 (t, 1H), 7.29 (s, 2H),7.31 (s, 1H), 7.52 (t, 1H), 7.74 (d, 1H), 7.97 (d, 1H), 8.37 (s, 1H).Anal Calcd for C₂₃H₂₇N₄O₆P.0.9 C₄H₁₀N₂.1.2 H₂O: C, 54.56; H, 6.61; N,13.87. Found: C, 54.58; H, 6.74; N, 13.76.

EXAMPLE 43[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, N-methyl-D-glucamine salt

The title compound was prepared using the procedure as described inExample 39, substituting N-methyl-D-glucamine for triethylamine. ¹H NMR(methanol-d₄) δ: 1.32 (s, 9H), 1.90 (m, 1H), 2.59 (m, 1H), 2.69 (s, 3H),2.89 (m, 1H), 3.00 (m, 1H), 3.15 (d, 2H), 3.61-3.83 (m, 5H), 4.04 (m,1H), 4.54 (d, 2H), 5.29 (t, 1H), 7.28 (s, 2H), 7.31 (s, 1H), 7.52 (t,1H), 7.74 (d, 1H), 7.97 (d, 1H), 8.37 (s, 1H). Anal Calcd forC₂₃H₂₇N₄O₆P.1.3 C₇H₁₇NO₅.0.6H₂O: C, 51.33; H, 6.75; N, 9.88. Found: C,51.45; H, 6.61; N, 9.78.

EXAMPLE 47N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-hydroxy-3-methoxypropyl)-1H-indazol-4-yl]urea

A mixture of 2-methoxymethyl-oxirane (0.18 g, 4.0 mmol), Example 56J(0.35 g, 1.0 mmol) and K₂CO₃ (0.14 g, 1.0 mmol) in ethanol (4.0 mL) wereheated at 120° C. for 10 minutes in the microwave (Personal Chemistry).After filtration, concentration of the filtrate and chromatography(ethyl acetate, 100%) two regioisomers were obtained: title compound(0.17 g, 26%) and compound described in Example 48 (0.11 g, 24%). MS(ESI) m/z: 437.14 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.84 (m, 1H),2.45 (m, 1H), 2.84 (m, 1H), 2.94 (m, 1H), 3.25 (s, 3H), 4.05 (q, 1H),4.28 (dd, 1H), 4.34 (dd, 1H), 5.06 (d, 1H), 5.16 (q, 1H), 6.66 (d, 1H),7.15 (d, 1H), 7.24 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.68 (d, 1H),8.02 (s, 1H), 8.55 (s, 1H).

EXAMPLE 48N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[2-(2-hydroxy-3-methoxypropyl)-2H-indazol-4-yl]urea

The title compound was prepared and isolated as described in Example 47with yield of 0.11 g (24%). MS (ESI) m/z: 437.13 [M+H]⁺ ¹H NMR (DMSO-d₆)δ: 1.28 (s, 9H), 1.82 (m, 1H), 2.44 (m, 1H), 2.84 (m, 1H), 2.94 (m, 1H),3.22 (m, 1H), 3.29 (s, 3H), 4.05 (m, 1H), 4.31 (dd, 1H), 4.45 (dd, 1H),5.13 (q, 1H), 5.27 (d, 1H), 6.56 (d, 1H), 7.13 (m, 2H), 7.26 (s, 2H),7.30 (s, 1H), 7.52 (dd, 1H), 8.21 (s, 1H), 8.45 (s, 1H).

EXAMPLE 49 methyl3-{4-[({[(IR)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropanoate

A mixture of oxirane-2-carboxylic acid methyl ester (0.51 g, 5.0 mmol),Example 56J (0.35 g, 1.0 mmol) and sodium tert-butoxide (0.1 g, 1.0mmol) in methanol (4.0 mL) was heated at 120° C. for 30 minutes inmicrowave (Personal Chemistry). After filtration, concentration of thefiltrate and chromatography (ethyl acetate:dichloromethane 1:1 to 3:1)two regioisomers were obtained: title compound (0.18 g, 40%) andcompound described in Example 50 (0.12 g, 27%). MS (ESI) m/z: 451.12[M+H]⁺. ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.84 (m, 1H), 2.44 (m, 1H),2.84 (m, 1H), 2.94 (m, 1H), 3.60 (s, 3H), 4.49-4.64 (m, 3H), 5.14 (q,1H), 6.65 (d, 1H), 7.13 (d, 1H), 7.22 (d, 1H), 7.27 (s, 2H), 7.31 (s,1H), 7.68 (d, 1H), 8.02 (s, 1H), 8.56 (s, 1H).

EXAMPLE 50 methyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoate

The title compound was prepared and isolated as described in Example 49with yield of 0.12 g (27%). MS (ESI) m/z: 451.11 [M+H]⁺ ¹H NMR (DMSO-d₆)δ: 1.28 (s, 9H), 1.81 (m, 1H), 2.47 (m, 1H), 2.84 (m, 1H), 2.93 (m, 1H),3.67 (s, 3H), 4.56 (m, 2H), 4.67 (m, 1H), 5.13 (q, 1H), 6.56 (d, 1H),7.11 (d, 2H), 7.26 (s, 2H), 7.30 (s, 1H), 7.53 (t, 1H), 8.21 (s, 1H),8.46 (s, 1H).

EXAMPLE 51 tert-butyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropylcarbamate

A mixture of oxiranylmethyl-carbamic acid tert-butyl ester (0.35 g, 2.0mmol), Example 56J (0.35 g, 1.0 mmol) and K₂CO₃ (0.14 g, 1.0 mmol) inacetonitrile (4.0 mL) were heated at 120° C. for 15 minutes in themicrowave (Personal Chemistry). The reaction mixture was cooled,filtered and concentrated. The crude material was purified on silica gel(ethyl acetate/hexane 65/35 to 80/20) to provide the title compound(0.12 g, 23%). MS (ESI) m/z: 522.15 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s,9H), 1.38 (s, 9H), 1.84 (m, 1H), 2.45 (m, 1H), 2.84 (m, 1H), 2.99 (m,3H), 3.92 (m, 1H), 4.23 (dd, 1H), 4,29 (dd, 1H), 5.01 (d, 1H), 5.14 (q,1H), 6.66 (d, 1H), 6.80 (t, 1H), 7.13 (d, 1H), 7.22 (d, 1H), 7.27 (s,2H), 7.31 (s, 1H), 7.68 (d, 1H), 8.02 (s, 1H), 8.56 (s, 1H).

EXAMPLE 523-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropanoicacid

A solution of compound from Example 49 (0.31 g, 0.68 mmol) in methanol(20 mL) was treated with 1IN NaOH (2 mL) for 16 hours. The mixture wascooled in ice bath, treated with 1N HCl (2 mL) and concentrated underreduced pressure. The residue was dissolved in dimethylsulfoxide-methanol, 1:1 (3 mL), filtered and the filtrated purified byHPLC (eluted with water/acetonitrile 10 to 100% contains 0.1%trifluoroacetic acid) (0.12 g, 27%). MS (ESI) m/z: 437.11 [M+H]⁺ ¹H NMR(DMSO-d₆) δ: 1.28 (s, 9H), 1.84 (m, 1H), 2.45 (m, 1H), 2.84 (m, 1H),2.94 (m, 1H), 4.40-4.62 (m, 3H), 5.14 (q, 1H), 6.65 (d, 1H), 7.15 (d,1H), 7.22 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.68 (d, 1H), 8.03 (s,1H), 8.56 (s, 1H).

EXAMPLE 533-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoicacid

The title compound was prepared using the procedure as described inExample 52, substituting Example 50 for Example 49. MS (ESI) m/z: 437.11[M+H]⁺ ¹H NMR (DMSO-d₆) δ: 1.28 (s, 9H), 1.82 (m, 1H), 2.45 (m, 1H),2.84 (m, 1H), 2.93 (m, 1H), 4.44 (dd, 1H), 4.52 (dd, 1H), 4.65 (dd, 1H),5.13 (q, 1H), 6.57 (d, 1H), 7.11 (d, 2H), 7.26 (s, 2H), 7.30 (s, 1H),7.54 (t, 1H), 8.23 (s, 1H), 8.47 (s, 1H).

EXAMPLE 54N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[2-(2-hydroxy-3-morpholin-4-ylpropyl)-2H-indazol-4-yl]urea

Charged an Emrys 5 mL process vial with 350 mg (1.0 mmol) Example 56J,290 mg (2.0 mmol) 4-[(±)-2,3-epoxypropyl]-morpholine, 139 mg (1.0 mmol)K₂CO₃ and 4 mL ethanol. The mixture was heated in a microwave at 120° C.for 30 minutes, filtered, rinsed with ethanol and concentrated. The ˜1:1mixture of regioisomers was purified on silica gel with 5-10% methanolin ethyl acetate to obtain 0.32 g of the title compound and 0.45 g ofthe compound described in Example 55. MS (ESI) m/z: 492.18 [M+H]⁺ ¹H NMR(DMSO-d₆) δ: 1.28 (s, 9H), 1.80 (m, 1H), 2.32 (dd, 2H), 2.42 (dd, 4H),2.47 (m, 1H), 2.84 (m, 1H), 2.93 (m, 1H), 3.57 (dd, 4H), 4.08 (m, 1H),4.23 (dd, 1H), 4.51 (dd, 1H), 5.07 (d, 1H), 5.13 (q, 1H), 6.57 (d, 1H),7.12 (m, 2H), 7.26 (s, 2H), 7.30 (s, 1H), 7.51 (dd, 1H), 8.24 (s, 1H),8.47 (s, 1H).

EXAMPLE 55N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-hydroxy-3-morpholin-4-ylpropyl)-1H-indazol-4-yl]urea

The title compound was prepared and isolated as described in Example 54with yield of 0.45 g MS (ESI) m/z: 492.19 [M+H]⁺ ¹H NMR (DMSO-d₆) δ:1.28 (s, 9H), 1.84 (m, 1H), 2.29 (dd, 2H), 2.36 (dd, 4H), 2.44 (m, 1H),2.84 (m, 1H), 2.94 (m, 1H), 3.52 (dd, 4H), 4.08 (m, 1H), 4.23 (dd, 1H),4.39 (dd, 1H), 4.85 (m, 1H), 5.14 (q, 1H), 6.71 (d, 1H), 7.15 (d, 1H),7.21 (d, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.67 (d, 1H), 8.02 (s, 1H),8.59 (s, 1H).

EXAMPLE 56N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylureaEXAMPLE 56A 4-nitro-1H-indazole

2-Methyl-3-nitroaniline (20 g, 129.0 mmol) in acetic acid (-200 mL) wastreated with NaNO₂ (20 g, 290.0 mmol) in water (50 mL) at 4° C. withmechanical stirring. The reaction mixture was allowed to warm to roomtemperature and stir overnight. The solvent was removed under reducedpressure. The residue was treated with water (700 mL) and the mixturewas filtered. The solid was dried at 45° C. in a vacuum oven overnightto provide the title compound. ¹H NMR (DMSO-d₆) δ 8.56 (s, 1H), 8.2-8.05(dd, 2H), 7.6 (t, 1H).

EXAMPLE 56B methyl 4-nitro-1H-indazole-1-carboxylate

NaH (0.3 g, 12.5 mmol) in N,N-dimethylformamide (5 mL) was treated withExample 56A (1.33 g, 10 mmol) at 0° C. The reaction mixture was allowedto warm to room temperature and stir for 1 hour. The mixture was treatedwith methyl chloroformate (0.9 mL,11.7 mol) and stirred at roomtemperature for 3 hours. The mixture was treated with water and filteredto provide the title compound as a solid. ¹H NMR (300 MHz, DMSO-d₆) δ4.19 (s, 3H), 7.9 (t, 1H), 8.38 (d, 1H), 8.62 (d, 1H), 8.85 (s, 1H).

EXAMPLE 56C methyl 4-amino-1H-indazole-1-carboxylate

Example 56B (1.66 g, 7.5 mmol) and 10% Pd/C were combined in ethanol (20mL) and exposed to a hydrogen atmosphere. The reaction mixture washeated at 80° C. for 20 minutes, allowed to cool to room temperature,and filtered through Celite. The filtrate was evaporated to providetitle compound. ¹H NMR (300 MHz, DMSO-d₆) δ 6.1 (s, 2H), 6.41 (dd, 1H),7.21 (m, 2H), 8.42 (s, 1H).

EXAMPLE 56D 1-(4-tert-butylphenyl)-3-chloro-1-propanone

A solution of tert-butyl benzene (31 ml, 200 mmol) and3-chloro-propionyl chloride (19 ml, 200 mmol) in methylene chloride (75ml) was added dropwise to a suspension of aluminum chloride (29.33 g,220 mmol) in methylene chloride (300 ml) at 0° C. The reaction mixturewas allowed to warm to ambient temperature, stirred for 16 hours, andquenched with water dropwise. The reaction mixture was washed withwater, dried with magnesium sulfate, and the filtrate was evaporatedunder reduced pressure to provide the title compound which was usedwithout further purification in the next step.

EXAMPLE 56E 5-tea-butyl-1-indanone

Example 56D (22.25 g, 99 mmol) was dissolved in concentrated sulfuricacid (100 ml) and heated on a water bath at 95° C. for 2.5 hours. Thereaction mixture was cooled, poured onto ice, and extracted with diethylether. The combined organic extracts were washed with saturated aqueoussodium bicarbonate, dried with magnesium sulfate, and the filtrate wasevaporated under reduced pressure to provide the title compound whichwas used without further purification in the next step.

EXAMPLE 56F 5-tert-butyl-1-indanone O-methyloxime

Example 56E (13.41 g, 71.23 mmol) and methoxyamine hydrochloride (6.68g, 80 mmol) were disolved in pyridine (75 ml) and stirred at ambienttemperature for 16 hours. The mixture was evaporated under reducedpressure and the residue was partitioned between water and diethylether. The combined organic layers were washed with IN aqueoushydrochloric acid, dried with magnesium sulfate, and the filtrate wasevaporated under reduced pressure to provide the title compound whichwas used without further purification in the next step.

EXAMPLE 56G 5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine

Example 56F (4.37 g, 20.2 mmol) and 10% palladium on carbon (2.2 g) werecombined in methanol (50 ml) and ammonia (10 ml) and placed in a Parrapparatus which was charged with hydrogen to 60 psi. The reaction wasshaken at 50° C. for 16 hours. The reaction mixture was filtered and thefiltrate was evaporated under reduced pressure. The residue was treatedwith diethyl ether (100 ml) and extracted with hydrochloric acid (1N,3×50 ml). The combined aqueous extracts were neutralized with sodiumhydroxide (6 g) in water (25 ml) and extracted with diethyl ether. Theorganic extracts were combined, dried with magnesium sulfate, and thefiltrate was evaporated under reduced pressure to provide the titlecompound which was used without further purification in the next step.

EXAMPLE 56H (1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine

Example 56G (11.70 g, 61.9 mmol, 44.4% ee), N-acetyl-(D)-leucine (11.78g 68.1 mmol) and methanol (120 mL) were combined and heated at 65° C.for 1 hour. The solution was allowed to cool to ambient temperature. Thesolids were filtered and washed with toluene. The solid was thenresuspended in methanol (125 mL) and brought to reflux. The solution wasallowed to cool to ambient temperature and the solids were filtered. Thesolid was dried at 40° C. under reduced pressure to provide the titlecompound. The solid was treated with IN NaOH (100 mL) and extracted withmethyl-t-butyl ether. Organic phase was concentrated to obtain free base(3.8 g, 98.7% ee, determined by chiral HPLC with Chirobiotic column fromAstec using mobile phase of 0.1% acetic acid and 0.06% triethylamine inmethanol) (98.7% ee)

EXAMPLE 56I methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate

Example 56C (4.59 g, 24 mmol) in toluene (800 ml) was treated withphosgene (20% in toluene, 25.4 ml, 48 mmol). The mixture was heated atreflux for 3 hours, cooled, and the solvent removed under vacuum. Theresidue in diethyl ether (800 ml) and triethyl amine (20 ml) wasfiltered and then treated with Example 56H (3.78 g, 20 mmol). Afterstirring at ambient temperature for 16 hours, the solvent was removedunder vacuum and the residue triturated with a 1:1 mixture of diethylether and hexanes to provide the title compound. ¹H NMR (DMSO-d₆) δ 1.28(s, 9H), 1.78-1.91 (m, 1H), 2.39-2.48 (m, 1H), 2.75-2.88 (m, 1H),2.91-3.02 (m, 1H), 4.04 (s, 3H), 5.17 (m, 1H), 6.73 (d, 1H), 7.27 (s,2H), 7.30 (m, 1H), 7.50 (m, 1H), 7.69 (d, 1H), 7.88 (d, 1H), 8.39 (s,1H), 8.84 (s, 1H); MS (ESI+) 407 (M+H)⁺; Elemental: Calculated forC₂₃H₂₆N₄O₃: C, 67.96; H, 6.45; N, 13.78; Found: C, 67.85; H, 6.51; N,13.56.

EXAMPLE 56JN-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea

Example 561 (5.67 g, 14 mmol) in tetrahydrofuran (20 ml) was treatedwith A 5M solution of sodium hydroxide in methanol (8 ml, 40 mmol).After stirring for 30 minutes, the reaction mixture was diluted withwater and filtered. The solid was air-dried to obtain desired compound.¹H NMR (DMSO-d₆) δ 1.27 (s, 9H), 1.75-1.88 (m, 1H), 2.40-2.48 (m, 1H),2.76-2.88 (m, 1H), 2.90-3.01 (m, 1H), 5.15 (m, 1H), 6.84 (br, 1H), 7.05(d, 1H), 7.20, (m, 1H), 7.26 (s, 2H), 7.31 (s, 1H), 7.69 (d, 1H), 8.17(s, 1H), 8.83 (s, 1H); MS (ESI+): 349 (M+H)⁺; Elemental: Calculated forC₂₁H₂₄N₄O.HCl: C, 65.53; H, 6.55; N, 14.56; Found: C, 65.29; H, 6.63; N,14.23.

EXAMPLE 56K (1R)-5-tert-butyl-indan-1-ylamine tosylate salt

A solution of the product from Example 56H (1.9 g, 10 mmol) in methanol(25 mL) was added to a solution of p-toluenesulfonic acid (1.76 g, 10.5mmol) in methanol (5 mL). The resultant solution was distilled underreduced pressure to approximately 5 mL. The internal temperature wasadjusted to ˜65° C., and water (50 mL) was added while maintaining theinternal temperature at 60° C. The product crystallized during theaddition. The mixture was held at ˜65° C. for 1 h, then gradually cooledto ˜20° C. After stirring at ˜20° C. for 2 h, the suspension wasfiltered through a polypropylene pad to collect the crude product Thewetcake was washed with water and dried to obtain title compound (2.81g, 80%).

EXAMPLE 57N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-{1-[(4-methylpiperazin-1-yl)carbonyl]-1H-indazol-4-yl}urea

A solution of the product from Example 56J (240 mg, 0.69 mmol) inN,N-dimethylformamide (5 mL) was treated with 60% NaH (45 mg, 1.13 mmol)and stirred at room temperature for 15 min. 4-methylpiperazine carbonylchloride (1.64 mmol) was then added, and the reaction mixture wasstirred overnight at 80° C. It was then cooled to room temperature andpoured into H₂O, and the resulting precipitate was collected byfiltration. Chromatography on silica gel (eluted with 97:3CH₂Cl₂-methanol) afforded the desired product. ¹H NMR (d₆-DMSO) δ 8.59(s, 1H), 8.07 (s, 1H), 7.72 (d, J=7.5 Hz, 1H), 7.28 (m, 3H), 7.17 (d,J=7.5 Hz, 1H), 6.66 (d, J=7.5 Hz, 1H), 5.17 (m, 1H), 4.44 (m, 2H), 3.48(m, 2H), 3.02 (m, 4H), 2.90 (m, 1H), 2.81 (m, 1H), 2.53 (s, 3H), 2.42(m, 1H), 1.80 (m, 1H), 1.27 (s, 9H). MS (DCI) m/z 475 (M+H).C₂₇H₃₄N₆O₂.0.5H₂O: C, 67.06; H, 7.29; N, 17.38; Found: C, 66.87; H,7.22; N, 17.04.

EXAMPLE 58N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-{2-[(4-methylpiperazin-1-yl)carbonyl]-2H-indazol-4-ylurea

The title compound was prepared and isolated as described in Example 57.¹H NMR (d₆-DMSO) δ 8.43 (s, 1H), 8.20 (s, 1H), 7.51 (d, J=1.0 and 7.5Hz, 1H), 7.31 (s, 1H), 7.25 (m, 2H), 7.17 (m, 2H), 6.58 (d, J=7.5 Hz,1H), 5.17 (m, 1H), 4.53 (m, 2H), 3.60 (m, 2H), 3.11 (m, 2H), 3.00 (m,2H), 2.92 (m, 1H), 2.81 (m, 1H), 2.60 (s, 3H), 2.42 (m, 1H), 1.80 (m,1H), 1.24 (s, 3H). MS (DCI) m/z 475 (M+H). C₂₇H₃₄N₆O₂.0.8H₂O: C, 66.32;H, 7.34; N, 17.19; Found: C, 66.62; H, 7.29; N, 16.78.

EXAMPLE 59N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea

To a 200 mL round bottom flask was added 1-hydroxybenzotriazole (HOBT)(3.50 mmol, 0.47 g), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimidehydrochloride (EDCI) (3.50 mmol, 0.67 g), N,N-dimethylglycine (2.90mmol, 0.30 g) and methylene chloride (36 mL) and the reaction wasstirred at room temperature for 10 minutes. To the flask was then addedExample 56J (2.90 mmol, 1.10 g) in 4 mL of DMF and the reaction wasstirred at room temperature for 24 hours. The reaction was not completeafter 24 hours so another equivalent of HOBT and EDCI was added andstirred at room temperature for 24 hours. The reaction was diluted withmethylene chloride (100 mL) and the organic layer was washed withsaturated sodium bicarbonate (100 mL), dried (sodium sulfate) andconcentrated in vacuo. The material was purified on SiO₂ and eluted withethyl acetate to give a oily white solid in 62%. ¹H NMR (DMSO-d₆, 300MHz); δ 1.28 (s, 9H), 1.79-1.91 (m, 1H), 2.38 (s, 6H), 2.73-3.01(m, 3H),4.04 (s, 2H), 5.13-5.20 (m, 1H), 6.70 (d, J=7.8 Hz, 1H), 7.27-7.54 (m,3H), 7.51 (t, J=8.14, 16.28, 1H), 7.88 (t, J=8.48, 13.91 Hz, 2H), 8.38(s, 1H), 8.84 (s, 1H). DCl/NH₃ m/z 434.

EXAMPLE 60N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N⁷11-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea,hydrochloride salt

The solid from Example 59 was taken up in ethyl acetate/diethyl ether(1/10) (20 mL) and 2N HCl in diethyl ether (2.0 eq) was added dropwiseand the mixture was stirred for 5 minutes. The reaction was concentratedin vacuo to give the title compound as a white solid. ¹H NMR (DMSO-d₆,300 MHz); δ1.28 (s, 9H), 1.77-1.83 (m, 1H), 2.42-2.53 (m, 1H), 2.73-2.94(m, 2H), 2.97 (s, 6H), 5.02 (s, 2H), 5.14-5.21 (m,1H), 7.25-7.35 (m,4H), 7.58 (t, J=7.80, 15.94 Hz, 1H), 7.83 (d, J=8.14 Hz, 1H), 8.03 (d,J=8.14 Hz, 1H), 8.93(s, 1H), 9.77 (s, 1H). Calc for C₂₅H₃₁N₅O₂.1.7HCl:C, 60.60; H, 6.65; N, 14. 13. Found: C, 60.91; H, 6.87; N, 13.85. MS(DCl/NH₃) m/z 434.

EXAMPLE 61(R)-1-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(2-methoxyethoxy)acetyl)-1H-indazol-4-yl)ureaEXAMPLE 61A 4-Nitrophenyl 2-(2-methoxyethoxy)acetate

2-(2-methoxyethoxy)acetic acid (Alfa, 2.68 g, 20 mmol) was dissolved indichloromethane (60 mL), and oxalyl chloride (5.2 mL, 60 mmol) was addedwith a few drops of dimethylformamide. The mixture was stirred for onehour, concentrated to a yellow slurry and dichloromethane (40 mL) wasadded. 4-nitrophenol (Aldrich, 2.78 g, 20 mmol) was dissolved inpyridine (2.4 mL, 30 mmol) and dichloromethane (60 mL), and then the(2-methoxyethoxy)acetyl chloride solution was added and the mixture wasstirred for one hour. A solution of 1:1 ethyl acetate:hexane was addedwhich precipitated the salts, which were then filtered through a silicagel plug. The filtrate was concentrated to a yellow oil andchromatographed on silica gel with 0-to-60% ethyl acetate in hexane.Obtained 4.33 g (85% yield) of Example 61A as a yellow solid. ¹H NMR(300 MHz, DMSO-d₆) δ ppm 3.26 (s, 3H), 3.50 (m, 2H), 3.71 (m, 2H), 4.48(s, 2H), 7.49 (d, J=9.15 Hz, 2H), 8.32 (d, J=9.15 Hz, 2H). MS (DCI) m/z273.08 (M+NH₄)⁺.

EXAMPLE 61B(R)-1-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(2-methoxyethoxy)acetyl)-1H-indazol-4-yl)urea

Example 56J (1.74 g, 5.0 mmol) was dissolved in tetrahydrofuran (80 mL),and then potassium tert-butoxide (1.0 M in THF, 5.5 mL, 5.5 mmol) wasadded. The solution stirred for 5 minutes, Example 61A (1.40 g, 5.5mmol) was added in tetrahydrofuran (20 mL), and the solution was stirredfor another 15 minutes. Ethyl acetate was added, the salts precipitated,and the mixture was filtered through a silica gel plug. The filtrate wasconcentrated and chromatographed on silica gel using 0-to-35% ethylacetate in dichloromethane as the eluent. Obtained 1.227 g (53% yield)of Example 61B as a solid. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.28 (s, 9H),1.85 (m, 1H), 2.45 (m, 1H), 2.82 (m, 1H), 2.96 (m, 1H), 3.27 (s, 3H),3.53 (m, 2H), 3.75 (m, 2H), 4.98 (s, 2H), 5.16 (q, J=7.34 Hz, 1H), 6.69(d, J=7.80 Hz, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.52 (t, J=7.97 Hz, 1H),7.86 (d, J=8.14 Hz, 1H), 7.89 (d, J=7.79 Hz, 1H), 8.39 (s, 1H), 8.85 (s,1H). MS (ESI) m/z 465.32 (M+H)⁺. Calcd for C₂₆H₃₂N₄O₄.0.22 Ethylacetate.0.15 H₂O: C, 66.34; H, 7.05; N, 11.51; Found: C, 66.32; H, 6.63;N, 11.45.

EXAMPLE 621-((R)-5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(3,5,5-trimethylhexanoyl)-1H-indazol-4-yl)ureaEXAMPLE 62A 4-Nitrophenyl 3,5,5-trimethylhexanoate

Dissolved 4-nitrophenol (Aldrich, 1.39 g, 10 mmol) in pyridine (1.2 mL,15 mmol) and dichloromethane (50 mL), chilled to 0° C., then added3,5,5-trimethylhexanoyl chloride (Aldrich, 1.9 mL, 10 mmol), warmed toambient temperature and stirred for 1.5 hours. Added ethyl acetate,precipitated salts, and filtered through silica gel plug. Concentratedfiltrate and chromatographed on silica gel with 0-to-20% ethyl acetatein hexane. Obtained 2.79 g (100% yield) of Example 62A as an oil. ¹H NMR(300 MHz, DMSO-d₆) δ ppm 0.92 (s, 9H), 1.05 (d, J=6.78 Hz, 3H), 1.18(dd, J=13.90, 6.44 Hz, 1H), 1.34 (dd, J=13.90, 4.07 Hz, 1H), 2.07 (m,1H), 2.47 (dd, J=14.92, 7.80 Hz, 1H), 2.62 (dd, J=14.92, 6.11 Hz, 1H),7.44 (d, J=9.16 Hz, 2H), 8.30 (d, J=9.16 Hz, 2H). MS (DCI) m/z 297.1(M+NH₄)⁺.

EXAMPLE 62B1-((R)-5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(3,5,5-trimethylhexanoyl)-1H-indazol-4-yl)urea

Dissolved Example 56J (1.394 g, 4.0 mmol) in tetrahydrofuran (50 mL),added potassium tert-butoxide (1.0 M in THF, 4.0 mL, 4.0 mmol), stirredfor 5 minutes, then added Example 62A (1.229 g, 4.4 mmol) intetrahydrofuran (20 mL). After stirring for 15 minutes, 1:1 ethylacetate:hexane was added, the salts precipitated, and were filteredthrough a silica gel plug. Concentrated filtrate to a foam andchromatographed on silica gel using 0-to-30% ethyl acetate in hexane.Obtained 1.771 g (91% yield) of Example 62B as a foam. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 0.88 (s, 9H), 1.02 (d, J=6.79 Hz, 3H), 1.19 (dd, J=6.78,3.05 Hz, 1H), 1.28 (s, 9H), 1.36 (dd, J=14.07, 190 Hz, 1H), 1.84 (m,1H), 2.23 (m, 1H), 2.45 (m, 1H), 2.82 (m, 1H), 2.95 (m, 1H), 3.05 (d,J=4.41 Hz, 1H), 3.08 (d, J=3.39 Hz, 1H), 5.16 (q, J=7.46 Hz, 1H), 6.69(d, J=7.80 Hz, 1H), 7.27 (s, 2H), 7.31 (s, 1H), 7.50 (t, J=7.97 Hz, 1H),7.88 (dd, J=8.14, 3.05 Hz, 2H), 8.39 (s, 1H), 8.82 (s, 1H). MS (ESI) m/z489.42 (M+H)⁺. Calcd for C₃₀H₄₀N₄O₂.0.19 Ethyl acetate: C, 73.10; H,8.28; N, 11.09; Found: C, 73.13; H, 8.12; N, 11.02.

EXAMPLE 63 2-Ethylhexyl4-(3-((R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylate

Dissolved Example 56J (1.045 g, 3.0 mmol) in dimethylformamide (20 mL),added potassium tert-butoxide (1.0M in THF, 3.0 mL, 3.0 mmol), stirredthe solution for 5 minutes, then added 2-ethylhexyl chloroformate(Aldrich, 0.65 mL, 3.3 mmol), and stirred solution for 20 minutes. Thesolution was partitioned between ethyl acetate (200 mL) and water (200mL), the organic layer was washed with brine and sodium sulfate and thenconcentrated to an oil and chromatographed on silica gel with 0-to-50%ethyl acetate in hexane. Obtained 1.475 g (97% yield) of Example 63 as afoam. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.87 (m, 6H), 1.33 (m, 17H), 1.81(m, 2H), 2.45 (m, 1H), 2.82 (m, 1H), 2.96 (m, 1H), 4.38 (dd, J=5.76,1.70 Hz, 2H), 5.16 (q, J=7.12 Hz, 1H), 6.70 (d, J=7.80 Hz, 1H), 7.27 (s,2H), 7.31 (s, 1H), 7.50 (t, J=8.14 Hz, 1H), 7.66 (d, J=8.48 Hz, 1H),7.89 (d, J=7.79 Hz, 1H), 8.39 (s, 1H), 8.83 (s, 1H). MS (ESI) m/z 505.43(M+H)⁺. Calcd for C₃₀H₄₀N₄O₃.0.14 Ethyl acetate: C, 71.00; H, 8.02; N,10.84; Found: C, 71.23; H, 8.36; N, 10.53.

EXAMPLE 64(R)-1-(1-(2-(2-Butoxyethoxy)acetyl)-1H-indazol-4-yl)-3-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)ureaEXAMPLE 64A 4-Nitrophenyl 2-(2-butoxyethoxy)acetate

Dissolved 2-(2-butoxyethoxy)acetic acid (TCI, 3.654 g, 20.7 mmol) indichloromethane (60 mL), added oxalyl chloride (5.4 mL, 62.2 mmol) and afew drops of dimethylformamide, stirred for 1 hour, concentrated to anoil and added dichloromethane (40 mL). This solution was added to asolution of 4-nitrophenol (Aldrich, 2.88 g, 20.7 mmol) in pyridine (2.5mL, 31.1 mmol) and dichloromethane (60 mL) and stirred for 1.5 hours.Added 1:1 ethyl acetate:hexane, precipitated the salts, and filteredthrough a silica gel plug. Concentrated the filtrate to a yellow oil andchromatographed on silica gel with 0-to-30% ethyl acetate in hexane.Residue was dissolved in ethyl acetate (200 mL), washed with 0.5 Mpotassium carbonate (200 mL), dried with brine and sodium sulfate, andthen evaporated. Recovered 5.63 g (91% yield) of Example 64A as an oil.¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.87 (t, J=7.29 Hz, 3H), 1.30 (m, 2H),1.48 (m, 2H), 3.40 (t, J=6.44 Hz, 2H), 3.54 (m, 2H), 3.71 (m, 2H), 4.48(s, 2H), 7.49 (d, J=9.16 Hz, 2H), 8.32 (d, J=9.16 Hz, 2H). MS (DCI) m/z315.14 (M+NH₄)⁺.

EXAMPLE 64B(R)-1-(1-(2-(2-Butoxyethoxy)acetyl)-1H-indazol-4-yl)-3-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea

Dissolved Example 56J (2.09 g, 6.0 mmol) in tetrahydrofuran (100 mL),added potassium tert-butoxide (1.0 M in THF, 6.0 mL, 6.0 mmol), stirredsolution for 5 minutes, and then added Example 64A (1.96 g, 6.6 mmol) intetrahydrofuran (40 mL), and stirred mixture for 15 minutes. Added 1:1ethyl acetate:hexane, precipitated the salts, and filtered throughsilica gel plug. Concentrated filtrate and chromatographed on silica gelwith 0-to-30% ethyl acetate in dichloromethane. Dissolved solid in ethylacetate (250 mL), washed with 0.5 M potassium carbonate (200 mL), driedwith brine, filtered through a silica gel plug, and concentrated thefiltrate. Recovered 2.13 g (70% yield) of Example 64B as a solid. ¹H NMR(300 MHz, DMSO-d₆) δ ppm 0.82 (t, J=7.29 Hz, 3H), 1.28 (m, 11H), 1.41(m, 2H), 1.86 (m, 1H), 2.45 (m, 1H), 2.82 (m, 1H), 2.96 (m, 1H), 3.38(t, J=6.44 Hz, 2H), 3.56 (m, 2H), 3.75 (m, 2H), 4.99 (s, 2H), 5.16 (q,J=7.12 Hz, 1H), 6.70 (d, J=7.80 Hz, 1H), 7.27 (s, 2H), 7.31 (s, 1H),7.52 (t, J=7.97 Hz, 1H), 7.86 (d, J=8.14 Hz, 1H), 7.90 (d, J=7.80 Hz,1H), 8.39 (s, 1H), 8.86 (s, 1H). MS (ESI) m/z 507.43 (M+H)⁺. Calcd forC₂₉H₃₈N₄O₄.0.25 Ethyl acetate: C, 68.16; H, 7.63; N, 10.60; Found: C,68.16; H, 7.74; N, 10.61.

EXAMPLE 651-(7-fluoro-2,2-dimethylchroman-4-yl)-3-(1-(2-methoxyethyl)-1H-indazol-4-yl)ureaEXAMPLE 65A 7-fluoro-2,2-dimethylchroman-4-one

A mixture of 4-fluoro-2-hydroxyacetophenone (Aldrich, 1.54 g, 10 mmol),acetone (0.95 mL, 12.9 mmol), and pyrrolidine (0.83 mL, 9.94 mmol) wasstirred in 3 mL toluene at room temperature for 1 h and at reflux(Dean-Stark trap) for 4 hours. After cooling to room temperature, themixture was diluted with ether (30 mL) and was washed with 2N HCl (10mL) and H₂O (10 mL). Drying over Na₂SO₄ and evaporation of volatiles invacuo afforded the crude title compound, which was used without furtherpurification.

EXAMPLE 65B 7-fluoro-2,2-dimethylchroman-4-amine

To a solution of Example 65A (415 mg, 2.14 mmol) in methanol (12 mL) wasadded methoxylamine hydrochloride (0.179 g, 2.14 mmol) and pyridine(0.87 mL, 10.8 mmol). The mixture was stirred overnight at roomtemperature and was then evaporated in vacuo. The residue waspartitioned between ethyl acetate and H₂O, and the organic layer wasdried over Na₂SO₄ and was evaporated in vacuo. The residue thus obtainedwas dissolved in methanol (8 mL) and was hydrogenated (balloon) over 10%Pd—C in the presence of 4 drops of concentrated HCl overnight at roomtemperature. The catalyst was filtered off (Celite), and the filtratewas evaporated in vacuo. The residue was taken up in ether (20 mL) andwas extracted with 1N HCl (3×10 mL). These acidic extracts were thenbasified to pH 10 with 2N NaOH and were extracted with ethyl acetate(3×10 mL). Drying over Na₂SO₄, followed by evaporation in vacuo, yieldedExample 65B, 158 mg (48%). ¹H NMR (300 MHz, DMSO-d₆) δ ppm 7.56 (m,1H),6.66 (m, 1H), 6.48 (m, 1H), 3.81 (m, 1H), 2.02 (m, 2H), 1.35 (s, 3H),1.20 (s, 3H). MS (ESI) m/z 196 (M+H).

EXAMPLE 65C methyl4-(3-(7-fluoro-2,2-dimethylchroman-4-yl)ureido)-1H-indazole-1-carboxylate

Example 65B (158 mg, 0.81 mmol) was stirred with Example 66E (269 mg,0.81 mmol) and DIEA (0.21 mL, 1.21 mmol) in 2 mL DMF at room temperaturefor 2 hours. The DMF was removed in vacuo, and the residue was dilutedwith H₂O. The precipitate thus formed was collected by filtration andwas air-dried to afford the title compound, which was used withoutfurther purification.

EXAMPLE 65D1-(7-fluoro-2,2-dimethylchroman-4-yl)-3-(1H-indazol-4-yl)urea

Example 65C (2.35 mmol, 0.57 mmol) was suspended in methanol (5 mL) andwas treated with 5N methanolic NaOH (0.6 mL, 3.0 mmol). The mixture wasstirred at room temperature for 30 minutes, and poured into H₂O (30 mL).The precipitate was collected by filtration and was air-dried to affordthe title compound, 68 mg (34%). ¹H NMR (300 MHz, DMSO-d₆) δ ppm 13.02(br, 1H), 8.72 (s, 1H), 8.31 (s, 1H), 7.67 (d, J=6.8 Hz, 1H), 7.36 (m,1H), 7.22 (m, 1H), 7.09 (m, 1H), 6.59-6.72 (m, 3H), 4.97 (m, 1H), 2.22(m, 1H), 1.78 (m, 1H), 1.42 (s, 3H), 1.30 (s, 3H). MS (ESI) m/z 355(M+H).

EXAMPLE 65E1-(7-fluoro-2,2-dimethylchroman-4-yl)-3-(1-(2-methoxyethyl)-1H-indazol-4-yl)urea

A solution of Example 65D (500 mg, 1.41 mmol) in DMF (7 mL) was treatedwith 60% sodium hydride (68 mg, 1.7 mmol) at room temperature, and themixture was stirred at this temperature for 1 hour. Bromoethyl methylether (0.15 mL, 1.6 mmol) was then added, and the mixture was stirredovernight at room temperature. After this time, most of the DMF wasevaporated in vacuo, then water (50 mL) was added. The resulting stickyresidue was collected by filtration and was then chromatographed onsilica gel (98:2 CH₂Cl₂—CH₃OH) to afford the title compound, 131 mg(23%). ¹H NMR (300 MHz, DMSO-d₆) δ ppm 8.73 (s, 1H), 8.07 (s, 1H), 7.69(d, J=6.44 Hz, 1H), 7.32 (dd, J=15.09, 7.63 Hz, 1H), 7.18-7.26 (m, 2H),6.71-6.79 (m, 2H), 6.61 (dd, J=10.85, 2.71 Hz, 1H), 4.96 (m, 1H), 4.51(t, J=5.43 Hz, 2H), 3.75 (t, J=5.43 Hz, 2H), 3.18 (s, 3H), 2.20 (dd,J=13.39, 6.27 Hz, 1H), 1.78 (dd, J=13.05, 11.02 Hz, 1H), 1.41 (s, 3H),1.30 (s, 3H). MS (ESI⁺) m/z 413 (M+H), 435 (M+Na).

EXAMPLE 66 3-(Dimethylamino)propyl4-(3-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylateEXAMPLE 66A 4-Bromo-5-fluoro-2,3-dihydro-1H-inden-1-one

5-Fluoro-1-indanone (Aldrich, 6.0 g, 40 mmol) was charged in threeportions to aluminum chloride (13.32 g, 100 mmol). After mixing bymechanical stirrer for 40 minutes, bromine (2.5 mL, 48 mmol) was addedover 15 minutes. The mixture was heated in a hot water bath (internaltemperature 45-50° C.) for 2 hours. More bromine (0.1 mL) was added viasyringe, then heating continued for another 30 minutes. The solution waspoured onto a mixture of 12N hydrochloric acid (16 mL) and ice (80 g).The residual tar in the flask was rinsed out with the quenched solution.The product was extracted into ethyl acetate and the combined organiclayers were washed twice with water (60 mL), dried over sodium sulfate,and concentrated. The product was isolated by flash chromatography onsilica gel with 10% ethyl acetate in heptane. Obtained 5.90 g (64.5%yield) of Example 66A as a light yellow solid. ¹H NMR (300 MHz, DMSO-d₆)δ 2.73 (t, J=5.77 Hz, 2H), 3.04 (t, J=5.77 Hz, 2H), 7.44 (t, J=8.48 Hz,1H), 7.70 (dd, J=8.31, 4.92 Hz, 1H). MS (DCI) m/z 247.89 (M+NH₄)⁺.

EXAMPLE 66B 4-Bromo-5-fluoro-2,3-dihydro-1H-inden-1-one O-methyl oxime

Methoxylamine hydrochloride (1.92 g, 22.9 mmol) was added to Example 66A(4.777 g, 20.9 mmol) in pyridine (30 mL) and stirred for 3 hours atambient temperature. Concentrated the mixture to a slurry, added ethylacetate (200 mL), washed with 1N hydrochloric acid (200 mL), dried withbrine, filtered through a silica gel plug, and concentrated thefiltrate. Obtained 5.186 g (96% yield) of Example 66B. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 2.86 (m, 2H), 2.99 (m, 2H), 3.90 (s, 3H), 7.29 (t, J=8.65Hz, 1H), 7.57 (dd, J=8.48, 5.09 Hz, 1H). MS (DCI) m/z 259.83 (M+H)⁺.

EXAMPLE 66C 4-Cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-one O-methyloxime

Example 66B (1.29 g, 5.0 mmol) was added to a mixture ofcyclopropylboronic acid (Aldrich, 558 mg, 6.5 mmol), potassium phosphate(3.71 g, 17.5 mmol), palladium(II) acetate (56 mg, 0.25 mmol) andtricyclohexylphosphine (140 mg, 0.5 mmol) in toluene (20 mL) with water(1 mL). Heated the mixture at 100° C. for 1.5 hours on the microwave(Personal Chemistry). After cooling, the mixture was filtered throughcelite and rinsed with ethyl acetate. Concentrated the filtrate to anoil and chromatographed on silica gel with 0-to-15% ethyl acetate inhexane. Obtained 1.03 g (94% yield) of Example 66C. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 0.81 (m, 2H), 0.93 (m, 2H), 1.76 (m, 1H), 2.82 (m, 2H),3.06 (m, 2H), 3.87 (s, 3H), 7.03 (dd, J=11.19, 8.48 Hz, 1H), 7.39 (dd,J=8.31, 4.92 Hz, 1H). MS (DCI) m/z 220.07 (M+H)⁺.

EXAMPLE 66D 4-Cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-amine

Example 66C (1.03 g, 4.7 mmol), Raney nickel (10 g), and 20% ammonia inmethanol (90 mL) were shaken under hydrogen (60 psi) for 4 hours atambient temperature. The catalyst was removed by filtration and thesolvent evaporated under reduced pressure, giving 828 mg (92% yield) ofExample 66D as a light yellow oil. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.73(m, 2H), 0.88 (m, 2H), 1.59 (m, 1H), 1.73 (m, 1H), 1.85 (br s, 2H), 2.34(m, 1H), 2.70 (m, 1H), 2.96 (ddd, J=16.02, 8.73, 3.05 Hz, 1H), 4.11 (t,J=7.46 Hz, 1H), 6.88 (dd, J=11.36, 8.31 Hz, 1H), 7.14 (dd, J=8.14, 5.09Hz, 1H). MS (DCI) m/z 192.0 (M+H)⁺.

EXAMPLE 66E Methyl4-({[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}amino)-1H-indazole-1-carboxylate

Example 56C (1.9 g, 10 mmol) and disuccinimidyl carbonate (Fluka, 2.8 g,11 mmol) were mixed in acetonitrile (100 mL) for 48 hours under nitrogenatmosphere. The solid was isolated by filtration, washed withacetonitrile (10 mL) and dried under vacuum at ambient temperature togive Example 66E (2.56 g, 77%). This product was used without furtherpurification.

EXAMPLE 66F1-(4-Cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea

Example 66E (1.44 g, 4.33 mmol) was added to Example 66D (828 mg, 4.33mmol) in diisopropylethylamine (0.75 mL, 4.33 mmol) anddimethylformamide (30 mL) at ambient temperature. After 1 hour themixture was diluted with water (100 mL), the resulting white precipitatewas filtered off, washed with water and air-dried. Suspended the wetcake in triethylamine (1.2 mL, 8.66 mmol), methanol (100 mL) and water(10 mL). Refluxed the mixture for 30 minutes, cooled to ambienttemperature, diluted with water (300 mL), collected the precipitate byfiltration, rinsed with water and allowed to dry. The resulting filtercake was further dried to constant weight, yielding 1.439 g (95% yield)of Example 66F as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.78 (m, 2H), 0.93 (m, 2H), 1.78 (m,1H), 1.87 (m, 1H), 2.47 (m, 1H), 2.87 (m, 1H), 3.05 (m, 1H), 5.14 (q,J=7.46 Hz, 1H), 6.69 (d, J=7.80 Hz, 1H), 6.96 (dd, J=11.36, 8.31 Hz,1H), 7.06 (d, J=8.48 Hz, 1H), 7.16 (dd, J=8.13, 4.74 Hz, 1H), 7.21 (t,J=8.14 Hz, 1H), 7.67 (d, J=7.12 Hz, 1H), 8.04 (s, 1H), 8.59 (s, 1H),12.99 (s, 1H). MS (ESI) m/z 351.09 (M+H)⁺. Calcd for C₂₀H₁₉FN₄O: C,68.56; H, 5.47; N, 15.99; Found: C, 68.43; H, 5.41; N, 15.34.

EXAMPLE 66G 3-(Dimethylamino)propyl 2,5-dioxopyrrolidin-1-yl carbonate

To a flask containing dichloromethane (200 mL) was addeddi-(N-succinimidyl)carbonate 5.50 g, 21.50 mmol) and3-(dimethylamino)propan-1-ol (2.43 g, 23.60 mmol) and the mixture wasstirred at room temperature for 12 hours. The mixture was concentratedin vacuo, purified on SiO₂ eluting with 1% CH₃OH in CH₂Cl₂ to giveExample 66G (3.7 g) in 70% yield. MS(+APCI)m/z 245 (M+H)⁺.

EXAMPLE 66H 3-(Dimethylamino)propyl4-(3-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylatetrifluoroacetate

To a solution of Example 66F (0.24 g, 0.70 mmol) and Example 66G (0.335g, 1.40 mmol) in N,N-dimethylformamide (10 mL) was added a solution of1N KO-t-Bu (0.8 mL, 0.80 mmol) and the mixture stirred 12 hours atambient temperature. The resulting solution was concentrated and theresidue was purified on reverse phase HPLC eluting withacetonitrile/0.1% TFA in H₂O to give Example 66H (0.124 g) in 34%. ¹HNMR (300 MHz, CD₃OD) δ ppm 0.80-0.84 (m, 2H), 0.92-0.97 (m, 2H),1.60-1.82 (m, 1H), 1.86-2.12 (m, 2H), 2.28-2.38 (m, 1H), 2.60-2.72 (m,1H), 2.97 (s, 6H), 3.40 (t, J=7.80, 15.26 Hz, 2H), 3.71 (t, J=6.44,13.22 Hz, 1H), 4.21 (t, J=6.10, 11.87 Hz, 1H), 4.61 (t, J=5.77, 11.87Hz, 2H), 5.27 (t, J=7.46, 14.58 Hz, 1H), 6.83-6.98 (m, 1H), 7.14-7.18(m, 1H), 7.42-7.67 (m, 2H), 7.87-7.96 (m, 1H), 8.40 (d, J=1.02 Hz, 1H).MS(+APCI)m/z 480 (M+H)⁺. Calc for C₂₆H₃₀N₅O₃F:1.0TFA:C, 56.66; H, 5.26;N, 11.80. Found: C, 56.84; H, 5.43; N, 11.92.

EXAMPLE 671-(4-Cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureatrifluoroacetate EXAMPLE 67A 4-Bromo-2,3-dihydro-1H-inden-1-one O-methyloxime

Methoxylamine hydrochloride (5.7 g, 68.2 mmol) was added to4-bromo-1-indanone (Aldrich, 13.477 g, 63.9 mmol) in pyridine (50 mL)and stirred for 3 hours at ambient temperature. Concentrated the mixtureto a slurry, added ethyl acetate (200 mL), washed with 1N hydrochloricacid (200 mL), dried with brine, filtered through a silica gel plug, andconcentrated the filtrate. Obtained 15.248 g (99% yield) of Example 67A.¹H NMR (300 MHz, DMSO-d₆) δ ppm 2.83 (m, 2H), 2.96 (m, 2H), 3.91 (s,3H), 7.25 (t, J=7.80 Hz, 1H), 7.57 (dd, J=7.63, 0.84 Hz, 1H), 7.61 (dd,J=7.79, 1.01 Hz, 1H). MS (DCI) m/z 241.90 (M+H)⁺.

EXAMPLE 67B 4-Cyclopropyl-2,3-dihydro-1H-inden-1-one O-methyl oxime

Example 67A (1.92 g, 8.0 mmol) was added to a mixture ofcyclopropylboronic acid (Aldrich, 893 mg, 10.4 mmol), potassiumphosphate (5.94 g, 28.0 mmol), palladium(II) acetate (90 mg, 0.4 mmol)and tricyclohexylphosphine (224 mg, 0.8 mmol) in toluene (32 mL) withwater (1.6 mL). Heated the mixture at 100° C. for 3 hours on themicrowave (Personal Chemistry). After cooling, the mixture was filteredthrough celite and rinsed with ethyl acetate. Concentrated the filtrateto an oil and chromatographed on silica gel with 0 to 10% ethyl acetatein hexane. Obtained 1.32 g (82% yield) of Example 67B. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 0.68 (m, 2H), 0.95 (m, 2H), 1.90 (m, 1H), 2.82 (m, 2H),3.05 (m, 2H), 3.88 (s, 3H), 6.90 (d, J=7.46 Hz, 1H), 7.18 (t, J=7.63 Hz,1H), 7.36 (d, J=7.80 Hz, 1H). MS (DCI) m/z 202.09 (M+H)⁺.

EXAMPLE 67C 4-Cyclopropyl-2,3-dihydro-1H-inden-1-amine

Example 67B (1.32 g, 6.56 mmol), Raney nickel (6.0 g), and 20% ammoniain methanol (40 mL) were shaken under hydrogen (60 psi) for 4 hours atambient temperature. The catalyst was removed by filtration and thesolvent evaporated under reduced pressure, giving 1.11 g (97% yield) ofExample 67C. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.61 (m, 2H), 0.90 (m, 2H),1.58 (dq, J=12.29, 8.45 Hz, 1H), 1.85 (m, 3H), 2.35 (rn, 1H), 2.70 (dt,J=16.05, 7.97 Hz, 1H), 2.97 (ddd, J=15.85, 8.73, 3.22 Hz, 1H), 4.17 (t,.1-7.46 Hz, 1H), 6.66 (d, J=7.80 Hz, 1H), 7.09 (m, 2H). MS (DCI) m/z174.12 (M+H)⁺.

EXAMPLE 67D1-(4-Cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea

Example 66E (2.13 g, 6.41 mmol) was added to Example 67C (1.11 g, 6.41mmol) in diisopropylethylamine (1.12 mL, 6.41 mmol) anddimethylformamide (50 mL) at ambient temperature. After 1 hour themixture was diluted with water (200 mL), the resulting white precipitatewas filtered off, washed with water and air dried. Obtained 2.44 g (98%yield) of methyl4-(3-(4-cyclopropyl-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylateas a white solid. Suspended 1.94 g of this intermediate in triethylamine(1.4 mL, 10.0 mmol), methanol (150 mL) and water (15 mL). Refluxed themixture for 30 minutes, cooled to ambient temperature, diluted withwater (500 mL), collected the white precipitate by filtration, rinsedwith water and air-dried. The wet cake was freeze-dried to constantweight, yielding 1.60 g (97% yield) of Example 67D. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 0.66 (m, 2H), 0.94 (m, 2H), 1.84 (m, 1H), 1.91 (m, 1H),2.48 (m, 1H), 2.87 (dt, J=15.94, 7.97 Hz, 1H), 3.07 (ddd, J=15.94, 8.81,4.07 Hz, 1H), 5.20 (q, J=7.46 Hz, 1H), 6.70 (d, J=7.80 Hz, 1H), 6.78 (m,1H), 7.06 (d, J=8.14 Hz, 1H), 7.13 (d, J=4.41 Hz, 2H), 7.22 (t, J=7.97Hz, 1H), 7.68 (d, J=7.12 Hz, 1H), 8.04 (s, 1H), 8.58 (s, 1H), 12.99 (s,1H). MS (ESI) m/z 333.08 (M+H)⁺. Calcd for C₂₀H₂₀N₄O.0.23 H₂O: C, 71.38;H, 6.13; N, 16.65; Found: C, 71.40; H, 5.95; N, 16.42.

EXAMPLE 67E1-(4-Cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureatrifluoroacetate

The title compound was prepared as described in Example 68E substitutingExample 67D (0.18 g, 0.50 mmol) for Example 68D and HPLC purification(acetonitrile/0.1% TFA in H₂O) instead of HCl treatment. The materialwas recrystallized from THF (10 mL) to give 0.056 g (25% yield). ¹H NMR(300 MHz, CD₃OD) δ ppm 0.63-0.67 (m, 2H), 0.90-0.96 (m, 2H), 1.83-1.93(m, 2H), 2.53-2.64 (m, 1H), 2.79-2.89 (m, 1H), 2.96-3.05 (m, 1H), 3.31(s, 6H), 5.06 (s, 2H), 5.27-5.28 (m, 1H), 6.96-7.01 (m, 2H), 7.24 (d,J=7.67 Hz, 1H), 7.39 (t, J=8.28, 15.96 Hz, 1H), 7.57 (d, J=7.98 Hz, 1H),7.75 (d, J=7.98 Hz, 1H), 8.53 (s, 1H). MS(+APCI)m/z 418 (M+H)⁺. Calc forC₂₄H₂₇N₅O₂:1.0TFA:C, 58.75; H, 5.31; N,13.18. Found: C, 58.92; H, 5.18;N,13.26.

EXAMPLE 681-(5-Cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride EXAMPLE 68A 5-Bromo-2,3-dihydro-1H-inden-1-one O-methyloxime

Methoxylamine hydrochloride (6.75 g, 80.9 mmol) was added to5-bromo-1-indanone (Aldrich, 15.517 g, 73.5 mmol) in pyridine (7 5 mL)and stirred overnight at ambient temperature. Concentrated the mixtureto a slurry, added ethyl acetate (200 mL), washed with IN hydrochloricacid (200 mL), dried with brine, filtered through a silica gel plug, andconcentrated the filtrate. Obtained 17.56 g (99% yield) of Example 68Aas a beige solid. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 2.80 (m, 2H), 3.01 (m,2H), 3.89 (s, 3H), 7.47 (m, ²H), 7.63 (m, 1H). MS (DCI) m/z 239.96(M+H)⁺.

EXAMPLE 68B 5-Cyclopropyl-2,3-dihydro-1H-inden-1-one O-methyl oxime

Example 68A (960 mg, 4.0 mmol) was added to a mixture ofcyclopropylboronic acid (Aldrich, 447 mg, 5.2 mmol), potassium phosphate(2.97 g, 14.0 mmol), palladium(II) acetate (45 mg, 0.2 mmol) andtricyclohexylphosphine (112 mg, 0.4 mmol) in toluene (16 mL) with water(0.8 mL). Heated the mixture at 100° C. for 3 hours on the microwave(Personal Chemistry). After cooling, the mixture was filtered throughcelite and rinsed with ethyl acetate. Concentrated the filtrate to anoil and chromatographed on silica gel with 0-to-10% ethyl acetate inhexane. Obtained 657 mg (82% yield) of Example 68B. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 0.70 (m, 2H), 0.97 (m, 2H), 1.94 (m, 1H), 2.77 (m, 2H),2.94 (m, 2H), 3.86 (s, 3H), 6.99 (d, J=8.14 Hz, 1H), 7.06 (s, 1H), 7.42(d, J=7.80 Hz, 1H). MS (DCI) m/z 202.06 (M+H)⁺.

EXAMPLE 68C 5-Cyclopropyl-2,3-dihydro-1H-inden-1-amine

Example 68B (629 mg, 3.13 mmol), Raney nickel (3.0 g), and 20% ammoniain methanol (40 mL) were shaken under hydrogen (60 psi) for 6 hours atambient temperature. The catalyst was removed by filtration and thesolvent evaporated under reduced pressure, giving 509 mg (94% yield) ofExample 68C. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.60 (m, 2H), 0.88 (m, 2H),1.54 (dq, J=12.21, 8.59 Hz, 1H), 1.87 (m, 3H), 2.30 (m, 1H), 2.63 (m,1H), 2.78 (ddd, J=15.77, 8.65, 3.05 Hz, 1H), 4.12 (t, J=7.46 Hz, 1H),6.87 (m, 2H), 7.18 (d, J=7.46 Hz, 1H). MS (DCI) m/z 157.07 (M+H—NH₃)⁺.

EXAMPLE 68D1-(5-Cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea

Example 66E (977 mg, 2.94 mmol) was added to Example 68C (509 mg, 2.94mmol) in diisopropylethylamine (0.51 mL, 2.94 mmol) anddimethylformamide (30 mL) at ambient temperature. After 1 hour themixture was diluted with water (100 mL), the resulting white precipitatewas filtered off, washed with water and air dried. Suspended the wetcake in triethylamine (0.82 mL, 5.88 mmol), methanol (75 mL) and water(5 mL). Refluxed the mixture for 30 minutes, cooled to ambienttemperature, diluted with water (250 mL), collected the whiteprecipitate by filtration, rinsed with water and allowed to dry. Theresulting filter cake was further dried to constant weight, yielding 924mg (95% yield) of Example 68D. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.65 (m,2H), 0.92 (m, 2H), 1.78 (m, 1H), 1.91 (m, 1H), 2.44 (m, 1H), 2.78 (m,1H), 2.91 (m, 1H), 5.14 (q, J=7.46 Hz, 1H), 6.69 (d, J=7.80 Hz, 1H),6.97 (m, 2H), 7.06 (d, J=8.14 Hz, 1H), 7.21 (m, 2H), 7.68 (d, J=7.46 Hz,1H), 8.05 (s, 1H), 8.60 (s, 1H), 12.99 (s, 1H). MS (ESI) m/z 333.04(M+H)⁺. Calcd for C₂₀H₂₀N₄O.0.3 H₂O: C, 71.11; H, 6.15; N, 16.59; Found:C, 71.13; H, 6.04; N, 16.38.

EXAMPLE 68E1-(5-Cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride

To a round bottom flask containing 40 mL of CH₂Cl₂/DMF (10/1) was addedExample 68D (0.30 g, 1.10 mmol), 1-hydroxybenzotriazole hydrate (0.18 g,1.30 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride(0.256 g, 1.30 mmol), N,N-dimethylglycine (0.138 g, 1.30 mmol), and themixture was stirred at room temperature for 24 hours. The mixture wasdiluted with CH₂Cl₂ (100 mL), washed with sat NaHCO₃, dried (Na₂SO₄) andconcentrated in vacuo. The material was purified on SiO₂ eluting withethyl acetate. The material was taken up in ethyl acetate/diethyl ether(22 mL, 1/10) and 2M HCl in diethyl ether (2.0 eq) was added and thesolution stirred at room temperature for 5 minutes. The material wasconcentrated in vacuo to give Example 68E as a white solid (0.192 g) in42%. ¹H NMR (300 MHz, CD₃OD) δ ppm 0.62-0.66 (m, 2H), 0.91-0.96 (m, 2H),1.84-1.93 (m, 2H), 2.54-2.62 (m, 1H), 2.79-2.87 (m, 1H), 2.94-3.01 (m,1H), 3.11 (s, 6H), 5.02 (s, 2H), 5.25-5.29 (m, 1H), 6.93-6.96 (m, 2H),7.23 (d, J=7.67 Hz, 1H), 7.37 (t, J=8.28, 15.96 Hz, 1H), 7.56 (d, J=7.98Hz, 1H), 7.74 (d, J=7.98 Hz, 1H), 8.49 (s, 1H). MS(-FAPCI)m/z 418(M+H)⁺. Calc for C₂₄H₂₇N₅O₂:1.4 HCl:C, 61.52; H, 6.11; N,14.95. Found:C, 61.87; H, 6.15; N,14.82.

EXAMPLE 691-(1-(2-(Dimethylamino)acetyl)-1H-indazol-4-yl)-3-(4-(3,3-dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureaEXAMPLE 69A4-(3,3-Dimethylbut-1-ynyl)-5-fluoro-2,3-dihydro-1H-inden-1-one O-methyloxime

Example 66B (1.29 g, 5.0 mmol) was added to a mixture of3,3-dimethyl-1-butyne (Aldrich, 0.75 mL, 6.0 mmol), Pd(Ph₃P)₂Cl₂ (175mg, 0.25 mmol), copper(I) iodide (48 mg, 0.25 mmol) andtriphenylphosphine (262 mg, 1.0 mmol) in triethylamine (7.5 mL) anddimethylformamide (2.5 mL). The mixture was heated to 130° C. for 20minutes on the microwave (Personal Chemistry). Additional3,3-dimethyl-1-butyne (1.5 mL, 12.0 mmol) was added via syringe, thencontinued heating for another 20 minutes. After cooling, the mixture wasfiltered through celite, rinsed with ethyl acetate, and the filtrateconcentrated to an oil. The material was chromatographed on silica gelwith 0 to 10% ethyl acetate in hexane, yielding 1.32 g of impureproduct. Repeated chromatography on silica gel with 0 to 100%dichloromethane in hexane, to give 1.089 g (84% yield) of Example 69A.¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.31 (s, 9H), 2.84 (m, 2H), 2.99 (m,2H), 3.89 (s, 3H), 7.17 (dd, J=9.67, 8.65 Hz, 1H), 7.51 (dd, J=8.48,5.09 Hz, 1H). MS (DCI) m/z 260.06 (M+H)⁺.

EXAMPLE 69B 4-(3,3-Dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-amine

Example 69A (1.065 g, 4.11 mmol), Raney nickel (10 g), and 20% ammoniain methanol (90 mL) were shaken under hydrogen (60 psi) for 16 hours atambient temperature. The catalyst was removed by filtration and thesolvent evaporated under reduced pressure, giving 843 mg (88% yield) of(Z)-4-(3,3-dimethylbut-1-enyl)-5-fluoro-2,3-dihydro-1H-inden-1-amine asa green oil. This intermediate (700 mg, 3.0 mmol), Raney nickel (7.17g), and methanol (20 mL) were shaken under hydrogen (60 psi) for 16hours at 40° C. The mixture was filtered and retreated with catalyst(7.01 g) for 2 hours at 40° C., then 14 hours at ambient temperature.The mixture was filtered through a nylon membrane and the filtrate wasconcentrated to yield 389 mg (55% yield) of Example 69B. ¹H NMR (300MHz, DMSO-d₆) δ ppm 0.94 (s, 9H), 1.31 (m, 2H), 1.60 (m, 1H), 1.87 (brs, 2H), 2.34 (m, 1H), 2.63 (m, 1H), 2.84 (ddd, J=15.85, 8.73, 3.22 Hz,1H), 4.14 (t, J=7.80 Hz, 1H), 6.91 (dd, J=10.51, 8.14 Hz, 1H), 7.14 (dd,.J=7.97, 4.92 Hz, 1H). MS (DCI) m/z 236.1 (M+H)⁺.

EXAMPLE 69C1-(4-(3,3-Dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea

Example 66E (549 mg, 1.65 mmol) was added to Example 69B (389 mg, 1.65mmol) along with diisopropylethylamine (0.29 mL, 1.65 mmol) indimethylformamide (20 mL) at ambient temperature. After 1 hour, themixture was partitioned between ethyl acetate (200 mL) and water (200mL), and the organic layer was dried with brine and sodium sulfate, andthen evaporated under reduced pressure. The residue was chromatographedon silica gel with 10% methanol in ethyl acetate to obtain methyl4-(3-(4-(3,3-dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylateas a tan solid. This intermediate was dissolved in triethylamine (0.46mL, 3.31 mmol), methanol (50 mL) and water (5 mL). The mixture wasrefluxed for 1 hour, concentrated under reduced pressure andchromatographed on silica gel with 0 to 10% methanol in dichloromethaneto give 413 mg (63% yield) of Example 69C as a solid. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 0.97 (s, 9H), 1.35 (m, 2H), 1.87 (m, 1H), 2.55 (m, 2H),2.80 (dt, J=15.60, 7.80 Hz, 1H), 2.96 (ddd, J=16.28, 8.47, 4.41 Hz, 1H),5.17 (q, J=7.12 Hz, 1H), 6.70 (d, J=7.80 Hz, 1H), 6.99 (dd, J=10.18,8.47 Hz, 1H), 7.07 (d, J=8.47 Hz, 1H), 7.18 (m, 1H), 7.21 (t, J=8.14 Hz,1H), 7.67 (d, J=7.45 Hz, 1H), 8.04 (s, 1H), 8.59 (s, 1H), 12.99 (s, 1H).MS (ESI) m/z 395.23 (M+H)⁺. Calcd for C₂₃H₂₇FN₄O.0.25 H₂O.0.20 Methanol:C, 68.74; H, 7.04; N, 13.82; Found: C, 68.72; H, 7.09; N, 13.84.

EXAMPLE 69D1-(1-(2-(Dimethylamino)acetyl)-1H-indazol-4-yl)-3-(4-(3,3-dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureahydrochloride

The title compound was prepared as described in Example 68E substitutingExample 69C (0.150 g, 0.40 mmol) for Example 68D. The mixture waspurified on SiO₂ with ethyl acetate/methylene chloride (1/1) to give awhite solid. The material was taken up in ethyl acetate/diethyl ether(22 mL, 1/10) and 2M HCl in diethyl ether (2.0 eq) was added and stirredat room temperature for 5 minutes. The material was concentrated invacuo to give Example 69D (0.062 g) in 30% yield. ¹H NMR (300 MHz,CD₃OD) δ ppm 1.0 (s, 9H), 1.35-1.43 (m, 2H), 1.91-2.01 (m, 1H),2.59-2.69 (m, 2H), 2.81-2.89 (m, 1H), 2.97-3.07 (m, 2H), 3.10 (s, 6H),5.02 (s, 2H), 5.27-5.32 (m, 1H), 6.88-6.97 (m, 1H), 7.15-7.20 (m, 1H),7.58 (t, J=8.13, 15.93 Hz, 1H), 7.72 (d, J=7.80 Hz, 1H), 8.02 (d, J=8.14Hz, 1H), 8.47 (d, J=1.02 Hz, 1H). MS(+APCI)m/z 480 (M+H)⁺. Calc forC₂₇H₃₄N₅O₂F:1.1 HCl:1.0 H₂O:C, 60.31; H, 6.95; N,13.02. Found: C, 60.57;H, 7.32; N,12.83.

EXAMPLE 701-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride

The title compound was prepared as described in Example 68E,substituting Example 66F (0.250 g, 0.70 mmol) for Example 68D. Themixture was purified on SiO₂ with 1% methanol in ethyl acetate to give asolid. The material was taken up in ethyl acetate/diethyl ether (44 mL,1/10) and 2M HCl in diethyl ether (2.0 eq) was added and stirred at roomtemperature for 5 minutes. The material was concentrated in vacuo togive Example 70 (0.180 g) in 54%. ¹H NMR (300 MHz, CD₃OD) δ ppm0.80-0.84 (m, 2H), 0.92-0.97 (m, 2H), 1.74-1.79 (m, 1H), 1.87-2.00 (m,1H), 2.57-2.68 (m, 1H), 2.87-2.98 (m, 1H), 3.10-3.20 (m, 7H), 5.02 (s,2H), 5.25-5.30 (m, 1H), 6.83-6.90 (m, 1H), 7.14-7.18 (m, 1H), 7.58 (t,J=8.14, 15.93 Hz, 1H), 7.71 (d, J=8.14 Hz, 1H), 8.03 (d, J=7.46 Hz, 1H),8.46 (d, J=0.68 Hz, 1H). MS(+APCI)m/z 436 (M+H)⁺. Calc forC₂₄H₂₂N₅O₂F:1.2HCl:C, 60.15; H, 5.72; N,14.61. Found: C, 60.07; H, 5.76;N,14.28.

EXAMPLE 75(R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(methylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride EXAMPLE 75A (R)-benzyl2-(4-(3-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazol-1-yl)-2-oxoethyl(methyl)carbamate

The title compound was prepared as described in Example 68E substitutingExample 56J for Example 68D and2-((benzyloxycarbonyl)(methyl)amino)acetic acid for N,N-dimethylglycine.The mixture was purified on SiO₂ eluting with 5% CH₃OH in CH₂Cl₂ to giveExample 75A. ¹H NMR (300 MHz, CD₃OD) δ ppm 1.32 (s, 9H), 1.83-1.95 (m,1H), 2.55-2.65 (m, 1H), 2.81-2.89 (m, 1H), 2.92-3.06 (m, 1H), 4.76 (s,2H), 4.84 (s, 3H), 5.15 (s, 2H), 5.29 (t, J=7.46, 14.58 Hz, 1H),7.24-7.42 (m, 8H), 7.51 (t, J=7.80, 15.94 Hz, 1H), 7.75 (d, J=7.80 Hz,1H), 8.01 (d, J=7.84 Hz, 1H), 8.34 (s, 1H). MS(+APCI)m/z 554 (M+H)⁺.

EXAMPLE 75B(R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(methylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride

To a Parr flask containing methanol (100 mL) was added Example 75A (0.85g, 1.50 mmol), 10% Pd/C (0.20 g) and saturated HCl in methanol (1.1 eq).A hydrogen atmosphere (60 psi) was applied to the mixture and the vesselwas shaken at room temperature for 1 hour. The mixture was filtered,washed with methanol (50 mL) and concentrated in vacuo to give Example75B as a white solid (0.46 g) in 73% yield. ¹H NMR (300 MHz, CD₃OD) δppm 1.31 (s, 9H), 1.82-1.98 (m, 1H), 2.54-2.72 (m, 1H), 2.80-2.88 (m,1H), 2.91-3.07 (m, 1H), 3.83 (s, 3H), 3.91 (s, 2H), 5.25-5.33 (m, 1H),7.17 (d, J=7.46 Hz, 1H), 7.24-7.34 (m, 4H), 7.59 (d, J=7.46 Hz, 1H),8.01 (s, J=0.68 Hz, 1H). MS(+APCI)m/z 420 (M+H)⁺. Calc forC₂₄H₂₉N₅O₂:1.1HCl:0.40H₂O:C, 61.75; H, 6.67; N,15.00. Found: C, 62.12;H, 7.07; N, 14.75.

EXAMPLE 761-(1-(2-(Dimethylamino)acetyl)-1H-indazol-4-yl)-3-(7-(trifluoromethyl)chroman-4-yl)ureaEXAMPLE 76A 3-(3-Trifluoromethyl-phenoxy)propanoic acid

Sodium hydroxide (4.24 g, 106 mmol) was dissolved in water (50 ml).3-Trifluoromethyl-phenol (5.19 g, 32 mmol) was dissolved in 25 ml of thesodium hydroxide solution and heated to reflux. 3-Bromopropionic acid(9.79 g, 64 mmol) in the other 25 ml of sodium hydroxide solution wasadded dropwise over 15 minutes. The reflux was continued for 45 minutesmore, with portions of 10M sodium hydroxide solution added to maintainthe pH of the solution at appoximately pH 10. The reaction mixture wasthen cooled, acidified with hydrochloric acid, and extracted with ethylacetate. The combined organic layers were extracted with saturatedaqueous sodium bicarbonate, and the aqueous layers acidified withhydrochloric acid. The acidified aqueous layers were extracted withdiethyl ether. The ether layers were dried with magnesium sulfate, andthe solvent removed under vacuum to give 2.5 g of the crude productwhich was used directly in the next step.

¹H NMR (300 MHz, d₆-DMSO) δ 12.40 (broad s, 1H), 7.51 (t, J 7.5 Hz, 1H),7.24 (m, 3H), 4.23 (t, J 6.0 Hz, 2H), 2.71 (t, J 6.0 Hz, 2H).

EXAMPLE 76B 7-Trifluoromethyl-chroman-4-one

Polyphosphoric acid (10 mL) was heated in water bath and Example 76A(˜2.5 g) was added. After stirring for 30 minutes this mixture waspoured onto ice and extracted twice with diethyl ether. The combinedorganic layers were washed with water, aqueous NaHCO₃, and water andconcentrated. The residue was chromatographed on silica gel, and elutedwith 9:1ethyl acetate: hexanes to afford the title compound (0.84 g, 12%for 2 steps) as a solid. ¹H NMR (300 MHz, DMSO-d₆) δ 7.96 (d, J 7.5 Hz,1H), 7.40 (m, 2H), 4.62 (t, J 6.0 Hz, 2H), 2.88 (t, J 6.0 Hz, 2H). MS(DCl/NH₃) m/e 234 (M+NH₄)⁺.

EXAMPLE 76C 7-Trifluoromethyl-chroman-4-one O-methyl-oxime

A solution of Example 76B (0.84 g, 3.88 mmol) and methoxyl aminehydrochloride (0.65 g, 7.78 mmol, 2 eq.) in pyridine (10 mL) was stirredfor 18 hours at ambient temperature and concentrated under reducedpressure. The residue was dissolved in diethyl ether and washedsequentially with water, 1N HCl and water. The isolated organic layerwas concentrated and the residue chromatographed on silica gel, elutingwith 5:95 ethyl acetate:hexanes to afford the title product (0.71 g,74%). ¹H NMR (300 MHz, DMSO-d₆) δ 8.60 (d, J 7.5 Hz, 1H, major), 8.00(d, J 7.5 Hz, 1H, minor), 7.28 (m, 2H), 4.40 (t, J 6.0 Hz, 2H, major),4.24 (t, J 6.0 Hz, 2H, minor), 3.98 (s, 3H, minor), 3.96 (s, 3H, major),2.87 (t, J 6.0 Hz, 2H, minor), 2.70 (t, J 6.0 Hz, 2H, major). MS(DCI/NH₃) m/e 246 (M+H)⁺.

EXAMPLE 76D 7-Trifluoromethyl-chroman-4-ylamine

The title compound was prepared as described in Example 66D,substituting Example 76C for Example 66C. ¹H NMR (300 MHz, CDCl₃) δ7.43(d, 1H, J=8.1 Hz), 7.14(d, 1H, J=8.1 Hz), 7.06(s, 1H), 4.22-4.37 (m,2H), 4.08 (t, 1H, J=5.4 Hz), 2.12-2.22 (m, 1H), 1.82-1.92 (m, 1H). MS(DCI) m/e 218 (M+H)⁺.

EXAMPLE 76E4-[3-(7-Trifluoromethyl-chroman-4-yl)-ureido]-indazole-1-carboxylic acidmethyl ester

The title compound was prepared as described in Example 65C,substituting Example 76D for Example 65B. ¹H NMR (300 MHz, DMSO-d₆) δ8.92 (s, 1H), 8.40 (s, 1H), 7.85 (d, 1H, J=7.1 Hz), 7.71 (d, 1H, J=8.5Hz), 7.54 (m, 2H), 7.26 (d, 1H, J=7.8 Hz), 7.14 (s, 1H), 6.95 (d, 1H,J=8.1 Hz), 5.03 (m, 1H), 4.38 (m, 1H), 4.27 (m, 1H), 4.03 (s, 3H), 2.19(m, 1H), 2.09 (m, 1H). MS (ESI) m/e 435 (M+H)⁺.

EXAMPLE 76FN-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea

The title compound was prepared as described in Example 65D,substituting Example 76E for Example 65C. ¹H NMR (300 MHz, DMSO-d₆) δ13.00 (broad s, 1H), 8.67 (s, 1H), 8.04 (s, 1H), 7.67 (d, J=7.5 Hz, 1H),7.55 (d, J=7.5 Hz, 1H), 7.22 (m, 2H), 7.10 (m, 2H), 7.00 (d, J=7.5 Hz,1H), 5.00 (m, 1H), 4.41-4.20 (m, 2H), 2.22-2.00 (m, 2H). S (ESI) m/e 377(M+H)⁺. Calcd. For C₁₈H₁₅N₄O₂F₃.0.7H₂O: C, 55.59; H, 4.25; N, 14.40;Found: C, 55.51; H, 3.98; N, 14.65.

EXAMPLE 76G1-(1-(2-(Dimethylamino)acetyl)-1H-indazol-4-yl)-3-(7-(trifluoromethyl)chroman-4-yl)urea

The title compound was prepared as described in Example 68E,substituting Example 76F for Example 68D. The mixture was purified onSiO₂ eluting with 3% CH₃OH in CH₂Cl₂ to give the title compound as asolid (0.62 g) in 46% yield. ¹H NMR (300 MHz, CD₃OD) δ ppm 2.10-2.34(m,1H), 2.23-2.34 (m, 1H), 3.11 (s, 6H), 4.32-4.42 (m, 2H), 5.03 (s,2H), 5.12 (t, J=5.77, 11.87 Hz, 1H), 7.08-7.10 (m, 1H), 7.17-7.20 (m,1H), 7.52-7.63 (m, 2H)’, 7.72-7.75 (m, 1H), 7.98-8.05 (m, 1H), 8.50 (d,J=1.01 Hz, 1H). MS(+APCI)m/z 462 (M+H)^(÷). Calc forC₂₂H₂₂N₅O₃F₃:1.1HCl:C, 52.69; H, 4.64; N,13.96. Found: C, 52.64; H,4.88; N,13.76.

EXAMPLE 771-(8-Tert-butylchroman-4-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride EXAMPLE 77A 1-Tert-butyl-2-(prop-2-ynyloxy)benzene

2-Tert-butylphenol (15.02 g, 15.4 ml, 100 mmol), propargyl bromide (14.3ml of 80% in toluene, 128 mmol), and potassium carbonate (17.66 g, 128mmol) were stirred together in 200 ml of acetonitrile at ambienttemperature for 5 days. The solvent was removed under reduced pressure,and the residue taken into water and extracted with diethyl ether. Theorganic layers were combined, dried with magnesium sulfate, andfiltered. The solvent was evaporated under reduced pressure to give18.86 g of the title compound which was used without furtherpurification. ¹H NMR (300 MHz, CDCl₃) δ ppm 7.30 (dd, J=7.80, 1.70 Hz,1H), 7.15-7.22 (m, 1H), 6.90-6.98 (m, 2H), 4.73 (d, J=2.37 Hz, 2H), 2.48(t, J=2.37 Hz, 1H), 1.39 (s, 9H). MS (DCI) m/e 206 (M+NH₄)⁺.

EXAMPLE 77B 1-Tert-butyl-2-(3-chloroprop-2-ynyloxy)benzene

Example 77A (18.86 g, 100 mmol) was dissolved in 400 ml acetone.N-chlorosuccinimide (16.02 g, 120 mmol) and silver acetate (1.67 g, 10mmol) were added, and the mixture heated to reflux for 4 hours. Aftercooling, the silver salts were removed by filtration and the filtrateevaporated under reduced pressure. The residue was taken up in diethylether, washed with water and saturated aqueous sodium bicarbonate, driedwith magnesium sulfate, and filtered. The solvent removed under reducedpressure to give 26.13 g of Example 77B which was used without furtherpurification. ¹H NMR (300 MHz, CDCl₃) δ ppm 7.30 (dd, J=7.97, 1.53 Hz,1H), 7.19 (td, J=7.71, 1.86 Hz, 1H), 6.91-6.97 (m, 2H), 4.73 (s, 2H),1.38 (s, 9H). MS (DCI) m/e 223 (M+H)⁺

EXAMPLE 77C 8-Tert-butylchroman-4-one

Example 77B (25.8 g) in 250 ml ethylene glycol was heated to reflux for4 hours. The mixture was cooled, poured into water, and extracted withdiethyl ether. The organic layers were combined, washed with 1N sodiumhydroxide and saturated ammonium carbonate sequentially, dried withmagnesium sulfate, and filtered. Removal of solvent under reducedpressure gave a residue. The residues were filtered through a pad ofsilica gel with 1:1 methylene chloride:hexanes, and the filtrateevaporated under reduced pressure to give 13.51 g of Example 77C. ¹H NMR(300 MHz, CDCl₃) δ ppm 7.81 (dd, J=7.80, 1.70 Hz, 1H), 7.47 (dd, J=7.63,1.86 Hz, 1H), 6.95 (t, J=7.80 Hz, 1H), 4.51-4.58 (m, 2H), 2.79-2.85 (m,2H), 1.39 (s, 9H). MS (DCI) m/e 205 (M+H)⁺

EXAMPLE 77D 8-Tert-butylchroman-4-one O-methyl oxime

Example 77C (13.51 g, 66 mmol) was dissolved in 100 ml pyridine.Methoxylamine hydrochloride (10 g, 120 mmol) was added and the mixturestirred at ambient temperature for 16 hours. The pyridine was removedunder reduced pressure, and the residue partitioned between water anddiethyl ether. The mixture was extracted with diethyl ether, and thecombined organic layers washed with IN sodium hydroxide and 1Nhydrochloric acid sequentially, dried with magnesium sulfate, andfiltered. The solvent was removed under reduced pressure to give 14.44 gof Example 77D which was used without further purification.

¹H NMR (300 MHz, CDCl₃) δ ppm 7.79 (dd, .J=7.80, 1.70 Hz, 1H), 7.21-7.27(m, 1H), 6.87 (t, J=7.80 Hz, 1H), 4.18 (t, J=6.27 Hz, 2H), 3.98 (s, 3H),2.91 (t, J=6.27 Hz, 2H), 1.36 (s, 9H). MS (DCI) m/e 234 (M+H)⁺.

EXAMPLE 77E 8-Tert-butylchroman-4-amine

Example 77D (14.44 g, 61.9 mmol), 1.5 g of 10% palladium on carbon, and400 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psiand ambient temperature for 2.5 hours. The catalyst was removed byfiltration and the solvent evaporated under reduced pressure, giving13.50 g of Example 77E which was used without further purification. ¹HNMR (300 MHz, CDCl₃) δ ppm 7.14-7.24 (m, 3H) 6.81-6.89 (m, 1H) 4.22-4.29(m, 2H) 4.11 (t, J=5.09 Hz, 1H) 2.10-2.25 (m, 1H) 1.90 (td, J=9.16, 4.07Hz, 1H) 1.34-1.37 (m, 9H). MS (DCI) m/e 206 (M+H)⁺.

EXAMPLE 77F Methyl4-({[(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H-indazole-1-carboxylate

Example 77E (12.32 g, 60 mmol), Example 66E (19.94 g, 60 mmol), anddiisopropylethylamine (11.63 g, 16 ml, 90 mmol) were dissolved in 100 mlof N,N-dimethylformamide. The mixture was stirred at ambient temperaturefor 16 hours, and diluted with water. The precipitate that formed wascollected by filtration, air-dried, and then suspended in diethyl etherand hexane and filtered with a mixture of diethyl ether and hexanes togive 20.6 g of the titled compound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 8.77(s, 1H), 8.35 (s, 1H), 7.89 (d, J=7.46 Hz, 1H), 7.69 (d, J=8.48 Hz, 1H),7.46-7.55 (m, 1H), 7.16 (dd, J=8.14, 2.37 Hz, 2H), 6.83-6.93 (m, 2H),4.86-4.92 (m, 1H), 4.32-4.40 (m, 1H), 4.09-4.20 (m, 1H), 4.03 (s, 3H),2.09 (ddd, J=17.88, 8.90, 4.75 Hz, 2H), 1.34 (s, 9H). MS (ESI) m/e 423(M+H)⁺.

EXAMPLE 77GN-(8-Tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea

Example 77F (20.6 g, 48 mmol) was dissolved in a mixture of 100 mltetrahydrofuran and 75 ml methanol. Sodium hydroxide (5M in methanol, 50ml, 250 mmol) was added, and the mixture stirred at ambient temperaturefor 30 minutes. The mixture was diluted with water, and the precipitatethat formed was collected by filtration, giving 15.70 g of the titledcompound. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 13.00 (s, 1H), 8.51 (s, 1H),8.01 (s, 1H), 7.69 (d, J=7.46 Hz, 1H), 7.13-7.25 (m, 3H), 7.06 (d,J=8.14 Hz, 1H), 6.83-6.94 (m, 2H), 4.84-4.91 (m, 1H), 4.37 (dt, J=10.85,4.24 Hz, 1H), 4.06-4.19 (m, 1H), 1.99-2.14 (m, 2H), 1.35 (s, 9H). MS(ESI) m/e 365 (M+H)⁺.

EXAMPLE 77H1-(8-Tert-butylchroman-4-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride

The title compound was prepared as described in Example 68E,substituting 77G for Example 68D. The mixture was purified on SiO₂eluting with ethyl acetate/CH₂Cl₂ (1/4) followed by recrystallizationfrom THF to give the title compound as a solid in 67% yield. ¹H NMR (300MHz, CD₃OD) δ ppm 1.37 (s, 9H), 2.09-2.16 (m, 1H), 2.20-2.28 (m, 1H),3.10 (s, 6H), 4.21-4.27 (m, 1H), 4.32-4.37 (m, 1H), 5.02-5.04 (m, 3H),6.82 (t, J=7.68, 15.35 Hz, 1H), 7.18 (d, J=15.95 Hz, 2H), 7.57 (t,J=7.97, 15.02 Hz, 1H), 7.75 (d, J=7.98 Hz, 1H), 8.00 (d, J=8.29 Hz, 1H),8.48 (s, 1H). MS(+APCI)m/z 450 (M+H)⁺. Calc for C₂₅H₃₁N₅O₃:1.2HCl:C,60.87; H, 6.58; N,14.20. Found: C, 60.93; H, 6.82; N,13.95.

COMPOSITIONS OF THE INVENTION

The invention also provides pharmaceutical compositions comprising atherapeutically effective amount of a compound of formula (I) incombination with a pharmaceutically acceptable carrier. The compositionscomprise compounds of the invention formulated together with one or morenon-toxic pharmaceutically acceptable carriers. The pharmaceuticalcompositions can be formulated for oral administration in solid orliquid form, for parenteral injection or for rectal administration.

The term “pharmaceutically acceptable carrier,” as used herein, means anon-toxic, inert solid, semi-solid or liquid filler, diluent,encapsulating material or formulation auxiliary of any type. Someexamples of materials which can serve as pharmaceutically acceptablecarriers are sugars such as lactose, glucose and sucrose; starches suchas corn starch and potato starch; cellulose and its derivatives such assodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;powdered tragacanth; malt; gelatin; talc; cocoa butter and suppositorywaxes; oils such as peanut oil, cottonseed oil, safflower oil, sesameoil, olive oil, corn oil and soybean oil; glycols; such a propyleneglycol; esters such as ethyl oleate and ethyl laurate; agar; bufferingagents such as magnesium hydroxide and aluminum hydroxide; alginic acid;pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol,and phosphate buffer solutions, as well as other non-toxic compatiblelubricants such as sodium lauryl sulfate and magnesium stearate, as wellas coloring agents, releasing agents, coating agents, sweetening,flavoring and perfuming agents, preservatives and antioxidants can alsobe present in the composition, according to the judgment of one skilledin the art of formulations.

The pharmaceutical compositions of this invention can be administered tohumans and other mammals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments or drops), bucally or as an oral or nasal spray. Theterm “parenterally,” as used herein, refers to modes of administration,including intravenous, intramuscular, intraperitoneal, intrasternal,subcutaneous, intraarticular injection and infusion.

Pharmaceutical compositions for parenteral injection comprisepharmaceutically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions or emulsions and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers, diluents, solventsor vehicles include water, ethanol, polyols (propylene glycol,polyethylene glycol, glycerol, and the like, and suitable mixturesthereof), vegetable oils (such as olive oil) and injectable organicesters such as ethyl oleate, or suitable mixtures thereof Suitablefluidity of the composition may be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersions, and by the use of surfactants.

These compositions can also contain adjuvants such as preservativeagents, wetting agents, emulsifying agents, and dispersing agents.Prevention of the action of microorganisms can be ensured by variousantibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, sorbic acid, and the like. It also can bedesirable to include isotonic agents, for example, sugars, sodiumchloride and the like. Prolonged absorption of the injectablepharmaceutical form can be brought about by the use of agents delayingabsorption, for example, aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is oftendesirable to slow the absorption of the drug from subcutaneous orintramuscular injection. This can be accomplished by the use of a liquidsuspension of crystalline or amorphous material with poor watersolubility. The rate of absorption of the drug can depend upon its rateof dissolution, which, in turn, may depend upon crystal size andcrystalline form. Alternatively, a parenterally administered drug formcan be administered by dissolving or suspending the drug in an oilvehicle.

Suspensions, in addition to the active compounds, can contain suspendingagents, for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.

If desired, and for more effective distribution, the compounds of theinvention can be incorporated into slow-release or targeted-deliverysystems such as polymer matrices, liposomes, and microspheres. They maybe sterilized, for example, by filtration through a bacteria-retainingfilter or by incorporation of sterilizing agents in the form of sterilesolid compositions, which may be dissolved in sterile water or someother sterile injectable medium immediately before use.

Injectable depot forms are made by forming microencapsulated matrices ofthe drug in biodegradable polymers such as polylactide-polyglycolide.Depending upon the ratio of drug to polymer and the nature of theparticular polymer employed, the rate of drug release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides) Depot injectable formulations also are prepared byentrapping the drug in liposomes or microemulsions which are compatiblewith body tissues.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium just prior to use.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation also can be a sterile injectablesolution, suspension or emulsion in a nontoxic, parenterally acceptablediluent or solvent such as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that can be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, one or morecompounds of the invention is mixed with at least one inertpharmaceutically acceptable carrier such as sodium citrate or dicalciumphosphate and/or a) fillers or extenders such as starches, lactose,sucrose, glucose, mannitol, and salicylic acid; b) binders such ascarboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia; c) humectants such as glycerol; d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate; e) solutionretarding agents such as paraffin; f) absorption accelerators such asquaternary ammonium compounds; g) wetting agents such as cetyl alcoholand glycerol monostearate; h) absorbents such as kaolin and bentoniteclay; and i) lubricants such as talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate, andmixtures thereof. In the case of capsules, tablets and pills, the dosageform may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using lactose or milk sugar aswell as high molecular weight polyethylene glycols.

The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well-known in the pharmaceutical formulatingart. They can optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract in a delayedmanner. Examples of materials useful for delaying release of the activeagent can include polymeric substances and waxes.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating carriers such as cocoa butter,polyethylene glycol or a suppository wax which are solid at ambienttemperature but liquid at body temperature and therefore melt in therectum or vaginal cavity and release the active compound.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups andelixirs. In addition to the active compounds, the liquid dosage formsmay contain inert diluents commonly used in the art such as, forexample, water or other solvents, solubilizing agents and emulsifierssuch as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, oils (in particular, cottonseed, groundnut,corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring, and perfuming agents.

Dosage forms for topical or transdermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. A desired compound ofthe invention is admixed under sterile conditions with apharmaceutically acceptable carrier and any needed preservatives orbuffers as may be required. Ophthalmic formulation, eardrops, eyeointments, powders and solutions are also contemplated as being withinthe scope of this invention. The ointments, pastes, creams and gels maycontain, in addition to an active compound of this invention, animal andvegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulosederivatives, polyethylene glycols, silicones, bentonites, silicic acid,talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of thisinvention, lactose, talc, silicic acid, aluminum hydroxide, calciumsilicates and polyamide powder, or mixtures of these substances. Sprayscan additionally contain customary propellants such aschlorofluorohydrocarbons.

Compounds of the invention also can be administered in the form ofliposomes. As is known in the art, liposomes are generally derived fromphospholipids or other lipid substances. Liposomes are formed by mono-or multi-lamellar hydrated liquid crystals that are dispersed in anaqueous medium. Any non-toxic, physiologically acceptable andmetabolizable lipid capable of forming liposomes may be used. Thepresent compositions in liposome form may contain, in addition to thecompounds of the invention, stabilizers, preservatives, and the like.The preferred lipids are the natural and synthetic phospholipids andphosphatidylcholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example,Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, NewYork, N.Y., (1976), p 33 et seq.

Dosage forms for topical administration of a compound of this inventioninclude powders, sprays, ointments and inhalants. The active compound ismixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives, buffers or propellants. Ophthalmicformulations, eye ointments, powders and solutions are also contemplatedas being within the scope of this invention. Aqueous liquid compositionsof the invention also are particularly useful.

The compounds of the invention can be used in the form ofpharmaceutically acceptable salts, esters, or amides derived frominorganic or organic acids. The term “pharmaceutically acceptable salts,esters and amides,” as used herein, include salts, zwitterions, estersand amides of compounds of formula (I) which are, within the scope ofsound medical judgment, suitable for use in contact with the tissues ofhumans and lower animals without undue toxicity, irritation, allergicresponse, and the like, are commensurate with a reasonable benefit/riskratio, and are effective for their intended use.

The term “pharmaceutically acceptable salt” refers to those salts whichare, within the scope of sound medical judgment, suitable for use incontact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well-known in the art. The salts can be prepared insitu during the final isolation and purification of the compounds of theinvention or separately by reacting a free base function with a suitableorganic acid.

Representative acid addition salts include, but are not limited toacetate, adipate, alginate, citrate, aspartate, benzoate,benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate,digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate,fumarate, hydrochloride, hydrobromide, hydroiodide,2-hydroxyethansulfonate (isethionate), lactate, maleate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate,pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, phosphate, glutamate,bicarbonate, p-toluenesulfonate and undecanoate.

Also, the basic nitrogen-containing groups can be quaternized with suchagents as lower alkyl halides such as methyl, ethyl, propyl, and butylchlorides, bromides and iodides; dialkyl sulfates such as dimethyl,diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl,lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkylhalides such as benzyl and phenethyl bromides and others. Water oroil-soluble or dispersible products are thereby obtained.

Examples of acids which can be employed to form pharmaceuticallyacceptable acid addition salts include such inorganic acids ashydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acidand such organic acids as oxalic acid, maleic acid, succinic acid, andcitric acid.

Basic addition salts can be prepared in situ during the final isolationand purification of compounds of this invention by reacting a carboxylicacid-containing moiety with a suitable base such as the hydroxide,carbonate or bicarbonate of a pharmaceutically acceptable metal cationor with ammonia or an organic primary, secondary or tertiary amine.Pharmaceutically acceptable salts include, but are not limited to,cations based on alkali metals or alkaline earth metals such as lithium,sodium, potassium, calcium, magnesium, and aluminum salts, and the like,and nontoxic quaternary ammonia and amine cations including ammonium,tetramethylammonium, tetraethylammonium, methylamine, dimethylamine,trimethylamine, triethylamine, diethylamine, ethylamine and the such as.Other representative organic amines useful for the formation of baseaddition salts include ethylenediamine, ethanolamine, diethanolamine,piperidine, and piperazine.

The term “pharmaceutically acceptable ester,” as used herein, refers toesters of compounds of the invention which hydrolyze in vivo and includethose that break down readily in the human body to leave the parentcompound or a salt thereof. Examples of pharmaceutically acceptable,non-toxic esters of the invention include C₁-to-C₆ alkyl esters andC₅-to-C₇ cycloalkyl esters, although C₁-to-C₄ alkyl esters arepreferred. Esters of the compounds of formula (I) can be preparedaccording to conventional methods. Pharmaceutically acceptable esterscan be appended onto hydroxy groups by reaction of the compound thatcontains the hydroxy group with acid and an alkylcarboxylic acid such asacetic acid, or with acid and an arylcarboxylic acid such as benzoicacid. In the case of compounds containing carboxylic acid groups, thepharmaceutically acceptable esters are prepared from compoundscontaining the carboxylic acid groups by reaction of the compound withbase such as triethylamine and an alkyl halide, alkyl trifilate, forexample with methyl iodide, benzyl iodide, cyclopentyl iodide. They alsocan be prepared by reaction of the compound with an acid such ashydrochloric acid and an alkylcarboxylic acid such as acetic acid, orwith acid and an arylcarboxylic acid such as benzoic acid.

The term “pharmaceutically acceptable amide,” as used herein, refers tonon-toxic amides of the invention derived from ammonia, primary C₁-to-C₆alkyl amines and secondary C₁-to-C₆ dialkyl amines. In the case ofsecondary amines, the amine can also be in the form of a 5- or6-membered heterocycle containing one nitrogen atom. Amides derived fromammonia, C₁-to-C₃ alkyl primary amides and C₁-to-C₂ dialkyl secondaryamides are preferred. Amides of the compounds of formula (I) can beprepared according to conventional methods. Pharmaceutically acceptableamides can be prepared from compounds containing primary or secondaryamine groups by reaction of the compound that contains the amino groupwith an alkyl anhydride, aryl anhydride, acyl halide, or aroyl halide.In the case of compounds containing carboxylic acid groups, thepharmaceutically acceptable esters are prepared from compoundscontaining the carboxylic acid groups by reaction of the compound withbase such as triethylamine, a dehydrating agent such as dicyclohexylcarbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine,for example with methylamine, diethylamine, piperidine. They also can beprepared by reaction of the compound with an acid such as sulfuric acidand an alkylcarboxylic acid such as acetic acid, or with acid and anarylcarboxylic acid such as benzoic acid under dehydrating conditions aswith molecular sieves added. The composition can contain a compound ofthe invention in the form of a pharmaceutically acceptable prodrug.

The term “pharmaceutically acceptable prodrug” or “prodrug,” as usedherein, represents those prodrugs of the compounds of the inventionwhich are, within the scope of sound medical judgment, suitable for usein contact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, commensurate witha reasonable benefit/risk ratio, and effective for their intended use.Prodrugs of the invention can be rapidly transformed in vivo to a parentcompound of formula (I), for example, by hydrolysis in blood. A thoroughdiscussion is provided in T. Higuchi and V. Stella, Pro-drugs as NovelDelivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B.Roche, ed., Bioreversible Carriers in Drug Design, AmericanPharmaceutical Association and Pergamon Press (1987).

The invention contemplates pharmaceutically active compounds eitherchemically synthesized or formed by in vivo biotransformation tocompounds of formula (I).

METHODS OF THE INVENTION

Compounds and compositions of the invention are useful for amelioratingor preventing disorders involving TRPV1 receptor activation such as, butnot limited to, inflammatory thermal hyperalgesia, bladder overactivity,and urinary incontinence as described by Nolano, M. et al., Pain, Vol.81, pages 135-145, (1999); Caterina, M. J. and Julius, D., Annu. Rev.Neurosci. Vol. 24, pages 487-517 (2001); Caterina, M. J. et al., ScienceVol. 288 pages 306-313 (2000); Caterina, M. J. et al., Nature Vol. 389pages 816-824 (1997); Fowler, C. Urology Vol. 55 pages 60-64 (2000); andDavis, J. et al., Nature Vol. 405 pages 183-187.

The present invention also provides pharmaceutical compositions thatcomprise compounds of the present invention. The pharmaceuticalcompositions comprise compounds of the present invention that may beformulated together with one or more non-toxic pharmaceuticallyacceptable carriers.

In vivo Evaluation of TRPV1 Prodrugs

The pharmacokinetic behavior of prodrugs was evaluated in maleSprague-Dawley derived rats (n=3/group). Each compound was prepared as a10 μmol/ml solution in a vehicle of 10% DMSO in PEG-400. Groups of threerats received a 10 μmol/kg (1 ml/kg) intravenous or oral dose of eachcompound. The intravenous dose was administered in a jugular vein underlight isoflurane anesthetic; the oral dose was administered by gavage.Serial blood samples were obtained from a tail vein of each rat 0.1 (IVonly), 0.25, 0.5, 1, 1.5, 2, 4, 6 and 8 hours after dosing. Plasma wasseparated by centrifugation and stored frozen until analysis.

The plasma concentrations of the administered prodrug and a TRPV Iantagonist compound were determined by HPLC-MS/MS. The compounds wereremoved from the plasma using protein precipitation with acetonitrile.Following centrifugation, the supernatant was transferred to a cleancontainer and evaporated to dryness with nitrogen. The prodrug andparent compound were separated from co-extracted contaminant usingreverse phase HPLC, with MS/MS detection and quantitation. Spikedstandards were analyzed simultaneously with the samples. The plasma drugconcentration of each sample was calculated by least squares linearregression analysis (non-weighted) of the peak area ratio(parent/internal standard) of the spiked plasma standards versusconcentration.

Peak plasma concentrations (C_(max)) and the time to peak plasmaconcentration (T_(max)) were read directly from the plasma concentrationdata for each rat. The plasma concentration data were submitted tomulti-exponential curve fitting using WinNonlin(WinNonlin-Professional®, Version 3.2, Pharsight Corporation, MountainView, Calif.). All representative prodrug compounds transformed to aTRPV1 antagonist compound. C. ranges varied from 2% to 100% compared tothe 100% C. of the administered TRPV1 antagonist compound.

1. A compound of formula (I)

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or acombination thereof, wherein A is

R₁ is alkyl, cycloalkyl, alkenyl; halogen or haloalkyl; R₂ is hydrogenor heterocyclealkyl wherein the heterocycle moiety of theheterocyclealkyl is unsubstituted or substituted with 1, 2, 3 or 4substituents selected from the group consisting of alkyl, -alkyl-OR_(B),and -alkyl-N(R_(B))₂; R₃ is

wherein R₄ is —C(O)—O—(CH₂)_(m)R₅, —C(O)(CH₂)_(n)—R₆, —(CH₂)_(r)—R₇,—C(O)R₈, or —CH₂C(H)(OH)R₉ when R₂ is hydrogen; or R₄ is hydrogen whenR₂ is heterocyclealkyl; wherein the heterocycle moiety of theheterocyclealkyl is unsubstituted or substituted with 1, 2, 3 or 4substituents selected from the group consisting of alkyl, -alkyl-OR_(B),and -alkyl-N(R_(B))₂; m is 1, 2, or 3; n is 1, 2 or 3; r is 1, 2 or 3; tis 0, 1, 2, 3 or 4; u is 0, 1, 2 or 3; R₅ is alkyl,—O—P(O)(OR_(A))(OR_(A)), —P(O)(OR_(A))(OR_(A)), —OR_(A), —OC(O)(R_(A)),heterocycle, —C(O)OR_(A), —C(O)N(R_(B))₂, —C(O)(R_(A)), —NR_(A)R_(B), or—N(R_(B))C(O)OR_(A), R₆ is alkyl, —OC(O)(R_(A)), —OR_(A), —C(O)OR_(A),—NR_(A)R_(B), —OP(O)(OR_(A))(OR_(A)), or —P(O)(OR_(A))(OR_(A)); R₇ isalkoxy, heterocycle, —OC(O)(R_(A)), —OC(O)(hydroxyalkyl),—OP(O)(OR_(A))(OR_(A)), or —P(O)(OR_(A))(OR_(A)), R₈ is heterocycle orN(R_(8a))(R_(8b)) wherein R_(8a) and R_(8b) are independently hydrogenor alkyl; R₉ is alkoxyalkyl, —C(O)OR_(A), -alkyl-N(R_(B))C(O)OR_(A), orheterocyclealkyl; R₁₀ is alkyl; each occurence of R₁₁ are independentlyhydrogen, alkyl or aryl, or two R₁₁ groups that are attached to a singlecarbon atom together form a cycloalkyl ring; R_(A) is hydrogen, alkyl,alkoxyalkyl, aryl or arylalkyl; R_(B) is hydrogen or alkyl; theheterocycle and the heterocycle moiety of the heterocyclealkyl,represented by R₅, R₇, R₈, and R₉, are each independently substitutedwith 0, 1, 2 or 3 substituents independently selected from the groupconsisting of alkyl, haloalkyl, alkoxy, haloalkoxy, —C(O)OH,-alkyl-C(O)OH, and —N(Z_(A))(Z_(B)); Z_(A) and Z_(B) are eachindependently hydrogen, alkyl, —C(O)alkyl, formyl, aryl, or arylalkyl;and the aryl and the aryl moiety of the arylalkyl, represented by R_(A),Z_(A) and Z_(B) are each independently substituted with 0, 1, 2 or 3substituents selected from the group consisting of alkyl, haloalkyl,alkoxy and haloalkoxy.
 2. The compound of claim 1, wherein A is


3. The compound of claim 2, wherein R₁ is alkyl, cycloalkyl, alkenyl;halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —(CH₂)_(r)—R₇.
 4. The compound of claim 2, wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is ⁻C(O)(CH₂)_(n) ⁻R₆.
 5. The compound of claim 2, wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —CH₂C(H)(OH)R₉.
 6. The compound of claim 2, wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —C(O)R_(8.)
 7. The compound of claim 2, wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl; R₂ is heterocyclealkyl; R₃ is

and R₄ is hydrogen.
 8. The compound of claim 2, wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —C(O)—O—(CH₂)_(m)R_(5.)
 9. The compound of claim 8 wherein R₅is —O—P(O)(OR_(A))(OR_(A)).
 10. The compound of claim 8 wherein R₅ is—P(O)(OR_(A))(OR_(A)).
 11. The compound of claim 8 wherein R₅ is—OR_(A).
 12. The compound of claim 8 wherein R₅ is —OC(O)(R_(A)). 13.The compound of claim 8 wherein R₅ is heterocycle.
 14. The compound ofclaim 8 wherein R₅ is —C(O)OR_(A).
 15. The compound of claim 8 whereinR₅ is selected from the group consisting of —C(O)R_(A),—N(R_(B))C(O)OR_(A), —NR_(A)R_(B), and —C(O)N(R_(B))₂.
 16. The compoundof claim 2, wherein R₁ is alkyl, cycloalkyl, halogen or haloalkyl; R₂ ishydrogen; R₃ is

and R₄ is —C(O)R_(8.)
 17. The compound of claim 2, wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —CH₂C(H)(OH)R₉.
 18. The compound of claim 2, wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is selected from the group consisting of —C(O)—O—(CH₂)_(m)R₅,—C(O)(CH₂)_(n)—R₆, and —(CH₂)_(r)—R₇.
 19. The compound of claim 2,wherein R₁ is alkyl, cycloalkyl, halogen or haloalkyl; R₂ isheterocyclealkyl; R₃ is

and R₄ is hydrogen.
 20. The compound of claim 1, wherein A is


21. The compound of claim 20, wherein R₁ is alkyl, cycloalkyl, halogenor haloalkyl; R₂ 1S hydrogen; R₃ is

and R₄ is —(CH₂)_(r)—R₇.
 22. The compound of claim 20 wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —C(O)(CH₂)_(n)—R₆.
 23. The compound of claim 20 wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —CH₂C(H)(OH)R₉.
 24. The compound of claim 20 wherein R₁ isalkyl, cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —C(O)R₈.
 25. The compound of claim 20 wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl; R₂ is heterocyclealkyl; R₃ is

and R₄ is hydrogen.
 26. The compound of claim 20 wherein R₁ is alkyl,cycloalkyl, halogen or haloalkyl; R₂ is hydrogen; R₃ is

and R₄ is —C(O)—O—(CH₂)_(m)R_(5.)
 27. The compound of claim 26 whereinR₅ is —O—P(O)(OR_(A))(OR_(A)).
 28. The compound of claim 26 wherein R₅is —P(O)(OR_(A))(OR_(A)).
 29. The compound of claim 26 wherein R₅ is—OR_(A).
 30. The compound of claim 26 wherein R₅ is —OC(O)(R_(A)). 31.The compound of claim 26 wherein R₅ is heterocycle.
 32. The compound ofclaim 26 wherein R₅ is —C(O)OR_(A),
 33. The compound of claim 26 whereinR₅ is selected from the group consisting of —C(O)R_(A),—N(R_(B))C(O)OR_(A), —NR_(A)R_(B), and —C(O)N(R_(B))₂.
 34. The compoundof claim 1, wherein A is


35. The compound of claim 1, wherein A is


36. The compound of claim 1, wherein A is


37. The compound selected from the group consisting ofN-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-morpholin-4-ylethyl)-1H-indazol-4-yl]urea;2-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-oxoethylacetate;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-yl-N-(2-morpholin-4-ylethyl)urea;N-{1-[(benzyloxy)acetyl]-1H-indazol-4-yl}-N′-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(methoxyacetyl)-1H-indazol-4-yl]urea;4-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl1-4-oxobutanoicacid;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′t1-(N,N-dimethylglycyl)-1H-indazol-4-yl]ureatrifluoroacetic acid salt;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-(1-glycoloyl-1H-indazol-4-yl)urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-yl-N-(2-piperidin-1-ylethyl)urea;5-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-5-oxopentanoicacid; 2-(phosphonooxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-(benzyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-hydroxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-[(di-tert-butoxyphosphoryl)oxy]ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;3-(benzyloxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;3-hydroxypropyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;3-[(di-tert-butoxyphosphoryl)oxy]propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;3-(phosphonooxy)propyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-/V[1-(hydroxymethyl)-1H-indazol-4-yl)urea;{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}methylacetate;{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}methyl 3-hydroxypropanoate;{[bis(benzyloxy)phosphoryl]oxy}methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;(phosphonooxy)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;dibenzyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropylphosphate;3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropyldihydrogen phosphate; [bis(benzyloxy)phosphoryl]methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonieacid triethylamine salt; 2-methoxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;(2,2-dimethyl-1,3-dioxolan-4-yl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;(2-oxo-1,3-dioxolan-4-yl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-(benzyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-hydroxyethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-(benzyloxy)-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-{[(benzyloxy)carbonyl]amino}ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]aceticacid; 2-aminoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylatehydrochloride; 2-ethoxy-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;(diethoxyphosphoryl)methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-(diethylamino)-2-oxoethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-oxopropyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-(acetyloxy)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;2-(dimethoxyphosphoryl)ethyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;[bis(benzyloxy)phosphoryl]methyl4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonate,triethylamine salt;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, diethylaminoethanol salt;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, triethanolamine salt;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, piperazine salt;[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonicacid, N-methyl-D-glucamine salt;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-hydroxy-3-methoxypropyl)-1H-indazol-4-yl]urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[2-(2-hydroxy-3-methoxypropyl)-2H-indazol-4-yl]urea;methyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropanoate;methyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoate;tert-butyl3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropylcarbamate;3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropanoicacid;3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoicacid;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′t2-(2-hydroxy-3-morpholin-4-ylpropyl)-2H-indazol-4-yl]urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-hydroxy-3-morpholin-4-ylpropyl)-1H-indazol-4-yl]urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-{1-[(4-methylpiperazin-1-yl)carbonyl]-1H-indazol-4-yl}urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-{2-[(4-methylpiperazin-1-yl)carbonyl]-2H-indazol-4-yl}urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea,hydrochloride salt;((R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(2-methoxyethoxy)acetyl)-1H-indazol-4-yl)urea;1-((R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(3,5,5-trimethylhexanoyl)-1H-indazol-4-yl)urea;2-ethylhexyl4-(3-((R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylate;(R)-1-(1-(2-(2-butoxyethoxy)acetyl)-1H-indazol-4-yl)-3-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea;methyl4-(3-(7-fluoro-2,2-dimethylchroman-4-yl)ureido)-1H-indazole-1-carboxylate;1-(7-fluoro-2,2-dimethylchroman-4-yl)-3-(1-(2-methoxyethyl)-1H-indazol-4-yl)urea;3-(dimethylamino)propyl4-(3-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylate;1-(4-cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureatrifluoroacetate;1-(5-cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride;1-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)-3-(4-(3,3-dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-yl)urea;(R)-1-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)urea;(R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(methylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride;4-[3-(7-trifluoromethyl-chroman-4-yl)-ureido]-indazole-1-carboxylic acidmethyl ester;1-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)-3-(7-(trifluoromethyl)chroman-4-yl)urea;methyl4-({[(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;and1-(8-tert-butylchroman-4-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)ureahydrochloride.
 38. A pharmaceutical composition comprising atherapeutically effective amount of one or more compound of formula (I)as described in claim 1, or a therapeutically acceptable salt, solvate,or combination thereof, and a pharmaceutically acceptable carrier.
 39. Amethod of treating or preventing disorders that may be ameliorated byinhibiting TRPV1 activity in a mammal comprising administering atherapeutically effective amount of one or more compounds of formula (I)according to claim 1 or a pharmaceutically acceptable salt thereof. 40.A compound of formula (I) according according to claim 1 for use in themanufacture of a medicament for the treatment or prevention of a diseaseor condition that may be ameliorated by inhibiting TRPV1 activity.
 41. Acompound according to claim 36 wherein the disease or disorder isassociated with pain, inflammation, urinary incontinence and bladderdysfunction.
 42. A method of treating or preventing a disease ordisorders associated with neuropathic pain, inflammatory pain, or both,which method comprises administering a therapeutically effective amountof a compound of formula (I) according to claim 1 or a pharmaceuticallyacceptable salt thereof.
 43. A method of treating or preventing adisease or disorder associated with bladder overactivity or urinaryincontinence, or both, which method comprises administering atherapeutically effective amount of a compound of formula (I) accordingto claim 1 or a pharmaceutically acceptable salt thereof.
 44. Thecompound of claim 2 of formula (II),


45. The compound of claim 2 of formula (III),


46. The compound of claim 20 of formula (IV),


47. The compound of claim 20 of formula (V),